```
 d que stat l10
L9              STR
```




```
VAR G1=10/12/14/17/28/31
VAR G2=OH/38/40/11/36
VAR G3=OH/38/40/11/36
VAR G10=10/12/35
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   1
CONNECT IS E2  RC AT   4
CONNECT IS E2  RC AT   5
CONNECT IS E2  RC AT  14
CONNECT IS E2  RC AT  17
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT  41
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   6
NUMBER OF NODES IS  41

STEREO ATTRIBUTES: NONE
L10           0 SEA FILE=REGISTRY SSS SAM L9

  0.6% PROCESSED    2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      7056340 TO  7125500
PROJECTED ANSWERS:               0 TO        0
```

```
=> => d que l1
L1             5 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS


=> d que l2
L2             1 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS


=> d que l4
L1             5 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L3               TRANSFER  PLU=ON  L1 1- RN :      82 TERMS
L4            82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L3


=> d que stat l15
L1             5 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L3               TRANSFER  PLU=ON  L1 1- RN :      82 TERMS
L4            82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L3
L5               STR
```




```
VAR G1=10/12/14/17/28/31
VAR G2=OH/38/40/11/36
VAR G3=OH/38/40/11/36
VAR G10=10/12/35
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT  41
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  41

STEREO ATTRIBUTES: NONE
L15           28 SEA FILE=REGISTRY SUB=L4 SSS FUL L5

100.0% PROCESSED      42 ITERATIONS                          28 ANSWERS
SEARCH TIME: 00.00.01


=> d que l18
```

L1 5 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON US2007-839520/APPS
L3 TRANSFER PLU=ON L1 1- RN : 82 TERMS
L4 82 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L3
L5 STR



VAR G1=10/12/14/17/28/31
VAR G2=OH/38/40/11/36
VAR G3=OH/38/40/11/36
VAR G10=10/12/35
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 41
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE
L15 28 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L16 270 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON (1007839-71-5/CRN OR 1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR 1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR 1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR 1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR 1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR 1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR 21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR 79122-68-2/CRN OR 88-46-0/CRN)
L18 293 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON L15 OR L16

=> d his l15-l18

(FILE 'REGISTRY' ENTERED AT 15:28:55 ON 24 SEP 2009)
L15 28 S L5 SSS FUL SUB=L4
SAVE TEMP L15 PAG520PSET1/A
SELECT L15 1- RN
L16 270 S E13-E40/CRN
L17 2 S (21799-87-1 OR 88-46-0)/RN
L18 293 S L15 OR L16

```
=> d que nos l18
L1             5 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L3               TRANSFER  PLU=ON  L1 1- RN :      82 TERMS
L4            82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L3
L5               STR
L15           28 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L16          270 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR
                 1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
                 1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
                 1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
                 1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
                 1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
                 1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
                 21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
                 8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
                 79122-68-2/CRN OR 88-46-0/CRN)
L18          293 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L15 OR L16


=> d his l19-l21

     (FILE 'REGISTRY' ENTERED AT 15:28:55 ON 24 SEP 2009)
                SAVE TEMP L18 PAG520CROSS/A

     FILE 'STNGUIDE' ENTERED AT 15:38:22 ON 24 SEP 2009

     FILE 'WPIX' ENTERED AT 15:39:29 ON 24 SEP 2009
L19            1 S L5 SAM
L20            0 S L9 SAM
                 SELECT L2 1- DCR
L21           34 S E41-E145/AN.S
                 SAVE TEMP L21 PAG520WPIANS/A

     FILE 'STNGUIDE' ENTERED AT 15:46:16 ON 24 SEP 2009

=> d que l21
L21           34 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (1595296-K/AN.S OR
                 1595296-M/AN.S OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K
                 /AN.S OR 1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR
                 9091-U/AN.S OR DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/A
                 N.S OR DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S
                  OR DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S
                 OR DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR
                 DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR
                 DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR
                 DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR
                 DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR
                 DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/A
                 N.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR
                 DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/
                 AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR
                 12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.
                 S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR
                 1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K
                 /AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR
                 1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M
                 /AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR
                 1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K
                 /AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR
                 1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M
```

```
                /AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR
                1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/
                AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR
                528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR
                86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
                91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
                OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
                )


=> d his ful

     (FILE 'HOME' ENTERED AT 13:36:43 ON 24 SEP 2009)

     FILE 'STNGUIDE' ENTERED AT 13:36:46 ON 24 SEP 2009

     FILE 'ZCAPLUS' ENTERED AT 13:37:07 ON 24 SEP 2009
                E US2007-839520/APPS

     FILE 'HCAPLUS' ENTERED AT 13:37:18 ON 24 SEP 2009
L1             5 SEA SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
                SAVE TEMP L1 PAG520HCAAPP/A
                D SCAN

     FILE 'STNGUIDE' ENTERED AT 13:37:50 ON 24 SEP 2009

     FILE 'WPIX' ENTERED AT 13:51:40 ON 24 SEP 2009
L2             1 SEA SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
                D IALL CODE

     FILE 'STNGUIDE' ENTERED AT 13:53:16 ON 24 SEP 2009

     FILE 'HCAPLUS' ENTERED AT 13:54:58 ON 24 SEP 2009

     FILE 'WPIX' ENTERED AT 13:55:12 ON 24 SEP 2009
                SAVE TEMP L2 PAG520WPIAPP/A

     FILE 'STNGUIDE' ENTERED AT 13:55:26 ON 24 SEP 2009

     FILE 'REGISTRY' ENTERED AT 13:55:36 ON 24 SEP 2009

     FILE 'HCAPLUS' ENTERED AT 13:55:40 ON 24 SEP 2009
L3              TRA PLU=ON  L1 1- RN :      82 TERMS

     FILE 'REGISTRY' ENTERED AT 13:55:40 ON 24 SEP 2009
L4            82 SEA SPE=ON  ABB=ON  PLU=ON  L3
                SAVE TEMP L4 PAG520REGAPP/A

     FILE 'STNGUIDE' ENTERED AT 14:01:34 ON 24 SEP 2009

     FILE 'STNGUIDE' ENTERED AT 15:08:06 ON 24 SEP 2009
                D SAVED

     FILE 'LREGISTRY' ENTERED AT 15:08:46 ON 24 SEP 2009
L5              STR

     FILE 'REGISTRY' ENTERED AT 15:17:06 ON 24 SEP 2009
L6             0 SEA SSS SAM L5

     FILE 'LREGISTRY' ENTERED AT 15:17:28 ON 24 SEP 2009
```

```
L7              STR L5

     FILE 'REGISTRY' ENTERED AT 15:18:40 ON 24 SEP 2009
L8            1 SEA SSS SAM L7
                D SCAN

     FILE 'LREGISTRY' ENTERED AT 15:19:08 ON 24 SEP 2009
L9              STR L7

     FILE 'REGISTRY' ENTERED AT 15:19:25 ON 24 SEP 2009
L10           0 SEA SSS SAM L9

     FILE 'STNGUIDE' ENTERED AT 15:20:24 ON 24 SEP 2009

     FILE 'REGISTRY' ENTERED AT 15:21:28 ON 24 SEP 2009
L11           1 SEA SUB=L4 SSS SAM L5
                D SCAN

     FILE 'REGISTRY' ENTERED AT 15:21:58 ON 24 SEP 2009
                SAVE TEMP L9 PAG520PSTR/Q
L12          57 SEA SPE=ON  ABB=ON  PLU=ON  L4 AND C6/ES
                D SCAN

     FILE 'STNGUIDE' ENTERED AT 15:23:09 ON 24 SEP 2009

     FILE 'HCAPLUS' ENTERED AT 15:23:47 ON 24 SEP 2009
L13       86511 SEA SPE=ON  ABB=ON  PLU=ON  L12

     FILE 'STNGUIDE' ENTERED AT 15:23:52 ON 24 SEP 2009
                D QUE STAT L11

     FILE 'STNGUIDE' ENTERED AT 15:24:12 ON 24 SEP 2009
                D QUE STAT L10

     FILE 'REGISTRY' ENTERED AT 15:28:55 ON 24 SEP 2009
L14           1 SEA SUB=L4 SSS SAM L5
                D SCAN
L15          28 SEA SUB=L4 SSS FUL L5
                SAVE TEMP L15 PAG520PSET1/A
                D SCAN
                SELECT L15 1- RN
L16         270 SEA SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR 1007839-72-6/C
                RN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR 1007839-91-9/CRN
                OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR 1007839-96-4/CRN OR
                1007840-16-5/CRN OR 1007840-17-6/CRN OR 1007840-18-7/CRN OR
                1007840-19-8/CRN OR 1007840-20-1/CRN OR 1007840-21-2/CRN OR
                1007840-22-3/CRN OR 1007840-23-4/CRN OR 1007840-24-5/CRN OR
                1007849-27-5/CRN OR 159252-66-1/CRN OR 21799-87-1/CRN OR
                51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-8/CRN OR 60630-38-
                8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR 79122-68-2/CRN OR
                88-46-0/CRN)
L17           2 SEA SPE=ON  ABB=ON  PLU=ON  (21799-87-1 OR 88-46-0)/RN
                D SCAN
L18         293 SEA SPE=ON  ABB=ON  PLU=ON  L15 OR L16
                SAVE TEMP L18 PAG520CROSS/A

     FILE 'STNGUIDE' ENTERED AT 15:38:22 ON 24 SEP 2009
                D SAVED

     FILE 'WPIX' ENTERED AT 15:39:29 ON 24 SEP 2009
```

```
L19             1 SEA SSS SAM L5
L20             0 SEA SSS SAM L9
                  SELECT L2 1- DCR
L21            34 SEA SPE=ON  ABB=ON  PLU=ON  (1595296-K/AN.S OR 1595296-M/AN.S
                  OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K/AN.S OR
                  1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR 9091-U/AN.S OR
                  DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/AN.S OR
                  DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S OR
                  DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S OR
                  DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR
                  DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR
                  DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR
                  DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR
                  DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR
                  DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/A
                  N.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR
                  DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/
                  AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR
                  12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.
                  S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR
                  1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K
                  /AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR
                  1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M
                  /AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR
                  1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K
                  /AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR
                  1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M
                  /AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR
                  1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/
                  AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR
                  528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR
                  86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
                  91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
                  OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
                  )
                  D TRI 1-34
                  SAVE TEMP L21 PAG520WPIANS/A

FILE 'STNGUIDE' ENTERED AT 15:46:16 ON 24 SEP 2009
                  D SAVED
                  D QUE L1
                  D QUE L2
                  D QUE L4
                  D QUE STAT L15
                  D QUE L18
                  D QUE NOS L18
                  D QUE L21


FILE HOME

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 18, 2009 (20090918/UP).

FILE ZCAPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
```

FILE COVERS 1907 - 24 Sep 2009 VOL 151 ISS 13
FILE LAST UPDATED: 23 Sep 2009 (20090923/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

FILE HCAPLUS

FILE COVERS 1907 - 24 Sep 2009 VOL 151 ISS 13
FILE LAST UPDATED: 23 Sep 2009 (20090923/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

FILE WPIX
FILE LAST UPDATED: 18 SEP 2009 <20090918/UP>
MOST RECENT UPDATE: 200960 <200960/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.4 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
and FI-Terms have been updated with reclassifications to
mid-June 2009.
No update date (UP) has been created for the reclassified
documents, but they can be identified by
specific update codes (see HELP CLA for details)<<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdate

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2009 HIGHEST RN 1186189-89-8
DICTIONARY FILE UPDATES: 23 SEP 2009 HIGHEST RN 1186189-89-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE LREGISTRY
LREGISTRY IS A STATIC LEARNING FILE

CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

```
=> => d que stat l10
L6  (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L7               SEL  PLU=ON  L6 1- RN :      82 TERMS
L8  (        82)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L7
L9               STR
```




```
VAR G1=10/12/14/17/28/31
VAR G2=OH/38/40/11/36
VAR G3=OH/38/40/11/36
VAR G10=10/12/35
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT  41
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  41

STEREO ATTRIBUTES: NONE
L10          28 SEA FILE=REGISTRY SUB=L8 SSS FUL L9

100.0% PROCESSED      42 ITERATIONS                          28 ANSWERS
SEARCH TIME: 00.00.01


=> d que nos l17
L11 (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L12              SEL  PLU=ON  L11 1- RN :      82 TERMS
L13 (        82)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L12
L14              STR
L15 (        28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 (       270)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR
                 1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
                 1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
                 1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
                 1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
                 1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
                 1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
                 21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
                 8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
```

```
                79122-68-2/CRN OR 88-46-0/CRN)
L17         293 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L15 OR L16


=> d que nos l18
L11 (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L12               SEL  PLU=ON  L11 1- RN :      82 TERMS
L13 (        82)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L12
L14               STR
L15 (        28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 (       270)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR
                1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
                1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
                1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
                1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
                1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
                1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
                21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
                8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
                79122-68-2/CRN OR 88-46-0/CRN)
L17         293 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L15 OR L16
L18         129 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L17 NOT PMS/CI


=> d que nos l71
L11 (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L12               SEL  PLU=ON  L11 1- RN :      82 TERMS
L13 (        82)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L12
L14               STR
L15 (        28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 (       270)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR
                1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
                1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
                1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
                1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
                1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
                1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
                21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
                8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
                79122-68-2/CRN OR 88-46-0/CRN)
L17         293 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L15 OR L16
L18         129 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L17 NOT PMS/CI
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
```

```
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L53             QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54             QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L57             QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L58             QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L59         780 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L18
L60          11 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 (L)((L53 OR L54
                OR L55 OR L56))
L61          10 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L58
L62           6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L57
L63             QUE  SPE=ON  ABB=ON  PLU=ON  "DERMATOLOGICAL AGENTS"+PFT,
                OLD,NEW/CT
L64           3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L63
L65           1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L64 AND (L55 OR L56)
L66           7 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND (L55 OR L56)
L67          20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L60 OR L61 OR L62)
                OR (L64 OR L65 OR L66)
L68          20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L67 AND (L53 OR L54
                OR L55 OR L56)
L69          20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L67 OR L68)
L70          14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L69 AND (L21 OR L22
                OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
                OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
                OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
                OR L50 OR L51)
L71           6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L69 NOT L70


=> d que stat l114
L9              STR
```



VAR G1=10/12/14/17/28/31
VAR G2=OH/38/40/11/36
VAR G3=OH/38/40/11/36
VAR G10=10/12/35
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 41
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE
L19 34 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (1595296-K/AN.S OR 1595296-M/AN.S OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K/AN.S OR 1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR 9091-U/AN.S OR DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/AN.S OR DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S OR DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S OR DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/AN.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR 12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR 1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K/AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR 1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M/AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR 1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K/AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR 1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M/AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR 1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR 528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR

86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR 91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S)

L106 1009 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (R00180/SDCN OR R03057/SDCN OR R10974/SDCN OR R18653/SDCN OR R18808/SDCN OR RACANB/SDCN OR RACRCN/SDCN OR RACRCO/SDCN OR RACRCQ/SDCN OR RACRCY/SDCN OR RACRCZ/SDCN OR RACRDB/SDCN OR RACRDC/SDCN OR RACRDE/SDCN OR RACRDF/SDCN OR RACRDG/SDCN OR RACRDH/SDCN OR RACRDN/SDCN OR RACRDO/SDCN OR RACRDQ/SDCN OR RACRDR/SDCN OR RACRDS/SDCN OR RACRDV/SDCN OR RACRD0/SDCN OR RADRS8/SDCN OR RAF0PZ/SDCN OR RA0DJE/SDCN OR RA0HDM/SDCN OR RA00C8/SDCN OR RA00GT/SDCN OR RA00H3/SDCN OR RA00TQ/SDCN OR RA012O/SDCN OR RA0120/SDCN OR RA02SP/SDCN OR RA04OB/SDCN OR RA088T/SDCN OR RA1HNP/SDCN OR RA1YR6/SDCN OR RA6EV7/SDCN OR R00076/SDCN OR R00122/SDCN OR R00137/SDCN OR R00291/SDCN OR R00689/SDCN OR R01330/SDCN OR R01987/SDCN OR R02044/SDCN OR R02049/SDCN OR R02069/SDCN OR R03442/SDCN OR R04259/SDCN OR R06973/SDCN OR R09011/SDCN OR R10769/SDCN OR R11063/SDCN OR R12996/SDCN OR R20748/SDCN OR R21749/SDCN OR R23692/SDCN OR RAAJSH/SDCN OR RAALE1/SDCN OR RAAMCC/SDCN OR RAAMCD/SDCN OR RAAMCE/SDCN OR RAAMCF/SDCN OR RAAMCG/SDCN OR RAAMCI/SDCN OR RAAMCK/SDCN OR RAAMCN/SDCN OR RAAMCO/SDCN OR RAAMCP/SDCN OR RAAMCQ/SDCN OR RAAMCR/SDCN OR RAAMCS/SDCN OR RAAMCT/SDCN OR RAAMCW/SDCN OR RAAMCX/SDCN OR RAAMCY/SDCN OR RAAMCZ/SDCN OR RAAMDF/SDCN OR RAAMDG/SDCN OR RAAMDJ/SDCN OR RAAMDL/SDCN OR RAAMDM/SDCN OR RAAMDN/SDCN OR RAAMDO/SDCN OR RAAMDP/SDCN OR RAAMDR/SDCN OR RAAMDS/SDCN OR RAAMDT/SDCN OR RAAMDU/SDCN OR RAAMD0/SDCN OR RAAMD1/SDCN OR RAAMD2/SDCN OR RAAMD6/SDCN OR RAAM1I/SDCN OR RAAM1J/SDCN OR RAAM1K/SDCN OR RAAM1L/SDCN OR RAAM1M/SDCN OR RAAM1N/SDCN OR RAAM1O/SDCN OR RAAM1P/SDCN OR RAAM1Q/SDCN OR RAAM1R/SDCN OR RAAM1S/SDCN OR RAAM1T/SDCN OR RAAM1U/SDCN OR RAAM1V/SDCN OR RAAM1W/SDCN OR RAAM1X/SDCN OR RAAM1Y/SDCN OR RAAM1Z/SDCN OR RAAM2A/SDCN OR RAAM2B/SDCN OR RAAM2C/

L107 418 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA02SP/SDCN OR R18653/SDCN OR R01614/SDCN OR R04292/SDCN OR R13080/SDCN OR R23692/SDCN OR RA0DWB/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA01SC/SDCN OR RA02JW/SDCN OR RA04OB/SDCN OR RA1C7N/SDCN OR RA28R6/SDCN OR RA5D1M/SDCN OR R00095/SDCN OR R00298/SDCN OR R03361/SDCN OR R04116/SDCN OR R04227/SDCN OR R04654/SDCN OR R09668/SDCN OR RA0K9J/SDCN OR RA00C8/SDCN OR RA01E9/SDCN OR RA1HNP/SDCN OR RA43CA/SDCN OR RA74YB/SDCN OR RA74YC/SDCN OR RA74YE/SDCN OR RA74YZ/SDCN OR RA74Y7/SDCN OR RA74Y8/SDCN OR RA74ZA/SDCN OR RA74ZI/SDCN OR RA74ZY/SDCN OR RA74ZZ/SDCN OR RA74Z0/SDCN OR RA74Z1/SDCN OR RA74Z2/SDCN OR RA74Z3/SDCN OR RA74Z4/SDCN OR RA74Z5/SDCN OR RA74Z7/SDCN OR RA74Z8/SDCN OR RA74Z9/SDCN OR RA750A/SDCN OR RA750B/SDCN OR RA7500/SDCN OR RA7501/SDCN OR RA7502/SDCN OR RA7503/SDCN OR RA7505/SDCN OR RA7506/SDCN OR RA7507/SDCN OR RA7508/SDCN OR R00271/SDCN OR R00991/SDCN OR RA0CGV/SDCN OR RA0C4V/SDCN OR RA0HNY/SDCN OR RA0IKS/SDCN OR RA0KH3/SDCN OR RA0LMH/SDCN OR RA0MTA/SDCN OR RA0WLX/SDCN OR RA006H/SDCN OR RA01BE/SDCN OR RA01Q7/SDCN OR RA01SX/SDCN OR RA015V/SDCN OR RA02DZ/SDCN OR RA021Q/SDCN OR RA027G/SDCN OR RA027I/SDCN OR RA027J/SDCN OR RA03SR/SDCN OR RA03YX/SDCN OR RA03YY/SDCN OR RA05GM/SDCN OR RA05JM/SDCN OR RA05WC/SDCN OR RA07GX/SDCN OR RA1HN1/SDCN OR RA1QEQ/SDCN OR RA1QSX/SDCN OR RA1YFH/SDCN OR RA13IL/SDCN OR RA13XQ/SDCN OR RA152R/SDCN OR RA18TQ/SDCN OR RA2VNT/SDCN OR RA20DZ/SDCN OR RA3ITX/SDCN OR RA3SGW/SDCN OR RA41J1/SDCN OR RA44DH/SDCN OR RA6SD5/SDCN OR RA6VEH/SDCN OR RA6VEI/SDCN OR RA6VEJ/SDCN OR RA6VEK/SDCN OR

```
                RA6VEL/SDCN OR RA6VEM/SDCN OR RA6VEN/SDCN OR RA6VEO/SDCN OR
                RA6VEP/SDCN OR RA6VER/SDCN OR RA6VES/SDCN OR RA6VET/SDCN OR
                RA6VEU/SDCN OR RA6VEV/SDCN OR RA6VEW/SDCN OR RA6VEX/SDCN OR
                RA6VEY/SDCN OR RA6VEZ/SDCN OR RA6VFA/SDCN OR RA6VFB/SDCN OR
                RA6VFC/SDCN OR RA6VFD/SDCN OR RA6VFE/SDCN OR RA6VFF/SDCN OR
                RA6VFG/SDCN OR RA6VFH/SDCN OR RA6VFI/SDCN OR RA6VFJ/SDCN OR
                RA6VFK/SDCN OR RA6VFL
L108         324 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (RA00C8/SDCN OR RA0ETL/SD
                CN OR RA0ETQ/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA0K9J/SDCN
                OR RA0YL4/SDCN OR RA00GT/SDCN OR RA02JW/SDCN OR RA02SP/SDCN OR
                RA04OB/SDCN OR RA1HNP/SDCN OR RA28R6/SDCN OR RA43CA/SDCN OR
                R00477/SDCN OR R00669/SDCN OR R01119/SDCN OR R03562/SDCN OR
                R04115/SDCN OR R04292/SDCN OR R09668/SDCN OR R13080/SDCN OR
                R18653/SDCN OR R23692/SDCN OR RA00H1/SDCN OR RA00NS/SDCN OR
                RA01SC/SDCN OR RA012P/SDCN OR RA043B/SDCN OR RA043C/SDCN OR
                RA043E/SDCN OR RA043F/SDCN OR RA043G/SDCN OR RA043H/SDCN OR
                RA043I/SDCN OR RA043J/SDCN OR RA043K/SDCN OR RA043L/SDCN OR
                RA043M/SDCN OR RA043N/SDCN OR RA043O/SDCN OR RA043P/SDCN OR
                RA1C7N/SDCN OR RA1ILG/SDCN OR RA1ILH/SDCN OR RA1ILU/SDCN OR
                RA1ILW/SDCN OR RA1ILX/SDCN OR RA1ILY/SDCN OR RA1ILZ/SDCN OR
                RA1IMB/SDCN OR RA1IMK/SDCN OR RA1IMO/SDCN OR RA1IM0/SDCN OR
                RA1IM2/SDCN OR RA1IM4/SDCN OR RA1IM9/SDCN OR RA1INB/SDCN OR
                RA1IND/SDCN OR RA1IN0/SDCN OR RA1IN2/SDCN OR RA1IN5/SDCN OR
                RA1IN6/SDCN OR RA1IN7/SDCN OR RA1OOA/SDCN OR RA1OOC/SDCN OR
                RA1OOD/SDCN OR RA1OOF/SDCN OR RA1OO0/SDCN OR RA1OO2/SDCN OR
                RA1OO3/SDCN OR RA1OO4/SDCN OR RA1OO5/SDCN OR RA1OO6/SDCN OR
                RA1OO7/SDCN OR RA1OO8/SDCN OR RA1OO9/SDCN OR RA1WSI/SDCN OR
                RA1WSJ/SDCN OR RA1WSQ/SDCN OR RA1WTY/SDCN OR RA17JY/SDCN OR
                RA17KF/SDCN OR RA17KG/SDCN OR RA17K3/SDCN OR RA195G/SDCN OR
                RA195H/SDCN OR RA195I/SDCN OR RA195J/SDCN OR RA195K/SDCN OR
                RA195L/SDCN OR RA195M/SDCN OR RA195N/SDCN OR RA195O/SDCN OR
                RA2FSP/SDCN OR RA250K/SDCN OR RA250R/SDCN OR RA250S/SDCN OR
                RA250T/SDCN OR RA250V/SDCN OR RA250W/SDCN OR RA250X/SDCN OR
                RA250Y/SDCN OR RA2510/SDCN OR RA2511/SDCN OR RA2512/SDCN OR
                RA2513/SDCN OR RA2514/SDCN OR RA2515/SDCN OR RA2516/SDCN OR
                RA2517/SDCN OR RA2518/SDCN OR RA2519/SDCN OR RA33DB/SDCN OR
                RA33DC/SDCN OR RA33DD/SDCN OR RA33DO/SDCN OR RA33DP/SDCN OR
                RA33DW/SDCN OR RA33D7/SDCN OR RA33D8/SDCN OR RA33EN/SDCN OR
                RA33ER/SDCN OR RA33ES/SDCN OR RA33E1/S
L109        1658 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (L106 OR L107 OR L108)
L112        1685 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L109 OR L19
L114          22 SEA FILE=WPIX SUB=L112 SSS FUL L9

100.0% PROCESSED     436 ITERATIONS                          22 ANSWERS
SEARCH TIME: 00.00.08


=> d que l123
L9              STR
```



VAR G1=10/12/14/17/28/31
VAR G2=OH/38/40/11/36
VAR G3=OH/38/40/11/36
VAR G10=10/12/35
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 41
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 41

STEREO ATTRIBUTES: NONE
L19 34 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (1595296-K/AN.S OR 1595296-M/AN.S OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K/AN.S OR 1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR 9091-U/AN.S OR DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/AN.S OR DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S OR DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S OR DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/AN.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR 12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR 1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K/AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR 1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M/AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR 1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K/AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR 1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M/AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR 1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR 528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR

```
                86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
                91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
                OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
                )
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L53             QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54             QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L58             QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L74             QUE  SPE=ON  ABB=ON  PLU=ON  (B14-N17C OR C14-N17C OR B12
                -A07 OR C12-A07)/MC
L106       1009 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (R00180/SDCN OR R03057/SD
                CN OR R10974/SDCN OR R18653/SDCN OR R18808/SDCN OR RACANB/SDCN
                OR RACRCN/SDCN OR RACRCO/SDCN OR RACRCQ/SDCN OR RACRCY/SDCN OR
                RACRCZ/SDCN OR RACRDB/SDCN OR RACRDC/SDCN OR RACRDE/SDCN OR
                RACRDF/SDCN OR RACRDG/SDCN OR RACRDH/SDCN OR RACRDN/SDCN OR
                RACRDO/SDCN OR RACRDQ/SDCN OR RACRDR/SDCN OR RACRDS/SDCN OR
                RACRDV/SDCN OR RACRD0/SDCN OR RADRS8/SDCN OR RAF0PZ/SDCN OR
                RA0DJE/SDCN OR RA0HDM/SDCN OR RA00C8/SDCN OR RA00GT/SDCN OR
                RA00H3/SDCN OR RA00TQ/SDCN OR RA012O/SDCN OR RA0120/SDCN OR
                RA02SP/SDCN OR RA04OB/SDCN OR RA088T/SDCN OR RA1HNP/SDCN OR
                RA1YR6/SDCN OR RA6EV7/SDCN OR R00076/SDCN OR R00122/SDCN OR
                R00137/SDCN OR R00291/SDCN OR R00689/SDCN OR R01330/SDCN OR
                R01987/SDCN OR R02044/SDCN OR R02049/SDCN OR R02069/SDCN OR
                R03442/SDCN OR R04259/SDCN OR R06973/SDCN OR R09011/SDCN OR
                R10769/SDCN OR R11063/SDCN OR R12996/SDCN OR R20748/SDCN OR
                R21749/SDCN OR R23692/SDCN OR RAAJSH/SDCN OR RAALE1/SDCN OR
```

RAAMCC/SDCN OR RAAMCD/SDCN OR RAAMCE/SDCN OR RAAMCF/SDCN OR RAAMCG/SDCN OR RAAMCI/SDCN OR RAAMCK/SDCN OR RAAMCN/SDCN OR RAAMCO/SDCN OR RAAMCP/SDCN OR RAAMCQ/SDCN OR RAAMCR/SDCN OR RAAMCS/SDCN OR RAAMCT/SDCN OR RAAMCW/SDCN OR RAAMCX/SDCN OR RAAMCY/SDCN OR RAAMCZ/SDCN OR RAAMDF/SDCN OR RAAMDG/SDCN OR RAAMDJ/SDCN OR RAAMDL/SDCN OR RAAMDM/SDCN OR RAAMDN/SDCN OR RAAMDO/SDCN OR RAAMDP/SDCN OR RAAMDR/SDCN OR RAAMDS/SDCN OR RAAMDT/SDCN OR RAAMDU/SDCN OR RAAMD0/SDCN OR RAAMD1/SDCN OR RAAMD2/SDCN OR RAAMD6/SDCN OR RAAM1I/SDCN OR RAAM1J/SDCN OR RAAM1K/SDCN OR RAAM1L/SDCN OR RAAM1M/SDCN OR RAAM1N/SDCN OR RAAM1O/SDCN OR RAAM1P/SDCN OR RAAM1Q/SDCN OR RAAM1R/SDCN OR RAAM1S/SDCN OR RAAM1T/SDCN OR RAAM1U/SDCN OR RAAM1V/SDCN OR RAAM1W/SDCN OR RAAM1X/SDCN OR RAAM1Y/SDCN OR RAAM1Z/SDCN OR RAAM2A/SDCN OR RAAM2B/SDCN OR RAAM2C/

L107 418 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA02SP/SDCN OR R18653/SDCN OR R01614/SDCN OR R04292/SDCN OR R13080/SDCN OR R23692/SDCN OR RA0DWB/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA01SC/SDCN OR RA02JW/SDCN OR RA04OB/SDCN OR RA1C7N/SDCN OR RA28R6/SDCN OR RA5D1M/SDCN OR R00095/SDCN OR R00298/SDCN OR R03361/SDCN OR R04116/SDCN OR R04227/SDCN OR R04654/SDCN OR R09668/SDCN OR RA0K9J/SDCN OR RA00C8/SDCN OR RA01E9/SDCN OR RA1HNP/SDCN OR RA43CA/SDCN OR RA74YB/SDCN OR RA74YC/SDCN OR RA74YE/SDCN OR RA74YZ/SDCN OR RA74Y7/SDCN OR RA74Y8/SDCN OR RA74ZA/SDCN OR RA74ZI/SDCN OR RA74ZY/SDCN OR RA74ZZ/SDCN OR RA74Z0/SDCN OR RA74Z1/SDCN OR RA74Z2/SDCN OR RA74Z3/SDCN OR RA74Z4/SDCN OR RA74Z5/SDCN OR RA74Z7/SDCN OR RA74Z8/SDCN OR RA74Z9/SDCN OR RA750A/SDCN OR RA750B/SDCN OR RA7500/SDCN OR RA7501/SDCN OR RA7502/SDCN OR RA7503/SDCN OR RA7505/SDCN OR RA7506/SDCN OR RA7507/SDCN OR RA7508/SDCN OR R00271/SDCN OR R00991/SDCN OR RA0CGV/SDCN OR RA0C4V/SDCN OR RA0HNY/SDCN OR RA0IKS/SDCN OR RA0KH3/SDCN OR RA0LMH/SDCN OR RA0MTA/SDCN OR RA0WLX/SDCN OR RA006H/SDCN OR RA01BE/SDCN OR RA01Q7/SDCN OR RA01SX/SDCN OR RA015V/SDCN OR RA02DZ/SDCN OR RA021Q/SDCN OR RA027G/SDCN OR RA027I/SDCN OR RA027J/SDCN OR RA03SR/SDCN OR RA03YX/SDCN OR RA03YY/SDCN OR RA05GM/SDCN OR RA05JM/SDCN OR RA05WC/SDCN OR RA07GX/SDCN OR RA1HN1/SDCN OR RA1QEQ/SDCN OR RA1QSX/SDCN OR RA1YFH/SDCN OR RA13IL/SDCN OR RA13XQ/SDCN OR RA152R/SDCN OR RA18TQ/SDCN OR RA2VNT/SDCN OR RA20DZ/SDCN OR RA3ITX/SDCN OR RA3SGW/SDCN OR RA41J1/SDCN OR RA44DH/SDCN OR RA6SD5/SDCN OR RA6VEH/SDCN OR RA6VEI/SDCN OR RA6VEJ/SDCN OR RA6VEK/SDCN OR RA6VEL/SDCN OR RA6VEM/SDCN OR RA6VEN/SDCN OR RA6VEO/SDCN OR RA6VEP/SDCN OR RA6VER/SDCN OR RA6VES/SDCN OR RA6VET/SDCN OR RA6VEU/SDCN OR RA6VEV/SDCN OR RA6VEW/SDCN OR RA6VEX/SDCN OR RA6VEY/SDCN OR RA6VEZ/SDCN OR RA6VFA/SDCN OR RA6VFB/SDCN OR RA6VFC/SDCN OR RA6VFD/SDCN OR RA6VFE/SDCN OR RA6VFF/SDCN OR RA6VFG/SDCN OR RA6VFH/SDCN OR RA6VFI/SDCN OR RA6VFJ/SDCN OR RA6VFK/SDCN OR RA6VFL

L108 324 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA00C8/SDCN OR RA0ETL/SDCN OR RA0ETQ/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA0K9J/SDCN OR RA0YL4/SDCN OR RA00GT/SDCN OR RA02JW/SDCN OR RA02SP/SDCN OR RA04OB/SDCN OR RA1HNP/SDCN OR RA28R6/SDCN OR RA43CA/SDCN OR R00477/SDCN OR R00669/SDCN OR R01119/SDCN OR R03562/SDCN OR R04115/SDCN OR R04292/SDCN OR R09668/SDCN OR R13080/SDCN OR R18653/SDCN OR R23692/SDCN OR RA00H1/SDCN OR RA00NS/SDCN OR RA01SC/SDCN OR RA012P/SDCN OR RA043B/SDCN OR RA043C/SDCN OR RA043E/SDCN OR RA043F/SDCN OR RA043G/SDCN OR RA043H/SDCN OR RA043I/SDCN OR RA043J/SDCN OR RA043K/SDCN OR RA043L/SDCN OR RA043M/SDCN OR RA043N/SDCN OR RA043O/SDCN OR RA043P/SDCN OR RA1C7N/SDCN OR RA1ILG/SDCN OR RA1ILH/SDCN OR RA1ILU/SDCN OR RA1ILW/SDCN OR RA1ILX/SDCN OR RA1ILY/SDCN OR RA1ILZ/SDCN OR

```
                RA1IMB/SDCN OR RA1IMK/SDCN OR RA1IMO/SDCN OR RA1IM0/SDCN OR
                RA1IM2/SDCN OR RA1IM4/SDCN OR RA1IM9/SDCN OR RA1INB/SDCN OR
                RA1IND/SDCN OR RA1IN0/SDCN OR RA1IN2/SDCN OR RA1IN5/SDCN OR
                RA1IN6/SDCN OR RA1IN7/SDCN OR RA1OOA/SDCN OR RA1OOC/SDCN OR
                RA1OOD/SDCN OR RA1OOF/SDCN OR RA1OO0/SDCN OR RA1OO2/SDCN OR
                RA1OO3/SDCN OR RA1OO4/SDCN OR RA1OO5/SDCN OR RA1OO6/SDCN OR
                RA1OO7/SDCN OR RA1OO8/SDCN OR RA1OO9/SDCN OR RA1WSI/SDCN OR
                RA1WSJ/SDCN OR RA1WSQ/SDCN OR RA1WTY/SDCN OR RA17JY/SDCN OR
                RA17KF/SDCN OR RA17KG/SDCN OR RA17K3/SDCN OR RA195G/SDCN OR
                RA195H/SDCN OR RA195I/SDCN OR RA195J/SDCN OR RA195K/SDCN OR
                RA195L/SDCN OR RA195M/SDCN OR RA195N/SDCN OR RA195O/SDCN OR
                RA2FSP/SDCN OR RA250K/SDCN OR RA250R/SDCN OR RA250S/SDCN OR
                RA250T/SDCN OR RA250V/SDCN OR RA250W/SDCN OR RA250X/SDCN OR
                RA250Y/SDCN OR RA2510/SDCN OR RA2511/SDCN OR RA2512/SDCN OR
                RA2513/SDCN OR RA2514/SDCN OR RA2515/SDCN OR RA2516/SDCN OR
                RA2517/SDCN OR RA2518/SDCN OR RA2519/SDCN OR RA33DB/SDCN OR
                RA33DC/SDCN OR RA33DD/SDCN OR RA33DO/SDCN OR RA33DP/SDCN OR
                RA33DW/SDCN OR RA33D7/SDCN OR RA33D8/SDCN OR RA33EN/SDCN OR
                RA33ER/SDCN OR RA33ES/SDCN OR RA33E1/S
L109        1658 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (L106 OR L107 OR L108)
L112        1685 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L109 OR L19
L114          22 SEA FILE=WPIX SUB=L112 SSS FUL L9
L118          16 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (RASW2T/DCN OR RASW2U/DCN
                  OR RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW3A/DCN OR
                RASW3B/DCN OR RASW3C/DCN OR RASW3D/DCN OR RASW3E/DCN OR
                RASW3F/DCN OR RASW3G/DCN OR RASW3H/DCN OR RASW39/DCN OR
                RAUHHC/DCN OR RAUHHD/DCN OR RAUHHE/DCN OR RAUHHF/DCN OR
                RAUHHG/DCN OR RAUHHH/DCN OR RAUHH9/DCN OR RA2Y7A/DCN) OR
                L114/DCR
L119           6 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L118 AND (L58 OR L74 OR
                (L55 OR L56))
L120          14 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L118 AND (L53 OR L54 OR
                L55 OR L56)
L121          14 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (L119 OR L120)
L122          13 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L121 AND (L21 OR L22 OR
                L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
                L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR
                L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR
                L50 OR L51)
L123           1 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L121 NOT L122


=> d que stat l130
L126            STR
```



```
VAR G1=10/12/14/17/28/31
VAR G2=OH/38/40/11/36
VAR G3=OH/38/40/11/36
VAR G10=10/12
VAR G11=AK/43
NODE ATTRIBUTES:
CONNECT IS E2  RC AT  14
CONNECT IS E2  RC AT  17
CONNECT IS E2  RC AT  33
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT  41
GGCAT   IS UNS  AT  43
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  43

STEREO ATTRIBUTES: NONE
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)

100.0% PROCESSED  547534 ITERATIONS                          1799 ANSWERS
SEARCH TIME: 00.00.08



=> d que nos l131
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI


=> d que stat l143
L141            STR
```



REP G1=(0-6) CH2
VAR G2=OH/84/51/62/70/77
VAR G3=OH/84/51/62/70/77
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 86
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 54

STEREO ATTRIBUTES: NONE
L143   173 SEA FILE=REGISTRY SSS FUL L141

100.0% PROCESSED 140832 ITERATIONS   173 ANSWERS
SEARCH TIME: 00.00.03

=> d que stat l148
L141   STR



REP G1=(0-6) CH2
VAR G2=OH/84/51/62/70/77
VAR G3=OH/84/51/62/70/77
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 86
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 54

STEREO ATTRIBUTES: NONE
L143   173 SEA FILE=REGISTRY SSS FUL L141
L146   STR



REP G1=(0-6) CH2
VAR G2=OH/84/51/62/70/77
VAR G3=OH/84/51/62/70/77

```
NODE ATTRIBUTES:
CONNECT IS E1  RC AT  86
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC  42  52  63  71   2
NUMBER OF NODES IS  54

STEREO ATTRIBUTES: NONE
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146

100.0% PROCESSED     160 ITERATIONS                          160 ANSWERS
SEARCH TIME: 00.00.01



=> d que nos l150
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149


=> d que nos l179
L3  (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4              SEL  PLU=ON  L3 1- RN :      82 TERMS
L5           82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L179         28 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150


=> d que nos l166
L11 (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L12             SEL  PLU=ON  L11 1- RN :      82 TERMS
L13 (        82)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L12
L14             STR
L15 (        28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 (       270)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR
                1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
                1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
```

```
                1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
                1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
                1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
                1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
                21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
                8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
                79122-68-2/CRN OR 88-46-0/CRN)
L17          293 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L15 OR L16
L18          129 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L17 NOT PMS/CI
L21              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24              QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28              QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29              QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33              QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34              QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38              QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42              QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43              QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44              QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45              QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46              QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50              QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51              QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L53              QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54              QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L55              QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56              QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L57              QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L58              QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L59          780 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L18
L63              QUE  SPE=ON  ABB=ON  PLU=ON  "DERMATOLOGICAL AGENTS"+PFT,
                OLD,NEW/CT
L64            3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L63
L126             STR
L128             SCR 1812 OR 1758
L130        1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131        1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141             STR
L143         173 SEA FILE=REGISTRY SSS FUL L141
L144         170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145         146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
```

```
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L151       1760 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L150
L152         11 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L151 AND L58
L153          8 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L151 AND L57
L154          9 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L151 AND (L55 OR L56)

L155         14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L152 OR L153 OR
                L154)
L156            QUE  SPE=ON  ABB=ON  PLU=ON  "SKIN, DISEASE"+PFT,OLD,NEW,
                NT/CT
L157         95 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L151 AND (L156 OR L64
                OR (L53 OR L54 OR L55 OR L56 OR L57))
L158        316 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L151 (L)(THU OR PKT
                OR PAC OR DMA OR BAC)/RL
L159         63 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L157 AND L158
L160            QUE  SPE=ON  ABB=ON  PLU=ON  DISEAS? OR DISORDER? OR SYND
                ROM? OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB
                ? OR DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
L161         18 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L159 AND ((L53 OR
                L54) (3A) L160)
L162         27 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L155 OR L161
L163         27 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L162 AND ((L53 OR L54
                OR L55 OR L56 OR L57 OR L58) OR L64)
L164         27 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L162 OR L163)
L165         14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L164 AND (L21 OR L22
                OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
                OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
                OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
                OR L50 OR L51)
L166         13 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L164 NOT L165


=> d his l214

     (FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:20:08 ON 25 SEP 2009)
L214          2 S L212 NOT L213

=> d que nos l214
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
```

```
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L186            QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS
L204            QUE  SPE=ON  ABB=ON  PLU=ON  WILLAN (1A) LEPRA
L205            QUE  SPE=ON  ABB=ON  PLU=ON  PARAPSORIA?
L210        333 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L150 AND (USPATFULL
                OR USPAT2 OR USPATOLD)/LC
L211        409 SEA L210
L212          5 SEA L211 AND (L55/CLM OR L56/CLM OR L186/CLM OR L204/CLM OR
                L205/CLM)
L213          3 SEA L212 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
                L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
                L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
                L46 OR L47 OR L48 OR L49 OR L50 OR L51)
L214          2 SEA L212 NOT L213


=> d que stat l169
L126            STR
```



VAR G1=10/12/14/17/28/31
VAR G2=OH/38/40/11/36
VAR G3=OH/38/40/11/36
VAR G10=10/12
VAR G11=AK/43
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 14
CONNECT IS E2 RC AT 17
CONNECT IS E2 RC AT 33
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS AT 41
GGCAT   IS UNS AT 43
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE
L128   SCR 1812 OR 1758
L169   82 SEA FILE=WPIX SSS FUL (L128 AND L126)

100.0% PROCESSED   25989 ITERATIONS (3 INCOMPLETE)   82 ANSWERS
SEARCH TIME: 00.00.43

=> d que stat l171
L141   STR



REP G1=(0-6) CH2
VAR G2=OH/84/51/62/70/77
VAR G3=OH/84/51/62/70/77
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 86
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 54

STEREO ATTRIBUTES: NONE
L171   15 SEA FILE=WPIX SSS FUL L141

100.0% PROCESSED   6752 ITERATIONS   15 ANSWERS
SEARCH TIME: 00.00.10

=> d que nos l172
L126   STR
L128   SCR 1812 OR 1758
L141   STR
L169   82 SEA FILE=WPIX SSS FUL (L128 AND L126)
L171   15 SEA FILE=WPIX SSS FUL L141
L172   97 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON L169 OR L171

=> d que nos l178
L21   QUE SPE=ON ABB=ON PLU=ON CUEVAS SANCHEZ, P?/AU,AUTH
L22   QUE SPE=ON ABB=ON PLU=ON CUEVASSANCHEZ, P?/AU,AUTH
L23   QUE SPE=ON ABB=ON PLU=ON CUEVAS, P?/AU,AUTH
L24   QUE SPE=ON ABB=ON PLU=ON SANCHEZ, P?/AU,AUTH
L25   QUE SPE=ON ABB=ON PLU=ON GIMENEZ GALLEGO, G?/AU,AUTH
L26   QUE SPE=ON ABB=ON PLU=ON GIMENEZGALLEGO, G?/AU,AUTH
L27   QUE SPE=ON ABB=ON PLU=ON GIMENEZ, G?/AU,AUTH
L28   QUE SPE=ON ABB=ON PLU=ON GALLEGO, G?/AU,AUTH
L29   QUE SPE=ON ABB=ON PLU=ON MORGAN, I?/AU,AUTH

```
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L53             QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54             QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L58             QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L74             QUE  SPE=ON  ABB=ON  PLU=ON  (B14-N17C OR C14-N17C OR B12
                -A07 OR C12-A07)/MC
L126            STR
L128            SCR 1812 OR 1758
L141            STR
L160            QUE  SPE=ON  ABB=ON  PLU=ON  DISEAS? OR DISORDER? OR SYND
                ROM? OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB
                ? OR DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
L169         82 SEA FILE=WPIX SSS FUL (L128 AND L126)
L171         15 SEA FILE=WPIX SSS FUL L141
L172         97 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L169 OR L171
L173        122 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (RABCOA/DCN OR RABCO3/DCN
                 OR RABCO8/DCN OR RABCO9/DCN OR RABNDP/DCN OR RABNDQ/DCN OR
                RAGHZJ/DCN OR RAGHZM/DCN OR RAHO0Q/DCN OR RAI7ME/DCN OR
                RAKQX2/DCN OR RALH0H/DCN OR RAL3SN/DCN OR RAL3SO/DCN OR
                RAL3SP/DCN OR RAL3SQ/DCN OR RAL3SR/DCN OR RAL3ST/DCN OR
                RANFVN/DCN OR RAN401/DCN OR RAN403/DCN OR RAPVAI/DCN OR
                RAPVAJ/DCN OR RAPVAK/DCN OR RAQW9I/DCN OR RAQW9P/DCN OR
                RAQW9R/DCN OR RAR1ZL/DCN OR RASW2T/DCN OR RASW2U/DCN OR
                RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW2Y/DCN OR
                RASW2Z/DCN OR RASW3A/DCN OR RASW3B/DCN OR RASW3C/DCN OR
                RASW3D/DCN OR RASW3E/DCN OR RASW3F/DCN OR RASW3G/DCN OR
                RASW3H/DCN OR RASW30/DCN OR RASW38/DCN OR RASW39/DCN OR
                RASW4A/DCN OR RASW50/DCN OR RASXL7/DCN OR RAUHHC/DCN OR
                RAUHHD/DCN OR RAUHHE/DCN OR RAUHHF/DCN OR RAUHHG/DCN OR
                RAUHHH/DCN OR RAUHH9/DCN OR RAUVSQ/DCN OR RAUVSR/DCN OR
                RAWFMV/DCN OR RAWUPX/DCN OR RAW47P/DCN OR RAW47Q/DCN OR
                RAW47R/DCN OR RAW47S/DCN OR RAW47T/DCN OR RAW47U/DCN OR
                RAXSIA/DCN OR RA0MNZ/DCN OR RA002O/DCN OR RA007X/DCN OR
                RA0083/DCN OR RA2NB0/DCN OR RA2Y7A/DCN OR RA3MBV/DCN OR
                RA4GNI/DCN OR RA4GOC/DCN OR RA4GOL/DCN OR RA4KMT/DCN OR
```

```
                RA4KMZ/DCN OR RA4KN3/DCN OR RA4KN4/DCN OR RA4NBT/DCN OR
                RA4NBW/DCN OR RA6Q5K/DCN OR RA63TX/DCN OR RA660M/DCN OR
                RA8AOM/DCN OR RA9JSH/DCN OR RA9JSI/DCN OR RA9XSQ/DCN OR
                RB0D0S/DCN OR RB0D0T/DCN OR RB0D0U/DCN OR RB0D0V/DCN OR
                R11693/DCN OR R11694/DCN OR R20556/DCN OR R21482/DCN) OR
                L172/DCR
L174          10 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L173 AND (L58 OR L74 OR
                (L55 OR L56))
L175           7 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L174 AND (L21 OR L22 OR
                L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
                L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR
                L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR
                L50 OR L51)
L176           3 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L174 NOT L175
L177           3 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L176 AND ((L53 OR L54 OR
                L55 OR L56) OR L160)
L178           3 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (L176 OR L177)


=> d que nos l190
L3   (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4               SEL  PLU=ON  L3 1- RN :      82 TERMS
L5            82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4
L21              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24              QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28              QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29              QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33              QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34              QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38              QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42              QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43              QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44              QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45              QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46              QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50              QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51              QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L55              QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56              QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L126             STR
L128             SCR 1812 OR 1758
```

```
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L179         28 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150
L180          7 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L150 AND MEDLINE/LC
L181        392 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L180
L182            SEL  PLU=ON  L179 1- NAME :      13 TERMS
L183         17 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L182
L184        399 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L181 OR L183
L185            QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L186            QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS
L187            QUE  SPE=ON  ABB=ON  PLU=ON  "SKIN DISEASES, PAPULOSQUAMO
                US"+PFT,OLD,NEW,NT/CT
L188          1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L184 AND ((L55 OR
                L56) OR L185 OR (L186 OR L187))
L189          1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L188 AND (L21 OR L22
                OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
                OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
                OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
                OR L50 OR L51)
L190          0 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L188 NOT L189


=> d que nos l199
L3  (          5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4              SEL  PLU=ON  L3 1- RN :      82 TERMS
L5             82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
```

```
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L179         28 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150
L182            SEL  PLU=ON  L179 1- NAME :      13 TERMS
L186            QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS
L191          4 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L150 AND EMBASE/LC
L192        794 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L191
L193         69 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L182
L194        838 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  (L192 OR L193)
L195            QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L196            QUE  SPE=ON  ABB=ON  PLU=ON  "ERYTHEMATOSQUAMOUS SKIN DIS
                EASE"+PFT,OLD,NEW,NT/CT
L197          2 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L194 AND ((L55 OR L56)
                OR L186 OR (L195 OR L196))
L198          1 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L197 AND (L21 OR L22
                OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
                OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
                OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
                OR L50 OR L51)
L199          1 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L197 NOT L198


=> d his l209

     (FILE 'BIOSIS, BIOTECHNO, CABA, DRUGU, VETU' ENTERED AT 11:16:26 ON 25
     SEP 2009)
L209          2 S L207 NOT L208

=> d que nos l209
L3  (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4              SEL  PLU=ON  L3 1- RN :      82 TERMS
L5            82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
```

```
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L53             QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54             QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L160            QUE  SPE=ON  ABB=ON  PLU=ON  DISEAS? OR DISORDER? OR SYND
                ROM? OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB
                ? OR DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
L179          28 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150
L182             SEL  PLU=ON  L179 1- NAME :      13 TERMS
L200          11 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L150 AND (BIOSIS OR
                BIOTECHNO OR CABA OR DRUGU OR VETU)/LC
L201        437 SEA L200
L202         45 SEA L182
L203        469 SEA (L201 OR L202)
L207          2 SEA L203 AND ((L53 OR L54) (5A) L160)
L208          0 SEA L207 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
                L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
                L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
                L46 OR L47 OR L48 OR L49 OR L50 OR L51)
L209          2 SEA L207 NOT L208


=> d his l218

     (FILE 'HCAPLUS, WPIX, PASCAL, JAPIO, MEDLINE, BIOSIS, EMBASE, CABA,
     CEABA-VTB, LIFESCI, KOSMET, BIOENG, BIOTECHNO, BIOTECHDS, DRUGU, DRUGB,
```

```
     VETU, VETB, SCISEARCH, CONFSCI, DISSABS, RDISCLOSURE' ENTERED AT 11:29:03
     ON 25 SEP 2009)
L218          1 S L216 NOT L217

     FILE 'STNGUIDE' ENTERED AT 11:33:45 ON 25 SEP 2009

     FILE 'REGISTRY' ENTERED AT 11:33:54 ON 25 SEP 2009

     FILE 'STNGUIDE' ENTERED AT 11:34:02 ON 25 SEP 2009

=> d que nos l218
L3  (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4              SEL  PLU=ON  L3 1- RN :      82 TERMS
L5            82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L58             QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
```

```
L149         133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150        1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L179          28 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150
L182             SEL  PLU=ON  L179 1- NAME :      13 TERMS
L186             QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS
L204             QUE  SPE=ON  ABB=ON  PLU=ON  WILLAN (1A) LEPRA
L205             QUE  SPE=ON  ABB=ON  PLU=ON  PARAPSORIA?
L215         425 SEA L182
L216          13 SEA L215 AND ((L55 OR L56) OR L186 OR (L204 OR L205) OR L58)
L217          12 SEA L216 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
                 L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
                 L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
                 L46 OR L47 OR L48 OR L49 OR L50 OR L51)
L218           1 SEA L216 NOT L217


=> dup rem l71 l123 l166 l214 l178 l190 l199 l209 l218
L190 HAS NO ANSWERS
DUPLICATE IS NOT AVAILABLE IN 'KOSMET, RDISCLOSURE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
FILE 'HCAPLUS' ENTERED AT 11:40:01 ON 25 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 11:40:01 ON 25 SEP 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 11:40:01 ON 25 SEP 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:40:01 ON 25 SEP 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:40:01 ON 25 SEP 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'DRUGU' ENTERED AT 11:40:01 ON 25 SEP 2009
COPYRIGHT (C) 2009 THOMSON REUTERS
PROCESSING COMPLETED FOR L71
PROCESSING COMPLETED FOR L123
PROCESSING COMPLETED FOR L166
PROCESSING COMPLETED FOR L214
PROCESSING COMPLETED FOR L178
PROCESSING COMPLETED FOR L190
PROCESSING COMPLETED FOR L199
PROCESSING COMPLETED FOR L209
PROCESSING COMPLETED FOR L218
L219          21 DUP REM L71 L123 L166 L214 L178 L190 L199 L209 L218 (8 DUPLICATES
REMOVED)
                 ANSWERS '1-15' FROM FILE HCAPLUS
                 ANSWERS '16-17' FROM FILE WPIX
                 ANSWERS '18-19' FROM FILE USPATFULL
                 ANSWER '20' FROM FILE EMBASE
                 ANSWER '21' FROM FILE DRUGU

=> file stnguide
FILE 'STNGUIDE' ENTERED AT 11:40:18 ON 25 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 18, 2009 (20090918/UP).

```
=> d ibib ed abs hitind hitstr 1-15
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' -
CONTINUE? (Y)/N:y



L219 ANSWER 1 OF 21  HCAPLUS  COPYRIGHT 2009 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2007:1163610  HCAPLUS  Full-text
DOCUMENT NUMBER:          148:69764
TITLE:                    Clinical study of calcium dobesilate in treatment of
                          diabetic skin ulcer
AUTHOR(S):                Liu, Qiliang; Hu, Jie; Zhang, Dengke; Fang, Degang
CORPORATE SOURCE:         163 Hospital of People's Liberation Army, Changsha,
                          410003, Peop. Rep. China
SOURCE:                   Yixue Linchuang Yanjiu (2007), 24(1), 59-60, 64
                          CODEN: YLYIAB; ISSN: 1671-7171
PUBLISHER:                Yixue Linchuang Yanjiu Zazhishe
DOCUMENT TYPE:            Journal
LANGUAGE:                 Chinese
ED   Entered STN:  16 Oct 2007
AB    The objective was to evaluate the efficacy and safety of calcium dobesilate in
      the treatment of diabetic skin ulcer.  Seventy-six cases of diabetic skin
      ulcer patients were randomly assigned to calcium dobesilate group or control
      group, 38 cases received oral calcium dobesilate, 38 cases received oral
      vitamin C.  The whole observation lasted 8 wk.  The efficacy of the calcium
      dobesilate group was much better than that of the control group, the total
      therapeutic effective rate was 94.74% in the calcium dobesilate group and
      52.63% in the control group (P<0.01).  NO adverse effect of liver and kidney
      function was found. Calcium dobesilate is effective and safe in the treatment
      of diabetic skin ulcer.
CC   1-10 (Pharmacology)
ST   diabetes mellitus complication skin ulcer sulfonic acid
IT   Diabetes mellitus
     Human
     Kidney
     Liver
       Skin, disease
         (clin. study of calcium dobesilate in treatment of diabetic
         skin ulcer)
IT   Sulfonic acids, biological studies
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (clin. study of calcium dobesilate in treatment of diabetic
        skin ulcer)
IT   50-81-7, Vitamin C, biological studies
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (clin. study of calcium dobesilate in treatment of diabetic
        skin ulcer)
IT   20123-80-2, Calcium dobesilate
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (clin. study of calcium dobesilate in treatment of diabetic
        skin ulcer)
IT   20123-80-2, Calcium dobesilate
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (clin. study of calcium dobesilate in treatment of diabetic
        skin ulcer)
```

RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

L219 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2005:238842 HCAPLUS Full-text
DOCUMENT NUMBER: 142:291452
TITLE: Modulating cell activity by using an agent that reduces the level of cholesterol within a cell
INVENTOR(S): Allen, Janet Marjorie; Overington, John Paul
PATENT ASSIGNEE(S): Inpharmatica Limited, UK
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023305	A2	20050317	WO 2004-GB3875	20040910
WO 2005023305	A3	20050616		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-21228 A 20030910
ED Entered STN: 18 Mar 2005
AB The invention discloses methods for modulating the activity of cells, and compns. useful in such methods. In particular, the invention relates to the use of an agent that reduces the level of cholesterol within a cell to modulate the activity of the cell, and to methods involving such use.
IC ICM A61K045-00
ICS A61K031-785; A61P037-00
CC 1-12 (Pharmacology)
Section cross-reference(s): 63
IT Dermatophagoides
Pet animal
Pollen

(allergy to; cell activity modulation with agent reducing level of cell cholesterol)

IT Dermatitis
(atopic; cell activity modulation with agent reducing level of cell cholesterol)

IT AIDS (disease)
Allergy
Allergy inhibitors
Alzheimer's disease
Analgesics
Animal cell
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-infective agents
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antibacterial agents
Anticholesteremic agents
Antidiabetic agents
Antihypertensives
Antimalarials
Antiparkinsonian agents
Antirheumatic agents
Antitumor agents
Antiulcer agents
Antiviral agents
Asthma
Atherosclerosis
Autoimmune disease
Burn
Campylobacter
Cell membrane
Chlamydia
Cirrhosis
Clostridium difficile
Clostridium tetani
Connective tissue, disease
Diabetes mellitus
Digestive tract, disease
Drug delivery systems
Drug screening
Dysmenorrhea
Ebola virus
Eczema
Emphysema
Escherichia coli
Fabry disease
Food allergy
Gastrointestinal agents
Gout
Headache
Hepatitis
Hepatitis virus
Herpesviridae
Human
Human herpesvirus
Human herpesvirus 4
Human immunodeficiency virus
Hypercholesterolemia

Hyperparathyroidism
Hypertension
Immunomodulators
Infection
Inflammation
Influenza virus
Injury
Leishmania
Listeria
Marburg virus
Mast cell
Measles virus
Multiple sclerosis
Muscular dystrophy
Mycobacterium tuberculosis
Myositis
Neoplasm
Nervous system agents
Osteoarthritis
Pain
Papillomavirus
Parasite
Parasiticides
Parkinson's disease
Pathogen
Phosphorylation, biological
Plasmodium (malarial genus)
Psoriasis
Respiratory syncytial virus
Rheumatoid arthritis
Salmonella
Sarcoidosis
Sepsis
Shigella
Signal transduction, biological
Sjogren syndrome
Toxoplasma gondii
Trypanosoma
Trypanosomicides
Urticaria
Vibrio cholerae
Wound
Wound healing promoters
(cell activity modulation with agent reducing level of cell cholesterol)

IT Dermatitis
(contact; cell activity modulation with agent reducing level of cell cholesterol)

IT Arthritis
(psoriatic arthritis; cell activity modulation with agent reducing level of cell cholesterol)

IT 51-26-3, Thyropropic acid 51-49-0, Dextrothyroxine 59-67-6D, Nicotinic acid, derivs. 64-18-6D, Formic acid, hydroxylated statin esters 64-19-7D, Acetic acid, hydroxylated statin esters 65-85-0D, Benzoic acid, hydroxylated statin esters 78-41-1, Triparanol 79-09-4D, Propanoic acid, hydroxylated statin esters 83-46-5, β-Sitosterol 90-26-6, α-Phenylbutyramide 107-92-6D, Butanoic acid, hydroxylated statin esters 109-52-4D, Pentanoic acid, hydroxylated statin esters 111-14-8D, Heptanoic acid, hydroxylated statin esters 112-05-0D, Nonanoic acid, hydroxylated statin esters 124-07-2D, Octanoic acid,

hydroxylated statin esters 142-62-1D, Hexan-1-oic acid, hydroxylated statin esters 334-48-5D, Decanoic acid, hydroxylated statin esters 503-49-1, Meglutol 541-15-1, Carnitine 597-71-7, Pentaerythritoltetraacetate 621-82-9D, Cinnamic acid, hydroxylated statin esters 637-07-0, Clofibrate 882-09-7, Clofibric acid 943-45-3D, Fibric acid, derivs. 959-10-4, Xenbucin 1239-29-8, Furazabol 1976-28-9 2398-81-4, Oxiniacic acid 5868-05-3, Niceritrol 6964-20-1, Tiadenol 9007-28-7, Chondroitin sulfate 9011-18-1, Dextran Sodium sulfate 9064-91-9, Detaxtran 10571-59-2, Nicoclonate 11041-12-6, Cholestyramine 11042-64-1, γ-Oryzanol 14417-88-0, Melinamide 14929-11-4, Simfibrate 16816-67-4, Pantethine 17365-01-4, Etiroxate 20568-07-4 23288-49-5, Probucol 23602-78-0, Benfluorex 23918-98-1, Eritadenine 25812-30-0, Gemfibrozil 27959-26-8, Nicomol 30299-08-2, Clinofibrate 31637-97-5, Etofibrate 32839-30-8, Eicosapentaenoic acid 41859-67-0, Bezafibrate 42597-57-9, Ronifibrate, biological studies 49562-28-9, Fenofibrate 50925-79-6, Colestipol 51037-30-0, Acipimox 52214-84-3, Ciprofibrate 54110-25-7, Pirozadil 54504-70-0, Theofibrate 55285-45-5, Pirifibrate 56227-39-5, Polidexide 57775-26-5, Sultosilic acid 69047-39-8, Binifibrate 72420-38-3, Acifran 73573-88-3, Mevastatin 73573-88-3D, Mevastatin, derivs. 75330-75-5, Lovastatin 75330-75-5D, Lovastatin, derivs. 79902-63-9, Simvastatin 79902-63-9D, Simvastatin, derivs. 81093-37-0, Pravastatin 81093-37-0D, Pravastatin, derivs. 93957-54-1, Fluvastatin 93957-54-1D, Fluvastatin, derivs. 134523-00-5, Atorvastatin 134523-00-5D, Atorvastatin, derivs. 145599-86-6, Cerivastatin 145599-86-6D, Cerivastatin, derivs. 147511-69-1, Pitavastatin 147511-69-1D, Pitavastatin, derivs. 163222-33-1, Ezetimibe 182815-44-7, Colesevelam hydrochloride 287714-41-4, Rosuvastatin 287714-41-4D, Rosuvastatin, derivs. 433289-84-0 847849-65-4 847849-66-5 847849-67-6 847849-68-7 847849-69-8 847849-69-8D, carboxylic acid esters 847849-70-1 847849-70-1D, carboxylic acid esters 847849-71-2 847849-71-2D, carboxylic acid esters 847849-72-3 847849-72-3D, carboxylic acid esters 847849-73-4 847849-73-4D, carboxylic acid esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cell activity modulation with agent reducing level of cell cholesterol)

IT 57775-26-5, Sultosilic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cell activity modulation with agent reducing level of cell cholesterol)

RN 57775-26-5 HCAPLUS

CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2004:378041 HCAPLUS Full-text
DOCUMENT NUMBER: 141:17539
TITLE: Calcium dobesilate (Cd) in pigmented purpuric dermatosis (PPD): a pilot evaluation
AUTHOR(S): Agrawal, Subhav Kumar; Gandhi, Vijay; Bhattacharya, Sambit Nath
CORPORATE SOURCE: Department of Dermatology and S.T.D., University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India
SOURCE: Journal of Dermatology (2004), 31(2), 98-103
CODEN: JDMYAG; ISSN: 0385-2407
PUBLISHER: Japanese Dermatological Association
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 11 May 2004
AB Pigmented purpuric dermatosis (PPD) is a chronic disorder of unknown etiol. It is quite common, and no therapy is significantly effective. Calcium dobesilate (Cd) has been tried successfully in many vascular disorders. The aim of this study was to evaluate the usefulness and efficacy of Cd in PPD. Nine male (patients (7 with Schamberg's and 1 each with lichenoid dermatosis of Gougerot and Blum and lichen aureus)) were given Cd 500 mg twice daily for two initial weeks and then 500 mg once daily for a total period of three months. All the patients were followed up for one year after cessation of therapy. The improvement was moderate in 11.11% and mild in 66.67% of cases; 22.22% did not show any improvement. New lesions stopped appearing in two weeks in all patients, and itching also improved in symptomatic cases without any significant side effects. Based upon the results of this pilot study we recommend Cd as the first line therapy for PPD.
CC 1-12 (Pharmacology)
ST calcium dobesilate pigmented purpuric dermatosis
IT Human
Skin, disease
(efficacy of calcium dobesilate in treatment of pigmented purpuric dermatosis)
IT 20123-80-2, Calcium dobesilate
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of calcium dobesilate in treatment of pigmented purpuric dermatosis)
IT 20123-80-2, Calcium dobesilate
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of calcium dobesilate in treatment of pigmented purpuric dermatosis)
RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2004:582074 HCAPLUS Full-text
DOCUMENT NUMBER: 141:293190
TITLE: Chronic venous diseases: Roles of various pathophysiological factors
AUTHOR(S): Boisseau, M. R.; de La Giclais, B.
CORPORATE SOURCE: Laboratoire de Pharmacologie, Biologie Vasculaire, Universite Victor Segalen Bordeaux 2, Bordeaux, 33076, Fr.
SOURCE: Clinical Hemorheology and Microcirculation (2004), 31(1), 67-74
CODEN: CHMIFQ; ISSN: 1386-0291
PUBLISHER: IOS Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
ED Entered STN: 21 Jul 2004
AB A review. Disturbances in haemodynamic, biochem. and enzymic factors have been observed in chronic venous diseases (CVD). These changes lead to the development of varices, telangiectasies and skin disorders. They affect vessels, blood, skin tissues and cells. It is now possible to describe their time course and interdependance of these changes. Orthostatism pressure on vein wall may lead to fluid leakage and edema, these resulting in vein enlargement. These processes may be further influenced by genetic or acquired risk factors. Skin microvessels suffer more from hypoxia than from hypertension. Indeed, hypoxia affects not only endothelial cells, but also red and white blood cells and modifies particularly, but not exclusively, TGF-β1 production This substance is, an important modulator of zinc dependent-metallo-proteinases and their tissue inhibitor of metallo-proteinases (TIMP) in the skin. Imbalance in this enzymic system seems to lead either to sclerosis or ulcer. Of course, other biochem. events (also in this review) play a role in vessel wall and skin deterioration in CVD. The aim of the present review is to assess the role of pathophysiol. factors in CVD and the influence of different therapies, including the venotropic agent calcium dobesilate, on some of these haemodynamic or biochem. aspects.
CC 14-0 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1
IT 20123-80-2, Calcium dobesilate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(roles of various pathophysiol. factors in chronic venous diseases)
IT 20123-80-2, Calcium dobesilate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(roles of various pathophysiol. factors in chronic venous diseases)

RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2003:241333 HCAPLUS Full-text
DOCUMENT NUMBER: 138:395873
TITLE: An open trial of calcium dobesilate in patients with venous ulcers and stasis dermatitis
AUTHOR(S): Kaur, Charandeep; Sarkar, Rashmi; Kanwar, Amrinder J.; Attri, Ashok K.; Dabra, Ajay K.; Kochhar, Suman
CORPORATE SOURCE: Departments of Dermatology and Venereology, Surgery, and Radiology, Government Medical College, Chandigarh, India
SOURCE: International Journal of Dermatology (2003), 42(2), 147-152
CODEN: IJDEBB; ISSN: 0011-9059
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 28 Mar 2003
AB Venous leg ulcers and associated stasis dermatitis are a major cause of morbidity, economic loss, and decreased quality of life in afflicted patients. Hence, there has been a renewal of interest in the medical management of varicose veins and ulcers. Calcium dobesilate, a capillotropic agent, has been found to be beneficial in the treatment of varicose veins. This is an open pilot study of 25 patients (15 with venous ulcers with/without stasis dermatitis, 10 with stasis dermatitis only) who were given calcium dobesilate, 500 mg twice daily, for 8 wk. The clin. parameters were graded (0-4; 0, absent; 1, mild; 2, moderate; 3, severe; 4, very severe) both before and after therapy, and included pain, itching, tiredness, heaviness, paresthesia, cramps, and leg swelling. Evaluation also included subjective changes in tenderness, oozing, and pigmentation, and measurement of the circumference of the leg for swelling and malleolar edema (measured in millimeters). The venous ulcer sizes were also recorded both before and after therapy. Color Doppler studies were performed to confirm the diagnosis of varicose veins, determine the competence of the valves, and to rule out deep vein thrombosis. Serum biochem., hemogram, and urinalysis were performed both before and after treatment. The results were analyzed statistically using the Wilcoxon rank sum test and Student's t-test. A statistically significant improvement was observed post-therapeutically in the clin. parameters of pain, itching, tiredness, heaviness, and leg swelling. There was also a significant decrease

in ulcer size. The serum biochem., hemogram, and urinalysis remained unaffected. Color Doppler studies before treatment revealed venous valvular incompetence in 20 patients. They were repeated in only 10 patients after treatment, four of whom showed improved valvular competence. Recurrence of venous ulcers was seen in five of 12 patients who were followed up after therapy. No significant side-effects were noted. Calcium dobesilate is an effective adjuvant therapy, with an absence of significant side-effects, in patients with venous ulcers and stasis dermatitis. More double-blind trials are required in the future to substantiate and evaluate the role of the drug in these two indications.

CC 1-9 (Pharmacology)

ST calcium dobesilate antiulcer capillary varicose vein ulcer dermatitis

IT Capillary vessel
Dermatitis
Human
Leg
(calcium dobesilate in patients with venous leg ulcers and stasis dermatitis)

IT Antiulcer agents
(capillotropic; calcium dobesilate in patients with venous leg ulcers and stasis dermatitis)

IT Ulcer
(cutaneous; calcium dobesilate in patients with venous leg ulcers and stasis dermatitis)

IT Skin, disease
(ulcer; calcium dobesilate in patients with venous leg ulcers and stasis dermatitis)

IT Vein, disease
(varicose; calcium dobesilate in patients with venous leg ulcers and stasis dermatitis)

IT 20123-80-2, Calcium dobesilate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium dobesilate in patients with venous leg ulcers and stasis dermatitis)

IT 20123-80-2, Calcium dobesilate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium dobesilate in patients with venous leg ulcers and stasis dermatitis)

RN 20123-80-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:1015029 HCAPLUS Full-text
DOCUMENT NUMBER: 151:280249
TITLE: Treatment of acne vulgaris, rosacea and rhinophym with inhibitors of the fibroblast growth factor receptor 2 and insulin-like growth factor 1 receptor signal pathways
INVENTOR(S): Melnik, Bodo
PATENT ASSIGNEE(S): Germany
SOURCE: PCT Int. Appl., 39pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009101199	A2	20090820	WO 2009-EP51749	20090216

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:		
EP 2008-101654	A	20080215
EP 2008-154022	A	20080403
US 2008-123294P	P	20080407
EP 2008-164431	A	20080916
EP 2008-168765	A	20081110

ED Entered STN: 20 Aug 2009
AB A composition for the treatment of acne vulgaris, rosacea and/or rhinophym comprises at least one inhibitor of the FGFR2 signal pathway and/or IGFR1 signal pathway. Also claimed is a bovine milk or a product of bovine milk having a reduced content of hormones, especially progesterone and growth factors, like IGF-1 and IGF-2, FGF1, and FGF2, or having a modified casein which has a reduced influence on IGF-1 levels. Further, use of Metforming for the prevention of adenocarcinomas, cardiovascular diseases and neurodegenerative diseases, is also presented.
CC 1-10 (Pharmacology)
Section cross-reference(s): 2, 17, 63
IT Skin, disease
(rosacea, rhinophym; acne vulgaris, rosacea and rhinophym treatment with inhibitors of fibroblast growth factor receptor 2 and insulin-like receptor 1 signal pathways)
IT Acne
(vulgaris; acne vulgaris, rosacea and rhinophym treatment with inhibitors of fibroblast growth factor receptor 2 and insulin-like receptor 1 signal pathways)
IT 57-92-1, Streptomycin 88-46-0 1143-38-0, Dithranol
1403-66-3, Gentamicin 1404-04-2, Neomycin 1405-10-3, Neomycin sulfate

3895-92-9, Chelerythrine chloride 4449-51-8, Cyclopamine 7542-37-2, Paromomycin 32986-56-4, Tobramycin 37517-28-5, Amikacin 56391-56-1, Netilmicin 63590-19-2, (-)-Balanol 64048-12-0, GANT 58 70226-44-7D, Heparan, sulfate derivs. 99533-80-9, K252a 109511-58-2, U0126 112953-11-4, UCN-01 120685-11-2, CGP41251 121263-19-2, Calphostin C 125313-65-7, Ro 31-7549 125314-64-9, Ro 31-8220 133052-90-1, GF109203X 133053-19-7, Go 6983 136194-77-9, Go 6976 151879-73-1, Aprinocarsen 152121-30-7, SB202190 152121-47-6, SB203580 152459-75-1, CGP53506 167869-21-8, PD 98059 169939-94-0, Ly333531 212631-79-3, PD 184352 219580-11-7, PD173074 365253-37-8, Ly317615 500579-04-4, GANT 61 914077-78-4 1184297-32-2, CGP 54345 1184297-33-3, BIRB 8796
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as inhibitor of FGFR2 signal pathway; acne vulgaris, rosacea and rhinophym treatment with inhibitors of fibroblast growth factor receptor 2 and insulin-like receptor 1 signal pathways)

IT 88-46-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as inhibitor of FGFR2 signal pathway; acne vulgaris, rosacea and rhinophym treatment with inhibitors of fibroblast growth factor receptor 2 and insulin-like receptor 1 signal pathways)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



L219 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:884915 HCAPLUS Full-text
DOCUMENT NUMBER: 151:190037
TITLE: Treatment of skin disorders with EGFR inhibitors
INVENTOR(S): Alexandrescu, Doru Traian
PATENT ASSIGNEE(S): Georgetown University, USA
SOURCE: PCT Int. Appl., 47pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009091889	A1	20090723	WO 2009-US31101	20090115

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2008-22067P P 20080118

ED Entered STN: 23 Jul 2009

AB Methods and compns. for the treatment of skin disorders (e.g., genetic skin disorders) are provided. The methods and compns. include an EGFR inhibitor. For genetic skin disorders that exhibit a high percentage of penetrance, or complete penetrance, such as Darier's disease, the methods and compns. provided herein can be used to prevent or reduce manifestation of symptoms of the disease.

CC 1-12 (Pharmacology)

ST EGFR inhibitor Cetuximab Erlotinib skin disorder cancer

IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(EGFR binding; treatment of skin disorders with EGFR inhibitors)

IT Disease, animal
(Hailey-Hailey, verrucous epidermal nevi, pityriasis rubra pilaris, Netherton, idiopathic vulgaris, monilethrix, Tay's; treatment of skin disorders with EGFR inhibitors)

IT Carcinoma
(bladder; treatment of skin disorders with EGFR inhibitors)

IT Bladder, neoplasm
(carcinoma; treatment of skin disorders with EGFR inhibitors)

IT Carcinoma
(cutaneous squamous cell; treatment of skin disorders with EGFR inhibitors)

IT Keratosis
(epidermolytic hyperkeratosis; treatment of skin disorders with EGFR inhibitors)

IT Skin, disease
(erythrokeratodermia variabilis; treatment of skin disorders with EGFR inhibitors)

IT Skin, disease
(erythrokeratodermica variabilis, eythrokeratodermia figurate variabilis, mutilating keratoderma of Vohwinkel, genetic; treatment of skin disorders with EGFR inhibitors)

IT Drug delivery systems
(feeding tube; treatment of skin disorders with EGFR inhibitors)

IT Keratosis
(follicularis; treatment of skin disorders with EGFR inhibitors)

IT Carboxylic acids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy, alpha and beta; treatment of skin disorders with EGFR inhibitors)

IT Keratosis
(hyper-, palmoplantar; treatment of skin disorders with EGFR inhibitors)

IT Keratosis

(hyperkeratosis, lenticularis perstans; treatment of skin disorders with EGFR inhibitors)
IT Pharmaceutical injections
(i.v. injections; treatment of skin disorders with EGFR inhibitors)
IT Skin, disease
(ichthyosis, erythrodermic and nonerythrodermic autosomal recessive lamellar, nonbullous congenital, vulgaris, Harlequin; treatment of skin disorders with EGFR inhibitors)
IT Epidermal growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; treatment of skin disorders with EGFR inhibitors)
IT Skin
(keratinization, monogenic, polygenic inherited disorder, complex; treatment of skin disorders with EGFR inhibitors)
IT Phototherapy
(laser therapy; treatment of skin disorders with EGFR inhibitors)
IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; treatment of skin disorders with EGFR inhibitors)
IT Transdermal drug delivery systems
(patches; treatment of skin disorders with EGFR inhibitors)
IT Carcinoma
(pharyngeal squamous cell; treatment of skin disorders with EGFR inhibitors)
IT Keratosis
(piliaris; treatment of skin disorders with EGFR inhibitors)
IT Pharynx, neoplasm
Skin, neoplasm
(squamous cell carcinoma; treatment of skin disorders with EGFR inhibitors)
IT Pharmaceutical emulsions
Topical drug delivery systems
(topical lotions; treatment of skin disorders with EGFR inhibitors)
IT Pharmaceutical patches
(transdermal; treatment of skin disorders with EGFR inhibitors)
IT Antitumor agents
Colorectal neoplasm
Dermatological agents
Esophagus, neoplasm
Human
Larynx, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Pharmaceutical creams
Pharmaceutical tablets
Prostate gland, neoplasm

Radiotherapy
Sjogren-Larsson syndrome
Stomach, neoplasm
Syringes
Topical drug delivery systems
(treatment of skin disorders with EGFR inhibitors)
IT Antisense nucleic acids
Corticosteroids
Flavonoids
Isoflavonoids
Retinoids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of skin disorders with EGFR inhibitors)
IT Cytotoxic agents
(tyrphostins; treatment of skin disorders with EGFR inhibitors)
IT 339177-26-3, Panitumumab
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ABX-EGF; treatment of skin disorders with EGFR inhibitors)
IT 205923-56-4, ERBITUX
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cetuximab; treatment of skin disorders with EGFR inhibitors)
IT 183319-69-9, TARCEVA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Erlotinib; treatment of skin disorders with EGFR inhibitors)
IT 60-18-4, Tyrosine, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metabolites; treatment of skin disorders with EGFR inhibitors)
IT 51-21-8, 5-Fluorouracil 58-05-9, Leucovorin 91-19-0D, Quinoxaline, derivs., quinazolones, quinazolinamines 94-36-0, Benzoyl peroxide, biological studies 108-95-2D, Phenol, stibenoids 289-95-2D, Pyrimidine, Ph derivs. 15663-27-1, Cisplatin 41575-94-4, Carboplatin 61825-94-3, Oxaliplatin 63177-57-1, Methyl 2,5-dihydroxycinnamate 79217-60-0, Cyclosporin 97682-44-5, Irinotecan 106685-40-9, Adapalene 118292-40-3, Tazarotene 153559-49-0, Bexarotene 180288-69-1, Trastuzumab 184475-35-2, Gefitinib 231277-92-2, Lapatinib 339186-68-4, Matuzumab 625853-93-2, ICR 62 667901-13-5, Zalutumumab 780758-10-3, Nimotuzumab
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of skin disorders with EGFR inhibitors)
IT 63177-57-1, Methyl 2,5-dihydroxycinnamate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of skin disorders with EGFR inhibitors)
RN 63177-57-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1079809 HCAPLUS Full-text
DOCUMENT NUMBER: 149:362249
TITLE: Cosmetic composition containing calcium dobesilate and others for treating acne and acari
INVENTOR(S): Duan, Yadong
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 19pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101254156	A	20080903	CN 2007-10055373	20070301
PRIORITY APPLN. INFO.:			CN 2007-10055373	20070301

ED Entered STN: 08 Sep 2008
AB The cosmetic composition contains 0.001-40% calcium dobesilate, and a suitable amount of cosmetic matrix such as lipid, waxes, antioxidant, antiseptic, humectant, surfactant, perfume, and colorant. The cosmetic composition can also contains active constituents such as metronidazole, aureomycin, retinoic acid, Stemona sessilifolia fine powder or extract, Salvia miltiorrhiza fine powder or extract, tanshinone, vitamins, Panax ginseng, minoxidilum, Glycyrrhiza uralensis, sodium fluoride, stannous fluoride, Panax notoginseng, propolis, and Zanthoxylum nitidum etc. The cosmetic composition may be used to produce the cosmetic formulations (such as solution, soap-type agent, cream, tincture, film or gel), shampoo and toothpaste for nursing and moistening skin, growing hair, preventing phalacrosis, protecting gingiva, fixing tooth, preventing and treating facial blood streak, facial petechia, seborrheic dermatitis, and acne.
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
IT Acari
Acne
Agrimonia pilosa
Aloe barbadensis
Alopecia
Angelica dahurica
Angelica sinensis
Astragalus membranaceus
Capsicum frutescens
Carthamus tinctorius
Citrus
Cosmetic creams
Cosmetic emulsions
Cosmetic gels

Cosmetic liquids
Curcuma longa
Dictamnus dasycarpus
Gastrodia elata
Gingival disease
Gynostemma pentaphyllum
Human
Hydnocarpus anthelminthicus
Microsorum fortunei
Natural products, pharmaceutical
Paeonia lactiflora
Panax ginseng
Panax notoginseng
Peach
Pearl
Platycladus orientalis
Polygonum multiflorum
Propolis
Prunus persica
Quisqualis indica
Royal jelly
Safflower
Salvia miltiorrhiza
Scutellaria baicalensis
Seborrhea
Selinum monnieri
Shampoos
Sophora flavescens
Stemona japonica
Syzygium aromaticum
Zanthoxylum nitidum
Zingiber corallinum
Zingiber officinale
(cosmetic composition containing calcium dobesilate and others for treating acne
and acari)

IT Acaricides
(cosmetic composition containing calcium dobesilate and others for treating skin acne and acari)

IT Skin, disease
(rosacea; cosmetic composition containing calcium dobesilate and others for treating acne and acari)

IT 50-81-7, Vitamin C, biological studies 51-75-2, Chlormethine 56-75-7, Chloromycetin 57-62-5, Aureomycin 60-54-8, Tetracycline 68-26-8, Vitamin A 79-57-2, Terramycin 94-36-0, Benzoyl peroxide, biological studies 114-07-8, Erythromycin 154-21-2, Lincomycin 302-79-4, Retinoic acid 443-48-1, Metronidazole 568-72-9, Tanshinone IIA 1404-04-2, Neomycin 1406-18-4, Vitamin E 7681-49-4, Sodium fluoride, biological studies 7704-34-9, Sulfur, biological studies 7772-99-8, Stannous chloride, biological studies 10118-90-8, Minocycline 10163-15-2, Sodium monofluorophosphate 19387-91-8, Tinidazole 20123-80-2, Calcium dobesilate 35825-57-1, Cryptotanshinone 38304-91-5, Minoxidil 54693-68-4, Tanshinone 69659-80-9, Tanshinone IIA sodium sulfonate
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cosmetic composition containing calcium dobesilate and others for treating acne
and acari)

IT 20123-80-2, Calcium dobesilate

RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cosmetic composition containing calcium dobesilate and others for treating acne
and acari)
RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

L219 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:39401 HCAPLUS Full-text
DOCUMENT NUMBER: 144:198760
TITLE: Manufacture of antiphlogistic and analgesic skin medicine for painless injection and cleaning wound
INVENTOR(S): Zhang, Lixin; Liu, Jinzhou
PATENT ASSIGNEE(S): Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 7 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1628848	A	20050622	CN 2003-10114609	20031217

PRIORITY APPLN. INFO.: CN 2003-10114609 20031217
ED Entered STN: 16 Jan 2006
AB The title medicine contains (by weight part) analgesic 0.001-10, disinfectant 0.001-10, hemostatic 0.001-10, anti-inflammatory agent 0.001-10 and solvent 20-99.996 (water or ethanol). The anodyne contains one or more of aspirin, procaine hydrochloride, triazolone, anadol, pentazocine lactate, fentanyl citrate and fortanodyn. The disinfectant contains one or more of iodine tincture, benzalkonium bromide, methyl violet and antibiotics. The hemostat contains one or more of etamsylate, carbazochrome, Vitamin K1, aminocaproic acid, aminomethylbenzoic acid and protamine. The anti-inflammatory agents contain one or more of ibuprofen, Somedon, aspirin, analgin, indomethacin or phenylbutazone. The title medicine has antiseptic, antiphlogistic, analgesic and hemostatic functions and can be used for painless injection and cleaning wound.
IC ICM A61K045-00
ICS A61P017-00; A61K033-18
CC 63-6 (Pharmaceuticals)
ST antiphlogistic analgesic skin medicine painless injection cleaning wound

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, bromides; manufacture of skin antiphlogistic and analgesic medicine for painless injection and cleaning wound)
IT Analgesics
Anti-inflammatory agents
Antibiotics
Disinfectants
Hemostatics
Human
Skin
(manufacture of skin antiphlogistic and analgesic medicine for painless injection and cleaning wound)
IT Protamines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of skin antiphlogistic and analgesic medicine for painless injection and cleaning wound)
IT Drug delivery systems
(transdermal; manufacture of skin antiphlogistic and analgesic medicine for painless injection and cleaning wound)
IT 50-33-9, Phenylbutazone, biological studies 50-78-2, Aspirin 51-05-8, Procaine hydrochloride 53-86-1, Indomethacin 56-91-7, 4-Aminomethylbenzoic acid 64-17-5, Ethanol, biological studies 68-89-3, Analgin 69-81-8, Carbazochrome 990-73-8, Fentanyl citrate 1319-82-0, Aminocaproic acid 2624-44-4, Etamsylate 7553-56-2, Iodine, biological studies 8004-87-3, Methyl violet 8075-54-5, Somedon 11104-38-4, Vitamin K1 14405-05-1, Anadol 15687-27-1, Ibuprofen 17146-95-1, Pentazocine lactate 17719-89-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of skin antiphlogistic and analgesic medicine for painless injection and cleaning wound)
IT 2624-44-4, Etamsylate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of skin antiphlogistic and analgesic medicine for painless injection and cleaning wound)
RN 2624-44-4 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N

CM 2

CRN 88-46-0
CMF C6 H6 O5 S



L219 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1297124 HCAPLUS Full-text
DOCUMENT NUMBER: 144:57481
TITLE: Preparation of polyvinyl alcohol hydrogel dressing containing drug and chitosan
INVENTOR(S): Jing, Xiabin; Yu, Haijun; Chen, Xuesi; Yang, Lixin; Xu, Xiaoyi; Zhang, Peibiao
PATENT ASSIGNEE(S): Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 20 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1579559	A	20050216	CN 2004-10010849	20040514
CN 1320931	C	20070613		
PRIORITY APPLN. INFO.:			CN 2004-10010849	20040514

ED Entered STN: 12 Dec 2005
AB The invention relates to a method for preparing polyvinyl alc. (PVA) hydrogel dressing containing drug and chitosan. The dressing consists (by weight) solid ingredients (10-20%) including synthetic and natural solid polymers, humectant (1-10%), plasticizer (1-10%), drug (0.1-2%), and solvent (balance) selected from redistd. water, normal saline solution, and neutral phosphate buffer solution The crosslinked PVA-hydrogel dressing is obtained by irradiation with 60Co γ-ray or high energy electron beam. The dressing can slowly release the drug and chitosan with antibacterial activity, has high content of moisture and moderate mech. strength, has good permeability to light and air, and meets the requirement for wet treatment of various wounds. The product can be used not only as the long-term dressing for mild skin trauma or chronic diseases of skin, but also as instant occlusive dressing for server skin wound.
IC ICM A61L015-28
ICS A61L015-44
CC 63-6 (Pharmaceuticals)
IT 50-70-4, Sorbitol, biological studies 55-56-1, Chlorhexidine 56-81-5, Glycerin, biological studies 57-15-8, Trichloro-tert-butyl alcohol 57-55-6, Propylene glycol, biological studies 107-21-1, Ethylene glycol, biological studies 1197-18-8, Tranexamic acid 1404-26-8, Polymyxin B 2624-44-4, Etamsylate 9000-07-1, Carrageenan 9002-18-0, Agar 9002-89-5, Polyvinyl alcohol 9003-01-4, Polyacrylic acid 9003-06-9, Acrylic acid-acrylamide copolymer 9003-39-8, Polyvinylpyrrolidone 9012-76-4, Chitosan 25322-68-3, Polyethylene glycol 85721-33-1, Ciprofloxacin 129313-99-1, Amycin B
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of polyvinyl alc. hydrogel dressing containing drug and

chitosan)
IT 2624-44-4, Etamsylate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of polyvinyl alc. hydrogel dressing containing drug and chitosan)
RN 2624-44-4 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N

CM 2

CRN 88-46-0
CMF C6 H6 O5 S



L219 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:702268 HCAPLUS Full-text
DOCUMENT NUMBER: 141:253493
TITLE: Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids
AUTHOR(S): Allain, Herve; Ramelet, Albert A.; Polard, Elisabeth; Bentue-Ferrer, Daniele
CORPORATE SOURCE: Service de Pharmacologie, Faculte de Medecine, Universite de Rennes 1, Rennes, Fr.
SOURCE: Drug Safety (2004), 27(9), 649-660
CODEN: DRSAEA; ISSN: 0114-5916
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
ED Entered STN: 27 Aug 2004
AB A review. The aim of the present review is to consider the adverse effects and the safety profile of calcium dobesilate. Calcium dobesilate (Doxium) is a veno-tonic drug, which is widely prescribed in more than 60 countries from Europe, Latin America, Asia and the Middle East for three main indications: chronic venous disease, diabetic retinopathy and the symptoms of hemorrhoidal attack. Data sources used for this review comprise the international literature (1970-2003), a postmarketing surveillance (PMS) report for calcium

dobesilate from OM Pharma (Geneva, Switzerland) covering the period 1974-1998, and periodic safety update reports (PSUR) covering the period 1995-2003 from the French Regulatory authorities pharmacovigilance database and OM Pharma. Data from the PMS report for 1974-1998 indicated that adverse events with calcium dobesilate did not occur very frequently and had the following distribution in terms of frequency: fever (26%), gastrointestinal disorders (12.5%), skin reactions (8.2%), arthralgia (4.3%), and agranulocytosis (4.3%). No deaths were attributed to calcium dobesilate in the PMS report. Using data on product use in the Swiss Compendium we estimated the prevalence of agranulocytosis to be 0.32 cases/million treated patients, i.e. ten times less than the calculated prevalence of agranulocytosis in the general population. Most adverse events are type B, i.e. rare and unrelated to the pharmacol. properties of calcium dobesilate. This review concludes that the risk of an adverse effect with calcium dobesilate 500-1500 mg/day is low and constant over time. The recently raised problem of agranulocytosis (a total of 13 known cases drawn from all data sources) appears to be related to methodol. bias. Such a review reinforces the need for a strong international pharmacovigilance organization using similar methods to detect and analyze the adverse effects of drugs.

CC 1-0 (Pharmacology)

IT 20123-80-2, Calcium dobesilate
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and hemorrhoids)

IT 20123-80-2, Calcium dobesilate
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and hemorrhoids)

RN 20123-80-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 91 THERE ARE 91 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:960660 HCAPLUS Full-text

DOCUMENT NUMBER: 138:19488

TITLE: Method and pharmaceutical compositions using anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases

INVENTOR(S): Hunter, William L.
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.
SOURCE: U.S., 180 pp., Cont.-in-part of U.S. Appl. 2002 37,919.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6495579	B1	20021217	US 1998-88546	19980601
US 20020037919	A1	20020328	US 1997-980549	19971201
US 6515016	B2	20030204		
CA 2607067	A1	19980611	CA 1997-2607067	19971202
EP 1070502	A2	20010124	EP 2000-123557	19971202
EP 1070502	A3	20011017		
EP 1070502	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1090637	A2	20010411	EP 2000-123537	19971202
EP 1090637	A3	20010912		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1092433	A2	20010418	EP 2000-123534	19971202
EP 1092433	A3	20010912		
EP 1092433	B1	20030806		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002226399	A	20020814	JP 2001-401899	19971202
EP 1582210	A2	20051005	EP 2005-11601	19971202
EP 1582210	A3	20051012		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1679937	A	20051012	CN 2005-10054770	19971202 <--
CN 101011576	A	20070808	CN 2006-10099927	19971202 <--
CN 101195028	A	20080611	CN 2006-10099895	19971202 <--
WO 9962510	A2	19991209	WO 1999-CA464	19990601
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020013298	A1	20020131	US 1999-368463	19990804
US 20020183380	A1	20021205	US 2002-67467	20020205
US 6689803	B2	20040210		
US 20030157187	A1	20030821	US 2002-172737	20020613
US 20050249770	A1	20051110	US 2005-102587	20050408
AU 2006220416	A1	20061026	AU 2006-220416	20060920
AU 2006220416	B2	20090205		
US 20080113035	A1	20080515	US 2007-891651	20070810
US 20080153900	A1	20080626	US 2007-891661	20070810
JP 2009161555	A	20090723	JP 2009-57154	20090310

PRIORITY APPLN. INFO.:			
	US 1996-32215P	P	19961202
	US 1997-63087P	P	19971024
	US 1997-980549	A2	19971201

CA	1997-2273240	A3 19971202
CN	1997-181581	A3 19971202
CN	2005-10054770	A3 19971202
EP	1997-945697	A3 19971202
EP	2000-123537	A3 19971202
JP	1998-524997	A3 19971202
JP	2001-401899	A3 19971202
US	1998-88546	A 19980601
US	1999-368463	B1 19990804
US	1999-368871	A1 19990804
US	2002-172737	B1 20020613
AU	2004-200715	A3 20040220
US	2005-102587	B1 20050408

ED Entered STN: 19 Dec 2002

AB Methods and compns. for treating or preventing inflammatory diseases, e.g. psoriasis or multiple sclerosis, are provided, comprising delivering to the site of inflammation an anti-microtubule agent (e.g. paclitaxel), or analog or derivative thereof.

IC ICM A61K031-425

INCL 514365000

CC 1-7 (Pharmacology)
Section cross-reference(s): 63

ST microtubule agent multiple sclerosis psoriasis antiinflammatory; paclitaxel multiple sclerosis psoriasis antiinflammatory

IT Anti-inflammatory agents
Antiarthritics
Arthritis
Cell proliferation
Chondrocyte
Drug delivery systems
Human
Inflammation
Microtubule
Multiple sclerosis
Neutrophil
Permeation enhancers
Prostate gland, neoplasm
Psoriasis
T cell (lymphocyte)
(anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases, and pharmaceutical compns.)

IT Skin
(keratinocyte; anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases, and pharmaceutical compns.)

IT 50-04-4, Cortisone acetate 52-21-1, Prednisolone acetate 57-22-7, Vincristine 59-05-2, Methotrexate 64-86-8, Colchicine 68-60-0, Tetrahydro S 69-33-0, Tubercidin 107-41-5, Hexylene glycol 145-63-1, Suramin 446-72-0, Genistein 459-73-4, Glycine ethyl ester 865-21-4, Vinblastine 7689-03-4, Camptothecin 7784-18-1, Aluminum fluoride 7789-20-0, Deuterium oxide 9050-30-0D, Heparan sulfate, fragments 10540-29-1, Tamoxifen 27774-13-6, Vanadyl sulfate 37353-31-4, Vanadate 38213-69-3 52205-73-9 63177-57-1 66107-60-6, Baccatin 70539-42-3 77699-47-9, Herbimycin 86102-31-0, TIMP 100827-28-9, Erbstatin 125697-93-0, Lavendustin C 149550-36-7, LY290181 152044-54-7, Epothilone B 174882-69-0, Pycnogenol 478183-56-1, BEOV s-phosphonate
RL: PAC (Pharmacological activity); BIOL (Biological study)
(anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases, and pharmaceutical compns.)

IT 63177-57-1

RL: PAC (Pharmacological activity); BIOL (Biological study)
(anti-microtubule agents for treating multiple sclerosis and other inflammatory diseases, and pharmaceutical compns.)
RN 63177-57-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT: 171 THERE ARE 171 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:783929 HCAPLUS Full-text
DOCUMENT NUMBER: 132:18780
TITLE: Compositions comprising antimicrotubule agents for treating or preventing inflammatory diseases
INVENTOR(S): Hunter, William L.
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 340 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962510	A2	19991209	WO 1999-CA464	19990601
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6495579	B1	20021217	US 1998-88546	19980601
AU 2006220416	A1	20061026	AU 2006-220416	20060920
AU 2006220416	B2	20090205		

PRIORITY APPLN. INFO.:		
US 1998-88546	A	19980601
US 1996-32215P	P	19961202
US 1997-63087P	P	19971024
US 1997-980549	A2	19971201
AU 2004-200715	A3	20040220

ED Entered STN: 10 Dec 1999
AB Methods and compns. for treating or preventing inflammatory diseases, e.g. psoriasis or multiple sclerosis, are provided, comprising the step of delivering to the site of inflammation an antimicrotubule agent, or analog or derivative thereof.

IC ICM A61K031-335
ICS A61K031-425; A61K031-365; A61K031-045; A61K031-505; A61K033-16; A61K031-40; A61K031-22
CC 1-7 (Pharmacology)
Section cross-reference(s): 63
IT Adhesion, biological
Angiogenesis inhibitors
Anti-inflammatory agents
Antiarthritics
Antitumor agents
Astrocyte
Cytotoxic agents
Drug delivery systems
Micelles
Microtubule
Neutrophil
Permeation enhancers
Psoriasis
Transplant rejection
(antimicrotubule agents for treating or preventing inflammatory diseases)
IT Skin
(keratinocyte; antimicrotubule agents for treating or preventing inflammatory diseases)
IT 50-04-4 52-21-1 57-22-7 59-05-2 64-86-8 145-63-1 446-72-0 865-21-4, Vincaleukoblastine 7689-03-4 9050-30-0D, fragments 10540-29-1 27774-13-6 37353-31-4, Vanadate 38213-69-3 52205-73-9 63177-57-1 66107-60-6 77699-47-9, Herbimycin 86102-31-0 100827-28-9 144676-04-0 174882-69-0, Pycnogenol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antimicrotubule agents for treating or preventing inflammatory diseases)
IT 63177-57-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antimicrotubule agents for treating or preventing inflammatory diseases)
RN 63177-57-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L219 ANSWER 14 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:623128 HCAPLUS Full-text
DOCUMENT NUMBER: 125:238664
ORIGINAL REFERENCE NO.: 125:44353a,44356a

TITLE: Treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compounds
INVENTOR(S): Stanwell, Caroline; Yuspa, Stuart H.; Burke, Terrence R., Jr.
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9625159	A1	19960822	WO 1996-US2301	19960214
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN				
US 5610185	A	19970311	US 1995-389845	19950217
CA 2212888	A1	19960822	CA 1996-2212888	19960214
CA 2212888	C	20061017		
AU 9649286	A	19960904	AU 1996-49286	19960214
AU 698414	B2	19981029		
EP 809493	A1	19971203	EP 1996-905555	19960214
EP 809493	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11503111	T	19990323	JP 1996-525201	19960214
AT 223715	T	20020915	AT 1996-905555	19960214
ES 2183938	T3	20030401	ES 1996-905555	19960214
PRIORITY APPLN. INFO.:			US 1995-389845 A	19950217
			WO 1996-US2301 W	19960214

ED Entered STN: 21 Oct 1996

AB Various hydroxylated aromatic compds., principally cinnamic acid derivs. and hydroxylated naphthoic acid and isoquinolinecarboxylic acid derivs. inhibit growth of hyperproliferative epithelial cells by crosslinking cellular proteins to form cornified envelope-like structures, resulting in cell death. The compds. are useful in control and prevention of hyperproliferative epithelial disorders, such as human papillomavirus-infected cell lesions, actinic keratosis, melanomas, and malignant and premalignant carcinomas. Thus, Me 2,5-dihydroxycinnamate (1 mM) induced cornification of primary mouse keratinocytes within 4 h. β-Phenylethyl 2,5-dihydroxycinnamate was prepared by reaction of 2,5-dihydroxybenzaldehyde with (carboxymethyl)triphenylphosphonium chloride β-phenylethyl ester.

IC ICM A61K031-215
ICS A61K031-235
CC 1-6 (Pharmacology)
Section cross-reference(s): 25
ST skin hyperproliferation treatment phenolic crosslinker; neoplasm inhibitor hydroxy arom compd
IT Virucides and Virustats
(for human papillomavirus; treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)
IT Cell proliferation

(treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)

IT Phenols, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)

IT Skin, neoplasm
(epidermis, treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)

IT Skin, disease
(epidermis, hyperproliferation, treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)

IT Virus, animal
(human papilloma, infection with; treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)

IT 60741-49-3P 63177-57-1P, Methyl 2,5-dihydroxycinnamate 104594-70-9P, 2-Phenylethyl caffeate 146515-44-8P, Methyl 5,6-dihydroxy-2-naphthoate 169232-10-4P, 2-Phenylethyl 3,4-difluorocinnamate 169232-11-5P, 2-Phenylethyl 2,5-dihydroxycinnamate 169232-12-6P, 2-Phenylethyl 2,3,4-trihydroxycinnamate 169232-14-8P 169232-18-2P, 2-Phenylethyl 6,7-dihydroxy-2-naphthoate 169232-19-3P, 2-Phenylethyl 5,6-dihydroxy-2-naphthoate 169232-21-7P 170562-65-9P, 2-Phenylethyl 3-(3,4-dihydroxyphenyl)propanoate 182205-60-3P, 2-(2-Naphthyl)ethyl caffeate 182205-61-4P, 2-(1-Naphthyl)ethyl caffeate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)

IT 60-12-8, β-Phenylethanol 60-19-5, Tyramine hydrochloride 103-80-0, Phenylacetyl chloride 331-39-5, Caffeic acid 773-99-9, 2-(1-Naphthyl)ethanol 1194-98-5, 2,5-Dihydroxybenzaldehyde 1485-07-0, 2-(2-Naphthyl)ethanol 2144-08-3, 2,3,4-Trihydroxybenzaldehyde 13677-79-7, 3,4,5-Trihydroxybenzaldehyde 72337-27-0, 6,7-Dimethoxy-2-naphthamide 126674-76-8, 5,6-Dimethoxy-2-naphthoic acid 132335-95-6 152152-17-5, 3,4-Difluorocinnamic acid 169232-24-0, Pentafluorophenyl 3-(3,4-dihydroxyphenyl)propanoate 182205-62-5, 5,6-Dihydroxy-2-naphthoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)

IT 113458-95-0P, 6,7-Dihydroxy-2-naphthoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)

IT 63177-57-1P, Methyl 2,5-dihydroxycinnamate 169232-11-5P, 2-Phenylethyl 2,5-dihydroxycinnamate

169232-14-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein-crosslinking compds.)

RN 63177-57-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, methyl ester (CA INDEX NAME)



RN 169232-11-5 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)-, 2-phenylethyl ester (CA INDEX NAME)



RN 169232-14-8 HCAPLUS
CN 2-Propenoic acid, 3-(2,4,5-trihydroxyphenyl)-, 2-phenylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L219 ANSWER 15 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1976:159773 HCAPLUS Full-text
DOCUMENT NUMBER: 84:159773
ORIGINAL REFERENCE NO.: 84:25899a,25902a
TITLE: Pharmacological study of some capillary acting substances
AUTHOR(S): Tarayre, J. P.; Lauressergues, H.; Vidal, M.; Tailhan,

Mrs. C.
CORPORATE SOURCE: Cent. Rech., P. Fabre S. A., Castres, Fr.
SOURCE: Annales Pharmaceutiques Francaises (1975), 33(10), 467-71
CODEN: APFRAD; ISSN: 0003-4509
DOCUMENT TYPE: Journal
LANGUAGE: French
ED Entered STN: 12 May 1984
AB In rats, aescin [6805-41-0] (60 and 120 mg/kg, orally), Na aescin [53028-06-1] (0.25-1 mg/kg, i.v.), diosmin [520-27-4] (600 mg/kg, orally), calcium dobesilate [20123-80-2] (500 mg/kg, orally), ethamsylate [2624-44-4] (500 mg/kg, orally), and folescutol [15687-22-6] (400 mg/kg, orally) increased capillary permeability in the histamine intradermal wheal test. Pyridinol carbamate [1882-26-4] (100-500 mg/kg, orally) had no effect. Only pyridinol carbamate and Na aescin decreased the localized swelling induced by plantar injection of dextran or carrageenin. Generalized edema from i.p. injection of dextran was decreased by aescin and pyridinol.
CC 1-5 (Pharmacodynamics)

=> d iall abeq tech abex hitstr 16-17
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' -
CONTINUE? (Y)/N:y

L219 ANSWER 16 OF 21 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-N22597 [77] WPIX
DOC. NO. CPI: C2008-413563 [77]
TITLE: New cinnamic amide derivative useful for treating diseases responsive to modulation of potassium channel, e.g., respiratory diseases, convulsion, erectile dysfunction, gastrointestinal dysfunction, ischemia, schizophrenia and sleep disorder
DERWENT CLASS: B05
INVENTOR: CHRISTOPHERSEN P; DEMNITZ J; GRUNNET M; JENSEN T D; JONES D S; MADSEN L S; NARDI A; NIELSEN E O; STROBAK D
PATENT ASSIGNEE: (NEUR-N) NEUROSEARCH AS
COUNTRY COUNT: 120

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008074755	A2	20080626	(200877)*	EN	45[1]	
WO 2008074755	A3	20081002	(200877)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008074755	A2	WO 2007-EP64015	20071217

PRIORITY APPLN. INFO: DK 2007-481 20070328
DK 2006-1657 20061218
US 2006-870781P 20061219
INT. PATENT CLASSIF.:
IPC ORIGINAL: A61K0031-00 [I,A]; A61K0031-00 [I,C]; A61P0015-00 [I,A];

A61P0015-00 [I,C]; C07C0205-00 [I,C]; C07C0205-56 [I,A]; C07C0233-00 [I,C]; C07C0233-29 [I,A]; C07C0233-44 [I,A]; C07C0233-55 [I,A]; C07C0261-00 [I,C]; C07C0261-04 [I,A]; C07C0309-00 [I,C]; C07C0309-51 [I,A]; C07C0309-76 [I,A]; C07C0311-00 [I,C]; C07C0311-16 [I,A]; C07C0311-46 [I,A]; C07C0311-51 [I,A]

ECLA: C07C0001-26+9/00; C07C0017-10+19/075; C07C0309-15; C07C0311-08; C07C0311-09; C07C0311-21; C07C0311-46; C07C0311-51

ICO: M07C0529:40

BASIC ABSTRACT:

WO 2008074755 A2 UPAB: 20081128

NOVELTY - A cinnamic amide derivative (I), is new.

DETAILED DESCRIPTION - A cinnamic amide derivative of formula (I), or its enantiomer, mixture of its enantiomers, or salt, is new.

R1=nitro, amino, hydroxy, carboxy, sulfonic acid, sulfonic acid alkyl ester, sulfamoyl, acetamido, methyl-sulfonyl-amino, phenyl-sulfonyl-amino, N-methyl-sulfonyl-carboxamide (methyl-sulfonyl-amino-carbonyl), N-phenyl-sulfonyl-carboxamide (phenyl-sulfonyl-amino-carbonyl), trifluoromethyl-sulfonyl-amino, trifluoromethyl-acetyl-amino, 2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl- ethyl, tetrazolyl, tetrazolyl-methoxy, 5-oxo-4,5-dihydro-(1,2,4)oxadiazol-3-yl or N-cyano-carboxamide;

R2 and R3=phenyl (optionally substituted with halo and/or trifluoromethyl), H, halo, trifluoromethyl, or hydroxy;

R4 and R5=H, halo, trifluoromethyl, nitro and/or phenyl;or

R4 and R5 together with the aromatic ring to which they are attached=benzo-fused carbocyclic aromatic ring;

R' and R'a=H;or

R' and R'a together with the carbon atoms of the aromatic ring to which they are attached=bicyclic carbocyclic or heterocyclic ring selected from 2H-chromenyl (optionally substituted with oxo to form a 2-oxo-2H-chromenyl derivative), or indolyl.

INDEPENDENT CLAIMS are included for the following:

(1) use of a combination of a cinnamic amide derivative (I); and a phosphodiesterase inhibitor; or an agent that potentiates endothelium-derived hyperpolarizing factor-mediated responses; or their salts, for the manufacture of a medicament for the treatment or alleviation of sexual dysfunction; and

(2) a kit of parts comprising at least two separate unit dosage forms cinnamic amide derivative (I); and a phosphodiesterase inhibitor; or an agent that potentiates endothelium-derived hyperpolarizing factor-mediated responses; and optionally instructions for the simultaneous, sequential or separate administration of the cinnamic amide derivative (I), and the phosphodiesterase inhibitor, or the agent, to a patient.

ACTIVITY - Respiratory-Gen.; Anticonvulsant; Vasotropic; Cardiant; CNS-Gen.; Muscular-Gen.; Nephrotropic; Uropathic; Hepatotropic; Gastrointestinal-Gen.; Laxative; Antidiarrheic; Cerebroprotective; Vulnerary; Antianginal; Antiparkinsonian; Neuroleptic; Nootropic; Tranquilizer; Antidepressant; Antimanic; Neuroprotective; Analgesic; Gynecological; Hypnotic; Immunosuppressive; Antiarrhythmic; Cardiovascular-Gen.; Hypotensive; Relaxant; Antidiabetic; Tocolytic; Cytostatic; Antiinflammatory; Auditory; Antimigraine; Endocrine-gen.; Ophthalmological; Osteopathic; Angiogenesis-inhibitor; Antiarthritic; Antirheumatic; Antipsoriatic; Antianemic.

MECHANISM OF ACTION - Ion channel modulator e.g. calcium activated potassium (BK) channel modulator.

(E)-N-(5-chloro-2-(1H-tetrazol-5-yl)-phenyl)-3-naphthalen-2-yl-acrylamide (I') was tested for BK channel opening activity using BK channels heterologously expressed in Xenopus laevis oocytes in terms of current. BK current was activated by repeated step protocols. The compound (I') (1 mu M) was added. The compound (I') showed marked increased in current of 6-9 mu M at 80-134 seconds.

USE - In the manufacture of a pharmaceutical composition/medicament for treating respiratory disease, epilepsy, convulsions, seizures, absence seizures, vascular spasms, coronary artery spasms, motor neuron diseases, myokymia, renal disorders, polycystic kidney disease, bladder hyperexcitability, bladder spasms, urinogenital disorders, urinary incontinence, bladder outflow obstruction, erectile dysfunction, gastrointestinal dysfunction, gastrointestinal hypomotility disorders, gastrointestinal motility insufficiency, postoperative ileus, constipation, gastroesophageal reflux disorder, secretory diarrhea, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, ataxia, traumatic brain injury, stroke, Parkinson's disease, bipolar disorder, psychosis, schizophrenia, autism, anxiety, mood disorders, depression, manic depression, psychotic disorders, dementia, learning deficiencies, age related memory loss, memory and attention deficits, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), dysmenorrhea, narcolepsy, sleeping disorders, sleep apnea, Raynaud's disease, intermittent claudication, Sjogren's syndrome, xerostomia, arrhythmia, cardiovascular disorders, hypertension, myotonic dystrophy, myotonic muscle dystrophia, spasticity, xerostomia, diabetes Type II, hyperinsulinemia, premature labor, cancer, brain tumors, inflammatory bowel disease , irritable bowel syndrome, colitis, colitis Crohn', immune suppression, hearing loss, migraine, pain, neuropathic pain, inflammatory pain, trigeminal neuralgia, vision loss, rhinorrhoea, ocular hypertension (glaucoma), baldness, cardiac arrhythmia, atrial arrhythmia, ventricular arrhythmia, atrial fibrillation, ventricular fibrillation, tachyarrhythmia, atrial tachyarrhythmia, ventricular tachyarrhythmia, bradyarrhythmia, or any other abnormal rhythm, e.g. caused by myocardial ischemia, myocardial infarction, cardiac hypertrophy or cardiomyopathy disease/disorder/condition responsive to modulation of potassium channel in a mammal including a human, and for treating sexual dysfunction i.e. male dysfunction and female dysfunction (claimed); and also for treating diseases such as bone metabolic disease, disease that is responsive to inhibition of angiogenesis, an ophthalmic angiogenesis related diseases, rheumatoid arthritis, psoriasis and sickle-cell anemia, and pain.

ADVANTAGE - The compound are potent ion channel modulator and treats disease, disorder or condition responsive to modulation of potassium channels without any harmful side effects. The compounds show calcium activated potassium channel opening activity in sub-micromolar and micromolar range, i.e., from below 1-100 mu M.

MANUAL CODE: CPI: B14-C01; B14-C09B; B14-E02; B14-E09; B14-E10; B14-F01; B14-F02; B14-F03; B14-F10; B14-G02; B14-G02D; B14-H01; B14-J01; B14-J05; B14-J05D; B14-J07; B14-K01; B14-L01; B14-L06; B14-N01; B14-N02; B14-N03; B14-N05; B14-N07; B14-N10; B14-N14; B14-N16; B14-N17C; B14-P02; B14-P03; B14-P04; B14-P04A; B14-S04A; B14-S16

TECH

ORGANIC CHEMISTRY - Preparation: No general method for preparation of cinnamic amide derivative (I) is given.

PHARMACEUTICALS - Preferred Components: The phosphodiesterase inhibitor is sildenafil, tadalafil or vardenafil. The agent that potentiates endothelium-derived hyperpolarizing factor-mediated responses is calcium dobesilate.

ABEX DEFINITIONS - Preferred Definitions: - R1=tetrazolyl; - R2=H, halo or 4-fluoro-phenyl; - R3=H or halo; - R4=H;and - R5=halo.

ADMINISTRATION - The composition is administered at a dosage of 0.1 mu g/kg to 10 mg/kg intravenously, and 1 mg/kg to 100 mg/kg per orally, or parenterally (including cutaneously, subcutaneously, intramuscularly, or intravenously).

SPECIFIC COMPOUNDS - 36 Compounds are specifically claimed as (I), e.g., (E)-N-(5-chloro-2-(1H-tetrazol-5-yl)-phenyl)-3-naphthalen-2-yl-acrylamide (I'), 6-chloro-2H-chromene-3-carboxylic

acid(5-chloro-2-(1H-tetrazol-5-yl)-phenyl)-amide; (E)-N-(5-chloro-2-hydroxy-phenyl)-3-(3-nitro-phenyl)-acrylamide; (E)-N-(5-chloro-2-(1H-tetrazol-5-yl)-phenyl)-3-(4-fluoro-3-trifluoromethyl-phenyl)-acrylamide; and 5-chloro-1H-indole-2-carboxylic acid (4'-fluoro-3-(1H-tetrazol-5-yl)-biphenyl-4-yl)-amide.

EXAMPLE - To a stirred suspension of 3-(2-naphthylacrylic acid) (2.27 g) in dichloromethane (DCM), oxalyl chloride (1.3 ml) was added drop wise at 0 degrees C, followed by 1-2 drops of dry N,N-dimethylformamide (DMF). After work up, (E)-3-naphthalen-2-yl-acryloyl chloride (A1) (2.48 g, 100% yield) was obtained. A solution of compound (C1) (0.22 g) in dry toluene (TOL) (10 ml) was added drop wise to a mixture of 5-chloro-2-(1H-tetrazol-5-yl)-phenylamine (0.199 g) in pyridine (1 ml) and dry TOL (5 ml). After work up, (E)-N-(5-chloro-2-(1H-tetrazol-5-yl-phenyl)-3-naphthalen-2-yl-acrylamide) (I') was obtained.

AN.S DCR-89832
CN.P CALCIUM DOBESILATE
CN.S Calcium; 2,5-dihydroxy-benzenesulfonate
SDCN R20556

CM 1

Ca

CM 2



L219 ANSWER 17 OF 21 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
ACCESSION NUMBER: 1996-020345 [02] WPIX
DOC. NO. CPI: C1996-006976 [02]
TITLE: Opiate antagonist and calcium salt in compsn. - for treatment of endorphin-mediated pathologies
DERWENT CLASS: B05; C03
INVENTOR: CIORCI R L; MINOIA P; SCIORSCI R L
PATENT ASSIGNEE: (CIOR-I) CIORCI R L; (MINO-I) MINOIA P; (SCIO-I) SCIORSCI R; (SCIO-I) SCIORSCI R L; (RAPH-I) RAPHAEL L G
COUNTRY COUNT: 64

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 9531985	A2	19951130	(199602)*	EN	19[0]	
AU 9526149	A	19951218	(199611)	EN		
WO 9531985	A3	19960104	(199622)	EN		
EP 760661	A1	19970312	(199715)	EN	[0]	
IT 1269826	B	19970415	(199744)	IT		
JP 10500423	W	19980113	(199812)	JA	19[0]	

KR 97703148	A	19970703 (199829)	KO	
US 5811451	A	19980922 (199845)	EN	
HU 77920	T	19981028 (199850)	HU	
EP 760661	B1	19981230 (199905)	EN	
DE 69507029	E	19990211 (199912)	DE	
ES 2128735	T3	19990516 (199926)	ES	
AU 708778	B	19990812 (199944)	EN	
CN 1151116	A	19970604 (200131)	ZH	
CN 1083264	C	20020424 (200519)	ZH	
JP 2007210995	A	20070823 (200757)	JA	11

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9531985 A2		WO 1995-EP1931	19950522
IT 1269826 B		IT 1994-MI1048	19940524
AU 9526149 A		AU 1995-26149	19950522
AU 708778 B		AU 1995-26149	19950522
CN 1151116 A		CN 1995-193758	19950522
CN 1083264 C		CN 1995-193758	19950522
DE 69507029 E		DE 1995-607029	19950522
EP 760661 A1		EP 1995-920851	19950522
EP 760661 B1		EP 1995-920851	19950522
DE 69507029 E		EP 1995-920851	19950522
ES 2128735 T3		EP 1995-920851	19950522
JP 10500423 W		JP 1995-530058	19950522
WO 9531985 A3		WO 1995-EP1931	19950522
EP 760661 A1		WO 1995-EP1931	19950522
JP 10500423 W		WO 1995-EP1931	19950522
KR 97703148 A		WO 1995-EP1931	19950522
US 5811451 A		WO 1995-EP1931	19950522
HU 77920 T		WO 1995-EP1931	19950522
EP 760661 B1		WO 1995-EP1931	19950522
DE 69507029 E		WO 1995-EP1931	19950522
HU 77920 T		HU 1996-3228	19950522
KR 97703148 A		KR 1996-706602	19961121
US 5811451 A		US 1996-737902	19961121
JP 2007210995 A	Div Ex	JP 1995-530058	19950522
JP 2007210995 A		JP 2006-303392	20061108

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 708778 B	Previous Publ	AU 9526149 A
DE 69507029 E	Based on	EP 760661 A
ES 2128735 T3	Based on	EP 760661 A
AU 9526149 A	Based on	WO 9531985 A
EP 760661 A1	Based on	WO 9531985 A
JP 10500423 W	Based on	WO 9531985 A
KR 97703148 A	Based on	WO 9531985 A
US 5811451 A	Based on	WO 9531985 A
HU 77920 T	Based on	WO 9531985 A
EP 760661 B1	Based on	WO 9531985 A
DE 69507029 E	Based on	WO 9531985 A
AU 708778 B	Based on	WO 9531985 A

PRIORITY APPLN. INFO: IT 1994-MI1048 19940524
INT. PATENT CLASSIF.:

MAIN:	A61K031-485; A61K045-06
SECONDARY:	A61K031-00
IPC ORIGINAL:	A61K0031-185 [I,C]; A61K0031-191 [I,A]; A61K0031-485 [I,A]; A61K0031-485 [I,C]; A61K0031-69 [I,A]; A61K0031-69 [I,C]; A61K0033-06 [I,A]; A61K0033-06 [I,C]; A61K0038-43 [I,C]; A61K0038-48 [I,A]; A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0001-06 [I,A]; A61P0013-00 [I,A]; A61P0013-00 [I,C]; A61P0015-00 [I,A]; A61P0015-00 [I,C]; A61P0017-00 [I,A]; A61P0017-00 [I,C]; A61P0017-02 [I,A]; A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0021-00 [I,A]; A61P0021-00 [I,C]; A61P0025-00 [I,A]; A61P0025-00 [I,C]; A61P0025-02 [I,A]; A61P0025-28 [I,A]; A61P0029-00 [I,A]; A61P0029-00 [I,C]; A61P0031-00 [I,A]; A61P0031-00 [I,C]; A61P0037-00 [I,C]; A61P0037-02 [I,A]; A61P0043-00 [I,A]; A61P0043-00 [I,C]; A61P0009-00 [I,C]; A61P0009-10 [I,A]
IPC RECLASSIF.:	A61K0031-185 [I,C]; A61K0031-19 [I,A]; A61K0031-195 [I,A]; A61K0031-485 [I,A]; A61K0031-485 [I,C]; A61K0038-00 [I,A]; A61K0038-00 [I,C]; A61K0038-08 [I,A]; A61K0038-08 [I,C]; A61K0038-33 [I,A]; A61K0038-33 [I,C]; A61K0038-43 [I,C]; A61K0038-46 [I,A]; A61K0038-48 [I,A]; A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0013-00 [I,C]; A61P0013-02 [I,A]; A61P0015-00 [I,A]; A61P0015-00 [I,C]; A61P0015-14 [I,A]; A61P0025-00 [I,A]; A61P0025-00 [I,C]; A61P0025-28 [I,A]; A61P0029-00 [I,A]; A61P0029-00 [I,C]; A61P0031-00 [I,C]; A61P0031-04 [I,A]; A61P0031-12 [I,A]; A61P0037-00 [I,A]; A61P0037-00 [I,C]; A61P0043-00 [I,A]; A61P0043-00 [I,C]
ECLA:	A61K0031-485+M; A61K0038-08+M; A61K0038-33+M
USCLASS NCLM:	514/443.000
NCLS:	514/816.000; 514/823.000
JAP. PATENT CLASSIF.:	
MAIN/SEC.:	A61K0031-191; A61K0031-485; A61K0031-69; A61K0033-06; A61K0037-547; A61K0045-06; A61P0001-04; A61P0001-06; A61P0013-00; A61P0015-00; A61P0017-00; A61P0017-02; A61P0019-02; A61P0019-08; A61P0019-10; A61P0021-00; A61P0025-00; A61P0025-02; A61P0025-28; A61P0029-00; A61P0031-00; A61P0037-02; A61P0043-00 111; A61P0043-00 121; A61P0043-00 171; A61P0009-10
FTERM CLASSIF.:	4C084; 4C086; 4C201; 4C206; 4C086/AA01; 4C206/AA01; 4C084/AA02; 4C086/AA02; 4C206/AA02; 4C084/AA03; 4C084/AA20; 4C084/AA24; 4C084/BA33; 4C084/BA44; 4C084/BA50; 4C086/CB23; 4C206/DA02; 4C086/DA43; 4C084/DB75; 4C084/DC03; 4C086/HA04; 4C086/HA14; 4C086/HA20; 4C084/MA02; 4C086/MA02; 4C206/MA02; 4C086/MA03; 4C206/MA03; 4C086/MA04; 4C206/MA04; 4C206/MA11; 4C084/MA17; 4C206/MA17; 4C206/MA25; 4C206/MA30; 4C084/MA35; 4C084/MA52; 4C084/MA66; 4C084/NA14; 4C086/NA14; 4C206/NA14; 4C084/ZA02.2; 4C086/ZA02; 4C206/ZA02; 4C084/ZA16.2; 4C086/ZA16; 4C206/ZA16; 4C084/ZA20.2; 4C086/ZA20; 4C084/ZA22.2; 4C086/ZA22; 4C206/ZA22; 4C084/ZA36.2; 4C086/ZA36; 4C206/ZA36; 4C084/ZA40.2; 4C086/ZA40; 4C206/ZA40; 4C084/ZA68.2; 4C086/ZA68; 4C206/ZA68; 4C084/ZA73.2; 4C086/ZA73; 4C206/ZA73; 4C084/ZA81.2; 4C086/ZA81; 4C206/ZA81; 4C084/ZA89.2; 4C086/ZA89; 4C206/ZA89; 4C084/ZA94.2; 4C086/ZA94; 4C206/ZA94; 4C084/ZA96.2; 4C086/ZA96; 4C206/ZA96; 4C084/ZA97.2; 4C086/ZA97; 4C206/ZA97; 4C084/ZB07.2; 4C086/ZB07; 4C206/ZB07;

4C084/ZB11.2; 4C086/ZB11; 4C206/ZB11; 4C084/ZB32.2; 4C086/ZB32; 4C206/ZB32; 4C084/ZC21.2; 4C084/ZC39.2; 4C086/ZC39; 4C206/ZC39; 4C084/ZC41.2; 4C086/ZC41; 4C206/ZC41; 4C084/ZC61.2; 4C086/ZC61; 4C206/ZC61; 4C084/ZC75.2; 4C086/ZC75; 4C206/ZC75

BASIC ABSTRACT:

WO 1995031985 A2 UPAB: 20050702

A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia, nervous conducibility disturbances, Alzheimer's disease , cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia, hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception. MANUAL CODE: CPI: B04-A04; B05-A01B; B14-L06; C04-A04; C05-A01B; C14-L06

Member(0006)

ABEQ JP 10500423 W UPAB 20050702

A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia, nervous conducibility disturbances, Alzheimer's disease , cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia, hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception.

Member(0008)

ABEQ US 5811451 A UPAB 20050702

A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia,

nervous conducibility disturbances, Alzheimer's disease , cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia, hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception.

Member(0010)
ABEQ EP 760661 B1 UPAB 20050702
A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia, nervous conducibility disturbances, Alzheimer's disease , cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia, hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception.

Member(0014)
ABEQ CN 1151116 A UPAB 20050702
A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia, nervous conducibility disturbances, Alzheimer's disease , cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia,

hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception.

AN.S DCR-89832
CN.P CALCIUM DOBESILATE
CN.S Calcium; 2,5-dihydroxy-benzenesulfonate
SDCN R20556

CM 1

Ca

CM 2



=> d ibib ab kwic hitstr 18-19
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' - CONTINUE? (Y)/N:y

L219 ANSWER 18 OF 21 USPATFULL on STN

ACCESSION NUMBER:	2009:83827 USPATFULL Full-text		
TITLE:	CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS		
INVENTOR(S):	Bezwada, Rao S., Hillsborough, NJ, UNITED STATES		
PATENT ASSIGNEE(S):	BEZWADA BIOMEDICAL, LLC, Hillsborough, NJ, UNITED STATES (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090076174	A1	20090319
APPLICATION INFO.:	US 2008-203761	A1	20080903 (12)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2007-969787P		20070904 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FELDMANGALE, P.A., 1700 Market Street, Suite # 3130, Philadelphia, PA, 19103, US
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 1464
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure.

CLM What is claimed is:
40. A therapeutic method for treating psoriasis, inflammatory bowel disease, skin cancer, or a brain tumor in a patient, comprising: administering to a patient in need of. . .

IT 50-27-1, Estriol 50-60-2, Phentolamine 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies 51-49-0, Dextrothyroxine 51-61-6, Dopamine, biological studies 52-53-9, Verapamil 53-16-7, Estrone, biological studies 53-86-1, Indomethacin 54-03-5, Hexobendine 54-31-9, Furosemide 54-49-9, Metaraminol 56-53-1, Diethylstilbestrol 58-74-2, Papaverine 59-92-7, Levodopa, biological studies 60-99-1, Levomepromazine 61-68-7, Mefenamic acid 62-44-2, Phenacetin 63-12-7, Benzquinamide 65-45-2, Salicylamide 66-97-7, Psoralen 69-72-7, Salicylic acid, biological studies 70-30-4, Hexachlorophene 72-33-3, Mestranol 77-07-6, Levorphanol 77-09-8, Phenolphthalein 80-03-5, Acediasulfone 81-81-2, Warfarin 82-02-0, Khellin 83-73-8, Diiodohydroxyquinoline 83-89-6, Mepacrine 84-16-2, Hexestrol 84-17-3, Dienestrol 86-42-0, Amodiaquine 87-28-5, 2-Hydroxyethyl salicylate 88-04-0, Chloroxylenol 89-57-6, Mesalazine 90-05-1, Guaiacol 90-33-5, Hymecromone 90-34-6, Primaquine 94-09-7, Benzocaine 94-23-5, Parethoxycaine 96-84-4, Iophenoic acid 97-23-4, Dichlorophen 97-24-5, Fenticlor 97-44-9, Acetarsol 99-45-6, Adrenalone 101-93-9, Phenacaine 103-90-2 104-14-3, Octopamine 104-46-1, Anethole 115-33-3, Oxyphenisatin acetate 119-36-8, Methyl salicylate 127-35-5, Phenazocine 129-20-4, Oxyphenbutazone 130-26-7, Clioquinol 130-79-0, Dimestrol 136-70-9, Protokylol 136-77-6, Hexylresorcinol 138-41-0, Carzenide 138-56-7, Trimethobenz-amide 144-14-9, Anileridine 147-27-3, Dimoxyline 148-24-3, Oxyquin-oline, biological studies 152-72-7, Acenocoumarol 153-87-7, Oxypertine 154-23-4, Cianidanol 298-81-7, Methoxsalen 304-84-7, Etamivan 322-35-0, Benserazide 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 365-26-4, Oxilofrine 370-14-9, Pholedrine 390-28-3, Methoxamine 395-28-8, Isoxsuprine 404-86-4, Capsaicin 435-97-2, Phenprocoumon 447-41-6, Buphenine 452-35-7, Ethoxzolamide 469-79-4, Ketobemidone 482-27-9, Isopimpinellin 484-20-8, Bergapten 486-47-5, Ethaverine 486-60-2, Bergaptol 487-48-9, Salacetamide 490-79-9, Gentisic acid 491-38-3D, Chromone, derivs. 499-67-2, Proxymetacaine 501-36-0, Resveratrol 514-68-1, Estriol succinate 520-27-4, Diosmin 524-99-2, Medrylamine 530-08-5, Isoetarine 530-59-6, Sinapic acid 530-78-9, Flufenamic acid 532-03-6, Methocarbamol 533-22-2, Hydroxystilbamidine isethionate 536-21-0, Norfenefrine 539-08-2, Lactylphenetidin 548-00-5, Ethyl biscoum-acetate 552-94-3, Salsalate 555-30-6, Methyldopa 569-57-3, Chlorotrianisene 575-74-6, Buclosamide 579-23-7, Cyclovalone 586-06-1, Orciprenaline 599-79-1, Salazosulfapyridine 606-17-7, Adipiodone 635-41-6, Trimetozine 709-55-7, Etilefrine 738-70-5,

Trimethoprim 979-32-8, Estradiol valerate 1076-38-6, 4-Hydroxycoumarin 1134-47-0, Baclofen 1135-24-6, Ferulic acid 1143-38-0, Dithranol 1227-61-8, Mefexamide 1406-18-4, Vitamin E 1421-14-3, Propanidid 1477-19-6, Benzarone 1981-58-4, Sulmet 2295-58-1, Flopropione 2321-07-5, Fluorescein 2618-25-9, Ioglycamic acid 2624-44-4, Etamsylate 3115-05-7, Iobenzamic acid 3215-70-1, Hexoprenaline 3380-34-5, Triclosan 3625-06-7, Mebeverine 3703-79-5, Bamethan 3735-45-3 4008-48-4, Nitroxo-line 4350-09-8, Oxitriptan 4991-65-5, Tioxolone 5011-34-7, Trimetazidine 5104-49-4, Flurbiprofen 6808-72-6, Glaziovine 7004-98-0, Epimestrol 7400-08-0, 4-Hydroxycinnamic acid 7683-59-2, Isoprenaline 8067-69-4, Halquinols 10238-21-8, Glibenclamide 10397-75-8, Iocarmic acid 13392-18-2, Fenoterol 13460-98-5, Theo-drenaline 13739-02-1, Diacerein 15301-40-3, Actinoquinol 15307-86-5, Diclofenac 15686-51-8, Clemastine 15687-22-6 15687-27-1, Ibuprofen 15687-41-9, Oxyfedrine 16034-77-8, Iocetamic acid 16110-51-3, Cromoglicic acid 16662-47-8, Gallopamil 17365-01-4, Etiroxate 18559-94-9, Salbutamol 19035-45-1 20168-99-4, Cinmetacin 22071-15-4, Ketoprofen 22345-47-7, Tofisopam 22494-42-4, Diflunisal 22619-35-8, Tioclomarol 22888-70-6, Silibinin 23031-25-6, Terbutaline 23210-56-2, Ifenprodil 23887-46-9, Cinepazide 25803-14-9, Clometacin 26171-23-3, Tolmetin 26652-09-5, Ritodrine 26750-81-2, Alibendol 28395-03-1, Bumetanide 30418-38-3, Tretoquinol 30751-05-4, Troxipide 30964-13-7, Cynarine 31127-82-9, Iodoxamic acid 31848-01-8, Morclofone 32828-81-2, Picotamide 32953-89-2, Rimiterol 33005-95-7, Tiaprofenic acid 34368-04-2, Dobutamine 34633-34-6, Bifluranol 35212-22-7, Ipriflavone 35795-16-5, Trimazosin 35898-87-4, Dilazep 36330-85-5, Fenbufen 36894-69-6, Labetalol 37106-97-1, Bentiromide 39718-89-3, Alminoprofen 40828-46-4, Suprofen 41340-25-4, Etodolac 42794-76-3, Midodrine 42924-53-8, Nabumetone 46817-91-8, Viloxazine 51022-74-3, Iotroxic acid 52443-21-7, Glucametacin 52479-85-3, Exifone 53164-05-9, Acemetacin 53370-90-4, Exalamide 53597-27-6, Fendosal 53716-49-7, Carprofen 53731-36-5, Floredil 53808-87-0, Tetroxoprim 53902-12-8, Tranilast 54063-40-0, Fenoxedil 54063-54-6, Reproterol 55905-53-8, Clebopride 57526-81-5, Prenalterol 59170-23-9, Bevantolol 62666-20-0, Progabide 63590-64-7, Terazosin 65271-80-9, Mitoxantrone 66564-14-5, Cinitapride 67227-57-0, Fenoldopam mesylate 68302-57-8, Amlexanox 68767-14-6, Loxoprofen 69049-73-6, Nedocromil 71771-90-9, Denopamine 73573-87-2, Formo-terol 73590-58-6, Omeprazole 74103-06-3, Ketorolac 74150-27-9, Pimoben-dan 74191-85-8, Doxazosin 75659-07-3, Dilevalol 80573-04-2, Balsalazide 81801-12-9, Xamoterol 81840-15-5, Vesnarinone 82640-04-8, Raloxifene hydrochloride 82952-64-5, Trimetrexate glucuronate 86197-47-9, Dopexamine 86880-51-5, Epanolol 89365-50-4, Salmeterol 89796-99-6, Aceclofenac 106133-20-4, Tamsulosin 120014-06-4, Donepezil
(controlled-release of biol. active compds. from multi-armed oligomers for cosmetics and pharmaceutical composition)

IT 2624-44-4, Etamsylate
(controlled-release of biol. active compds. from multi-armed oligomers for cosmetics and pharmaceutical composition)

RN 2624-44-4 USPATFULL

CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N

CM 2

CRN 88-46-0
CMF C6 H6 O5 S



L219 ANSWER 19 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2005:208563 USPATFULL Full-text
TITLE: Method of preparation of mixed phase co-crystals with active agents
INVENTOR(S): Goldman, David, Portland, CT, UNITED STATES
PATENT ASSIGNEE(S): MedCrystalForms, LLC, Hunt Valley, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050181041	A1	20050818
APPLICATION INFO.:	US 2004-8034	A1	20041209 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-528232P	20031209 (60)
	US 2004-559862P	20040406 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH STETSON AVENUE, CHICAGO, IL, 60601-6780, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2916
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful for the delivery of the active agent, as well as compositions comprising the mixed phase co-crystals.
CLM What is claimed is:
. . . antimigraine drugs, antinauseant drugs, antineoplastic drugs, antineoplastic adjuncts, antiparkinsonian drugs, antipheochromocytoma drugs, antipneumocystis drugs, antiprostatic hypertrophy drugs, antiprotozoal drugs, antipuritics, antipsoriatic drugs,

antipsychotic drugs, antipyretics, antirickettsial drugs, antiseborrheic drugs, antiseptics, antispasmodic drugs, antithrombotic drugs, antitussive drugs, antiulcerative drugs, antiurolithic drugs, antiviral. . .

IT 50-21-5, Lactic acid, biological studies 50-70-4, Sorbitol, biological studies 50-70-4D, Sorbitol, esters 50-81-7, Ascorbic acid, biological studies 50-99-7, D-Glucose, biological studies 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-50-1, biological studies 57-88-5, Cholesterol, biological studies 63-42-3, Lactose 65-85-0, Benzoic acid, biological studies 68-11-1, Thioglycolic acid, biological studies 69-65-8, D-Mannitol 69-72-7, Salicylic acid, biological studies 69-93-2, Uric acid, biological studies 77-92-9, Citric acid, biological studies 79-10-7, Acrylic acid, biological studies 87-69-4, Tartaric acid, biological studies 87-99-0, Xylitol 88-46-0, Hydroquinonesulfonic acid 89-65-6, IsoAscorbic acid 107-92-6, Butyric acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate 115-77-5D, Pentaerythritol, esters 115-83-3, Pentaerythritol tetrastearate 124-04-9, Adipic acid, biological studies 138-36-3, p-Bromophenylsulfonic acid 142-91-6, Isopropyl palmitate 144-62-7, Oxalic acid, biological studies 526-95-4, D-Gluconic acid 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies 546-93-0, Magnesium carbonate 585-88-6, Maltitol 1309-48-4, Magnesium oxide, biological studies 1327-43-1, Magnesium aluminum silicate 1338-41-6, Sorbitan monostearate 7631-86-9, Silica, biological studies 7778-18-9, Calcium sulfate 8007-43-0, Sorbitan sesquioleate 9002-96-4 9003-39-8, Povidone 9004-53-9, Dextrins 9004-54-0, Dextran, biological studies 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9004-81-3, Polyethylene glycol laurate 9004-95-9, Polyethylene glycol cetyl ether 9004-98-2, Polyethylene glycol oleyl ether 9004-99-3, Polyethylene glycol stearate 9005-00-9, Polyethylene glycol stearyl ether 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-64-5, Polysorbate 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9005-82-7, Amylose 9009-32-9, Polyglyceryl stearate 9011-21-6, Polyethylene glycol glyceryl stearate 9011-29-4, Polyethylene glycol sorbitan hexastearate 9036-19-5, Polyethylene glycol octylphenyl ether 9050-36-6, Maltodextrin 9062-73-1, Polyethylene glycol sorbitan laurate 9063-38-1, Sodium starch glycolate 10043-35-3, Boric acid, biological studies 10103-46-5, Calcium phosphate 12619-70-4, Cyclodextrin 12772-47-3, Pentaerythritol oleate 13081-97-5, Pentaerythritol distearate 14807-96-6, Talc, biological studies 18641-57-1, Compritol 888ATO 22882-95-7, Isopropyl linoleate 25168-73-4, Sucrose monostearate 25339-99-5, Sucrose monolaurate 25637-97-2, Sucrose dipalmitate 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate 26446-38-8, Sucrose monopalmitate 26658-19-5, Sorbitan tristearate 27195-16-0, Sucrose distearate 27321-96-6, Polyethylene glycol cholesteryl ether 36928-92-4 37353-59-6, Hydroxymethyl cellulose 51938-44-4, Sorbitan sesquistearate 54392-26-6, Sorbitan monoisostearate 57307-93-4, Pentaerythritol caprylate 59070-56-3 61725-93-7, Polyglyceryl distearate 64044-51-5 67660-31-5 68958-64-5, Polyethylene glycol glyceryl trioleate 69070-98-0, Polyoxyethylene sorbitan tetraoleate 74504-64-6, Polyglyceryl laurate 74811-65-7, Croscarmellose sodium 83138-62-9, Polyglyceryl isostearate 98913-68-9, Pentaerythritol isostearate 110540-43-7, Polyglyceryl pentaoleate 121548-04-7, Gelucire 44/14 354575-58-9, Polyethylene glycol sorbitan tetrastearate 403821-12-5, Polyglyceryl trioleate 691397-13-4, Pluronic 854602-44-1

(preparation of mixed phase co-crystals with pharmaceuticals)
IT 88-46-0, Hydroquinonesulfonic acid
(preparation of mixed phase co-crystals with pharmaceuticals)
RN 88-46-0 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



=> d ibib ed ab ind 20-21
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' -
CONTINUE? (Y)/N:y

L219 ANSWER 20 OF 21 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2007190672 EMBASE Full-text
TITLE: Pharmacological treatments for basal cell carcinoma.
AUTHOR: Lee, Seongmu; Goldberg, Robert A.; Leibovitch, Igal, Dr. (correspondence)
CORPORATE SOURCE: Division of Orbital and Ophthalmic Plastic and Reconstructive Surgery, David Geffen School of Medicine at UCLA, Jules Stein Eye Institute, 100 Stein Plaza #2-267, Los Angeles, CA 90095-7006, United States. leibovitch@gmail.com
AUTHOR: Selva, Dinesh; Leibovitch, Igal, Dr. (correspondence)
CORPORATE SOURCE: Department of Ophthalmology and Visual Sciences, University of Adelaide, SA, Australia. leibovitch@gmail.com
AUTHOR: Selva, Dinesh
CORPORATE SOURCE: South Australian Institute of Ophthalmology, Adelaide, SA, Australia.
AUTHOR: Huilgol, Shyamala C.
CORPORATE SOURCE: Department of Dermatology, Royal Adelaide Hospital, University of Adelaide, SA, Australia.
SOURCE: Drugs, (2007) Vol. 67, No. 6, pp. 915-934.
Refs: 167
ISSN: 0012-6667; E-ISSN: 0012-6667 CODEN: DRUGAY
COUNTRY: New Zealand
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 016 Cancer
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 15 May 2007
Last Updated on STN: 15 May 2007
ED Entered STN: 15 May 2007

Last Updated on STN: 15 May 2007

AB Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer, and its incidence continues to rise. Current management options are numerous and focus on tumour eradication while maximising cosmetic and functional capacity. Although surgery continues to be considered the main treatment modality, new pharmacological agents, such as immunomodulators, topical chemotherapeutic agents and photodynamic therapy, have emerged and show promising results. Pharmacological agents offer the potential for lower morbidity and improved tissue preservation compared with surgery and radiotherapy. However, pharmacological treatments possess higher failure rates when compared with surgery, and most studies have investigated only low-risk lesions. Several prospective, randomised, double-blind, vehicle-controlled studies have established the efficacy of imiquimod for superficial BCC. This review summarises the evidence regarding the mechanism, efficacy and safety of pharmacological agents based on the literature from the past 10 years. Experimental treatments that have been successfully utilised in the treatment of BCC are also discussed. Treatment of BCC with other agents, such as tazarotene, glycoalkaloid (BEC-5) cream, cidofovir and calcium dobesilate have been reported, but further studies are needed to ascertain the efficacy and adverse-effect profiles of these treatments.

CT Medical Descriptors:
actinic keratosis: DT, drug therapy
angioneurotic edema: SI, side effect
applciation site stinging: SI, side effect
application site burning: SI, side effect
application site discharge: SI, side effect
application site discomfort: SI, side effect
application site erythema: SI, side effect
application site hyperpigmentation: SI, side effect
application site pain: SI, side effect
application site pruritus: SI, side effect
application site rash: SI, side effect
application site reaction: SI, side effect
application site scabbing: SI, side effect
application site stinging: SI, side effect
application site ulcer: SI, side effect
*basal cell carcinoma: DT, drug therapy
*basal cell carcinoma: RT, radiotherapy
*basal cell carcinoma: SU, surgery
*basal cell carcinoma: TH, therapy
bullous pemphigoid: SI, side effect
cancer recurrence
cancer risk
chill: SI, side effect
clinical feature
clinical trial
combination chemotherapy
contact dermatitis: SI, side effect
controlled clinical trial
crusting: SI, side effect
cryotherapy
curettage
desiccation
desquamation: SI, side effect
dosage schedule comparison
drug absorption
drug efficacy
drug formulation
drug hypersensitivity: SI, side effect

drug mechanism
drug safety
drug tolerability
drug withdrawal
edema: SI, side effect
electrode
erosion: SI, side effect
erythema: SI, side effect
fatigue: SI, side effect
fever: SI, side effect
flu like syndrome: DT, drug therapy
flu like syndrome: SI, side effect
follow up
headache: SI, side effect
heart muscle ischemia: SI, side effect
histopathology
human
hyperpigmentation: SI, side effect
hyperthermia: SI, side effect
hypertrophic scar: SI, side effect
hypopigmentation: SI, side effect
injection site discomfort: SI, side effect
injection site edema: SI, side effect
injection site erythema: SI, side effect
injection site reaction: SI, side effect
leakage: SI, side effect
leukopenia: SI, side effect
monotherapy
multimodality cancer therapy
myalgia: SI, side effect
nausea: SI, side effect
nausea and vomiting: SI, side effect
nonhuman
pain: SI, side effect
papular rash: SI, side effect
*photodynamic therapy
photosensitivity: SI, side effect
pruritus: SI, side effect
psoriasis: SI, side effect
randomized controlled trial
review
rigor: SI, side effect
side effect: SI, side effect
single drug dose
skin disease: SI, side effect
skin edema: SI, side effect
skin induration: SI, side effect
skin irritation: SI, side effect
skin manifestation: SI, side effect
skin pigmentation
skin ulcer: SI, side effect
thrombocytopenia: SI, side effect
tissue preservation
treatment failure
unspecified side effect: SI, side effect
vomiting: SI, side effect

CT Drug Descriptors:
acetylsalicylic acid: DT, drug therapy
acetylsalicylic acid: PD, pharmacology
adrenalin: AE, adverse drug reaction

adrenalin: CT, clinical trial
adrenalin: CB, drug combination
adrenalin: DT, drug therapy
alkaloid derivative: DT, drug therapy
alkaloid derivative: PD, pharmacology
alpha2a interferon: AE, adverse drug reaction
alpha2a interferon: CT, clinical trial
alpha2a interferon: CB, drug combination
alpha2a interferon: DT, drug therapy
alpha2a interferon: IL, intralesional drug administration
alpha2b interferon: AE, adverse drug reaction
alpha2b interferon: CT, clinical trial
alpha2b interferon: AD, drug administration
alpha2b interferon: CB, drug combination
alpha2b interferon: DO, drug dose
alpha2b interferon: DT, drug therapy
alpha2b interferon: DL, intradermal drug administration
alpha2b interferon: IL, intralesional drug administration
aminolaevulinic acid: AE, adverse drug reaction
aminolaevulinic acid: DT, drug therapy
aminolaevulinic acid: PD, pharmacology
antineoplastic agent: DT, drug therapy
antineoplastic agent: IL, intralesional drug administration
antineoplastic agent: IV, intravenous drug administration
antineoplastic agent: TP, topical drug administration
bleomycin: AE, adverse drug reaction
bleomycin: DT, drug therapy
bleomycin: IL, intralesional drug administration
celecoxib: DT, drug therapy
celecoxib: PD, pharmacology
cidofovir: DT, drug therapy
cidofovir: PD, pharmacology
cidofovir: TP, topical drug administration
dobesilate calcium: DT, drug therapy
dobesilate calcium: PD, pharmacology
fluorouracil: AE, adverse drug reaction
fluorouracil: CT, clinical trial
fluorouracil: CB, drug combination
fluorouracil: DT, drug therapy
fluorouracil: PR, pharmaceutics
fluorouracil: PD, pharmacology
fluorouracil: TP, topical drug administration
glycoalkaloid: AE, adverse drug reaction
glycoalkaloid: DT, drug therapy
glycoalkaloid: TP, topical drug administration
imiquimod: AE, adverse drug reaction
imiquimod: CT, clinical trial
imiquimod: DO, drug dose
imiquimod: DT, drug therapy
imiquimod: PK, pharmacokinetics
imiquimod: PD, pharmacology
interferon: AE, adverse drug reaction
interferon: CT, clinical trial
interferon: DT, drug therapy
interferon: PD, pharmacology
methylaminolaevulinic acid: AE, adverse drug reaction
methylaminolaevulinic acid: CT, clinical trial
methylaminolaevulinic acid: DT, drug therapy
methylaminolaevulinic acid: PD, pharmacology
nonsteroid antiinflammatory agent: CT, clinical trial

nonsteroid antiinflammatory agent: DT, drug therapy
paracetamol: DT, drug therapy
photofrin: AE, adverse drug reaction
photofrin: DT, drug therapy
photofrin: PD, pharmacology
photosensitizing agent: AE, adverse drug reaction
photosensitizing agent: CT, clinical trial
photosensitizing agent: DT, drug therapy
photosensitizing agent: PD, pharmacology
photosensitizing agent: TP, topical drug administration
placebo
recombinant alpha interferon: AE, adverse drug reaction
recombinant alpha interferon: CT, clinical trial
recombinant alpha interferon: DT, drug therapy
recombinant alpha interferon: TU, intratumoral drug administration
tazarotene: CT, clinical trial
tazarotene: DT, drug therapy
tazarotene: PD, pharmacology
tazarotene: TP, topical drug administration

RN (acetylsalicylic acid) 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; (adrenalin) 51-43-4, 55-31-2, 6912-68-1; (alpha2a interferon) 76543-88-9; (alpha2b interferon) 99210-65-8; (bleomycin) 11056-06-7; (celecoxib) 169590-42-5; (cidofovir) 113852-37-2; (dobesilate calcium) 20123-80-2; (fluorouracil) 51-21-8; (imiquimod) 99011-02-6; (paracetamol) 103-90-2; (photofrin) 85189-42-0; (tazarotene) 118292-40-3

CN aspirin

L219 ANSWER 21 OF 21 DRUGU COPYRIGHT 2009 THOMSON REUTERS on STN

ACCESSION NUMBER: 2002-47264 DRUGU T S Full-text

TITLE: Clinical evaluation of the efficacy and safety of calcium dobesilate in patients with chronic venous insufficiency of the lower limbs.

AUTHOR: Arceo A; Berber A; Trevino C

CORPORATE SOURCE: BASF-Pharma

LOCATION: Mexico City, Mexico

SOURCE: Angiology (53, No. 5, 539-544, 2002) 2 Fig. 52 Ref.
CODEN: ANGIAB ISSN: 0003-3197

AVAIL. OF DOC.: R. Guttierrez de Velasco 213, Fracc. Res. Alameda, Leon, Gto. CP 37210, Mexico. (Email: adalarce@prodigy.net.mx).

LANGUAGE: English

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

AB The efficacy of calcium dobesilate (Doxium) was investigated in the treatment of 352 patients with chronic venous insufficiency (CVI). A significant improvement in subjective complaints such as edema and in reduction of body weight occurred in CVI patients. Most showed a considerable reduction in or disappearance of symptoms. Reduction in the volume of edema represented a reduction in the volume of total body water, possibly explaining, in addition to other factors, the significant reduction in body weight. Side-effects included headache, epigastralgia, dizziness, nausea and pyrosis. It was concluded that calcium dobesilate is an interesting therapeutic option and can be an alternative to phytotherapy and surgical procedures.

AN 2002-47264 DRUGU T S Full-text
T Therapeutics
S Adverse Effects
35 Adverse Reactions
58 Vasoactive

CT [01] CALCIUM-DOBESILATE *TR; CALCIUM-DOBESILATE *AE; DOBESILAT *RN; DOXIUM *TR; DOXIUM *AE; CHRON. *TR; VENOUS *TR; INSUFFICIENCY *TR;

VASCULAR-DISEASE *TR; HEADACHE *AE; EPIGASTRALGIA *AE; DIZZINESS *AE; NAUSEA *AE; PYROSIS *AE; GASTROENTEROPATHY *AE; GASTROENTEROPATHY *AE; ESOPHAGUS-DISEASE *AE; CASES *FT; IN-VIVO *FT; SYMPTOMATOLOGY *FT; BODY-WEIGHT *FT; HEMOSTATICS *FT; TR *FT; AE *FT

RN: 20123-80-2

```
=> d que nos l70
L11 (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L12               SEL  PLU=ON  L11 1- RN :      82 TERMS
L13 (        82)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L12
L14               STR
L15 (        28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 (       270)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR
                  1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
                  1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
                  1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
                  1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
                  1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
                  1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
                  21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
                  8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
                  79122-68-2/CRN OR 88-46-0/CRN)
L17          293 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L15 OR L16
L18          129 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L17 NOT PMS/CI
L21              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24              QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28              QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29              QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                 U,AUTH
L31              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33              QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34              QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38              QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42              QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43              QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44              QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45              QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46              QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50              QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51              QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                 PA
L53              QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54              QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L55              QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56              QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L57              QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L58              QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L59          780 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L18
L60           11 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 (L)((L53 OR L54
```

```
                OR L55 OR L56))
L61           10 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L58
L62            6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L57
L63               QUE  SPE=ON  ABB=ON  PLU=ON  "DERMATOLOGICAL AGENTS"+PFT,
                  OLD,NEW/CT
L64            3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L63
L65            1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L64 AND (L55 OR L56)
L66            7 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND (L55 OR L56)
L67           20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L60 OR L61 OR L62)
                  OR (L64 OR L65 OR L66)
L68           20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L67 AND (L53 OR L54
                  OR L55 OR L56)
L69           20 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L67 OR L68)
L70           14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L69 AND (L21 OR L22
                  OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
                  OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
                  OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
                  OR L50 OR L51)


=> d que nos l122
L9                STR
L19           34 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (1595296-K/AN.S OR
                  1595296-M/AN.S OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K
                  /AN.S OR 1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR
                  9091-U/AN.S OR DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/A
                  N.S OR DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S
                   OR DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S
                  OR DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR
                  DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR
                  DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR
                  DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR
                  DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR
                  DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/A
                  N.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR
                  DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/
                  AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR
                  12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.
                  S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR
                  1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K
                  /AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR
                  1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M
                  /AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR
                  1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K
                  /AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR
                  1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M
                  /AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR
                  1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/
                  AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR
                  528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR
                  86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
                  91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
                  OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
                  )
L21               QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22               QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23               QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24               QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25               QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26               QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
```

```
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L53             QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54             QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L58             QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L74             QUE  SPE=ON  ABB=ON  PLU=ON  (B14-N17C OR C14-N17C OR B12
                -A07 OR C12-A07)/MC
L106       1009 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (R00180/SDCN OR R03057/SD
                CN OR R10974/SDCN OR R18653/SDCN OR R18808/SDCN OR RACANB/SDCN
                OR RACRCN/SDCN OR RACRCO/SDCN OR RACRCQ/SDCN OR RACRCY/SDCN OR
                RACRCZ/SDCN OR RACRDB/SDCN OR RACRDC/SDCN OR RACRDE/SDCN OR
                RACRDF/SDCN OR RACRDG/SDCN OR RACRDH/SDCN OR RACRDN/SDCN OR
                RACRDO/SDCN OR RACRDQ/SDCN OR RACRDR/SDCN OR RACRDS/SDCN OR
                RACRDV/SDCN OR RACRD0/SDCN OR RADRS8/SDCN OR RAF0PZ/SDCN OR
                RA0DJE/SDCN OR RA0HDM/SDCN OR RA00C8/SDCN OR RA00GT/SDCN OR
                RA00H3/SDCN OR RA00TQ/SDCN OR RA012O/SDCN OR RA0120/SDCN OR
                RA02SP/SDCN OR RA04OB/SDCN OR RA088T/SDCN OR RA1HNP/SDCN OR
                RA1YR6/SDCN OR RA6EV7/SDCN OR R00076/SDCN OR R00122/SDCN OR
                R00137/SDCN OR R00291/SDCN OR R00689/SDCN OR R01330/SDCN OR
                R01987/SDCN OR R02044/SDCN OR R02049/SDCN OR R02069/SDCN OR
                R03442/SDCN OR R04259/SDCN OR R06973/SDCN OR R09011/SDCN OR
                R10769/SDCN OR R11063/SDCN OR R12996/SDCN OR R20748/SDCN OR
                R21749/SDCN OR R23692/SDCN OR RAAJSH/SDCN OR RAALE1/SDCN OR
                RAAMCC/SDCN OR RAAMCD/SDCN OR RAAMCE/SDCN OR RAAMCF/SDCN OR
                RAAMCG/SDCN OR RAAMCI/SDCN OR RAAMCK/SDCN OR RAAMCN/SDCN OR
                RAAMCO/SDCN OR RAAMCP/SDCN OR RAAMCQ/SDCN OR RAAMCR/SDCN OR
                RAAMCS/SDCN OR RAAMCT/SDCN OR RAAMCW/SDCN OR RAAMCX/SDCN OR
                RAAMCY/SDCN OR RAAMCZ/SDCN OR RAAMDF/SDCN OR RAAMDG/SDCN OR
                RAAMDJ/SDCN OR RAAMDL/SDCN OR RAAMDM/SDCN OR RAAMDN/SDCN OR
                RAAMDO/SDCN OR RAAMDP/SDCN OR RAAMDR/SDCN OR RAAMDS/SDCN OR
                RAAMDT/SDCN OR RAAMDU/SDCN OR RAAMD0/SDCN OR RAAMD1/SDCN OR
                RAAMD2/SDCN OR RAAMD6/SDCN OR RAAM1I/SDCN OR RAAM1J/SDCN OR
                RAAM1K/SDCN OR RAAM1L/SDCN OR RAAM1M/SDCN OR RAAM1N/SDCN OR
```

RAAM1O/SDCN OR RAAM1P/SDCN OR RAAM1Q/SDCN OR RAAM1R/SDCN OR RAAM1S/SDCN OR RAAM1T/SDCN OR RAAM1U/SDCN OR RAAM1V/SDCN OR RAAM1W/SDCN OR RAAM1X/SDCN OR RAAM1Y/SDCN OR RAAM1Z/SDCN OR RAAM2A/SDCN OR RAAM2B/SDCN OR RAAM2C/

L107 418 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA02SP/SDCN OR R18653/SDCN OR R01614/SDCN OR R04292/SDCN OR R13080/SDCN OR R23692/SDCN OR RA0DWB/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA01SC/SDCN OR RA02JW/SDCN OR RA04OB/SDCN OR RA1C7N/SDCN OR RA28R6/SDCN OR RA5D1M/SDCN OR R00095/SDCN OR R00298/SDCN OR R03361/SDCN OR R04116/SDCN OR R04227/SDCN OR R04654/SDCN OR R09668/SDCN OR RA0K9J/SDCN OR RA00C8/SDCN OR RA01E9/SDCN OR RA1HNP/SDCN OR RA43CA/SDCN OR RA74YB/SDCN OR RA74YC/SDCN OR RA74YE/SDCN OR RA74YZ/SDCN OR RA74Y7/SDCN OR RA74Y8/SDCN OR RA74ZA/SDCN OR RA74ZI/SDCN OR RA74ZY/SDCN OR RA74ZZ/SDCN OR RA74Z0/SDCN OR RA74Z1/SDCN OR RA74Z2/SDCN OR RA74Z3/SDCN OR RA74Z4/SDCN OR RA74Z5/SDCN OR RA74Z7/SDCN OR RA74Z8/SDCN OR RA74Z9/SDCN OR RA750A/SDCN OR RA750B/SDCN OR RA7500/SDCN OR RA7501/SDCN OR RA7502/SDCN OR RA7503/SDCN OR RA7505/SDCN OR RA7506/SDCN OR RA7507/SDCN OR RA7508/SDCN OR R00271/SDCN OR R00991/SDCN OR RA0CGV/SDCN OR RA0C4V/SDCN OR RA0HNY/SDCN OR RA0IKS/SDCN OR RA0KH3/SDCN OR RA0LMH/SDCN OR RA0MTA/SDCN OR RA0WLX/SDCN OR RA006H/SDCN OR RA01BE/SDCN OR RA01Q7/SDCN OR RA01SX/SDCN OR RA015V/SDCN OR RA02DZ/SDCN OR RA021Q/SDCN OR RA027G/SDCN OR RA027I/SDCN OR RA027J/SDCN OR RA03SR/SDCN OR RA03YX/SDCN OR RA03YY/SDCN OR RA05GM/SDCN OR RA05JM/SDCN OR RA05WC/SDCN OR RA07GX/SDCN OR RA1HN1/SDCN OR RA1QEQ/SDCN OR RA1QSX/SDCN OR RA1YFH/SDCN OR RA13IL/SDCN OR RA13XQ/SDCN OR RA152R/SDCN OR RA18TQ/SDCN OR RA2VNT/SDCN OR RA20DZ/SDCN OR RA3ITX/SDCN OR RA3SGW/SDCN OR RA41J1/SDCN OR RA44DH/SDCN OR RA6SD5/SDCN OR RA6VEH/SDCN OR RA6VEI/SDCN OR RA6VEJ/SDCN OR RA6VEK/SDCN OR RA6VEL/SDCN OR RA6VEM/SDCN OR RA6VEN/SDCN OR RA6VEO/SDCN OR RA6VEP/SDCN OR RA6VER/SDCN OR RA6VES/SDCN OR RA6VET/SDCN OR RA6VEU/SDCN OR RA6VEV/SDCN OR RA6VEW/SDCN OR RA6VEX/SDCN OR RA6VEY/SDCN OR RA6VEZ/SDCN OR RA6VFA/SDCN OR RA6VFB/SDCN OR RA6VFC/SDCN OR RA6VFD/SDCN OR RA6VFE/SDCN OR RA6VFF/SDCN OR RA6VFG/SDCN OR RA6VFH/SDCN OR RA6VFI/SDCN OR RA6VFJ/SDCN OR RA6VFK/SDCN OR RA6VFL

L108 324 SEA FILE=WPIX SPE=ON ABB=ON PLU=ON (RA00C8/SDCN OR RA0ETL/SDCN OR RA0ETQ/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA0K9J/SDCN OR RA0YL4/SDCN OR RA00GT/SDCN OR RA02JW/SDCN OR RA02SP/SDCN OR RA04OB/SDCN OR RA1HNP/SDCN OR RA28R6/SDCN OR RA43CA/SDCN OR R00477/SDCN OR R00669/SDCN OR R01119/SDCN OR R03562/SDCN OR R04115/SDCN OR R04292/SDCN OR R09668/SDCN OR R13080/SDCN OR R18653/SDCN OR R23692/SDCN OR RA00H1/SDCN OR RA00NS/SDCN OR RA01SC/SDCN OR RA012P/SDCN OR RA043B/SDCN OR RA043C/SDCN OR RA043E/SDCN OR RA043F/SDCN OR RA043G/SDCN OR RA043H/SDCN OR RA043I/SDCN OR RA043J/SDCN OR RA043K/SDCN OR RA043L/SDCN OR RA043M/SDCN OR RA043N/SDCN OR RA043O/SDCN OR RA043P/SDCN OR RA1C7N/SDCN OR RA1ILG/SDCN OR RA1ILH/SDCN OR RA1ILU/SDCN OR RA1ILW/SDCN OR RA1ILX/SDCN OR RA1ILY/SDCN OR RA1ILZ/SDCN OR RA1IMB/SDCN OR RA1IMK/SDCN OR RA1IMO/SDCN OR RA1IM0/SDCN OR RA1IM2/SDCN OR RA1IM4/SDCN OR RA1IM9/SDCN OR RA1INB/SDCN OR RA1IND/SDCN OR RA1IN0/SDCN OR RA1IN2/SDCN OR RA1IN5/SDCN OR RA1IN6/SDCN OR RA1IN7/SDCN OR RA1OOA/SDCN OR RA1OOC/SDCN OR RA1OOD/SDCN OR RA1OOF/SDCN OR RA1OO0/SDCN OR RA1OO2/SDCN OR RA1OO3/SDCN OR RA1OO4/SDCN OR RA1OO5/SDCN OR RA1OO6/SDCN OR RA1OO7/SDCN OR RA1OO8/SDCN OR RA1OO9/SDCN OR RA1WSI/SDCN OR RA1WSJ/SDCN OR RA1WSQ/SDCN OR RA1WTY/SDCN OR RA17JY/SDCN OR RA17KF/SDCN OR RA17KG/SDCN OR RA17K3/SDCN OR RA195G/SDCN OR RA195H/SDCN OR RA195I/SDCN OR RA195J/SDCN OR RA195K/SDCN OR

```
                RA195L/SDCN OR RA195M/SDCN OR RA195N/SDCN OR RA195O/SDCN OR
                RA2FSP/SDCN OR RA250K/SDCN OR RA250R/SDCN OR RA250S/SDCN OR
                RA250T/SDCN OR RA250V/SDCN OR RA250W/SDCN OR RA250X/SDCN OR
                RA250Y/SDCN OR RA2510/SDCN OR RA2511/SDCN OR RA2512/SDCN OR
                RA2513/SDCN OR RA2514/SDCN OR RA2515/SDCN OR RA2516/SDCN OR
                RA2517/SDCN OR RA2518/SDCN OR RA2519/SDCN OR RA33DB/SDCN OR
                RA33DC/SDCN OR RA33DD/SDCN OR RA33DO/SDCN OR RA33DP/SDCN OR
                RA33DW/SDCN OR RA33D7/SDCN OR RA33D8/SDCN OR RA33EN/SDCN OR
                RA33ER/SDCN OR RA33ES/SDCN OR RA33E1/S
L109        1658 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (L106 OR L107 OR L108)
L112        1685 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L109 OR L19
L114          22 SEA FILE=WPIX SUB=L112 SSS FUL L9
L118          16 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (RASW2T/DCN OR RASW2U/DCN
                  OR RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW3A/DCN OR
                RASW3B/DCN OR RASW3C/DCN OR RASW3D/DCN OR RASW3E/DCN OR
                RASW3F/DCN OR RASW3G/DCN OR RASW3H/DCN OR RASW39/DCN OR
                RAUHHC/DCN OR RAUHHD/DCN OR RAUHHE/DCN OR RAUHHF/DCN OR
                RAUHHG/DCN OR RAUHHH/DCN OR RAUHH9/DCN OR RA2Y7A/DCN) OR
                L114/DCR
L119           6 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L118 AND (L58 OR L74 OR
                (L55 OR L56))
L120          14 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L118 AND (L53 OR L54 OR
                L55 OR L56)
L121          14 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (L119 OR L120)
L122          13 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L121 AND (L21 OR L22 OR
                L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
                L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR
                L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR
                L50 OR L51)


=> d que nos l165
L11 (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L12               SEL  PLU=ON  L11 1- RN :      82 TERMS
L13 (        82)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L12
L14               STR
L15 (        28)SEA FILE=REGISTRY SUB=L13 SSS FUL L14
L16 (       270)SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR
                1007839-72-6/CRN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR
                1007839-91-9/CRN OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR
                1007839-96-4/CRN OR 1007840-16-5/CRN OR 1007840-17-6/CRN OR
                1007840-18-7/CRN OR 1007840-19-8/CRN OR 1007840-20-1/CRN OR
                1007840-21-2/CRN OR 1007840-22-3/CRN OR 1007840-23-4/CRN OR
                1007840-24-5/CRN OR 1007849-27-5/CRN OR 159252-66-1/CRN OR
                21799-87-1/CRN OR 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-
                8/CRN OR 60630-38-8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR
                79122-68-2/CRN OR 88-46-0/CRN)
L17          293 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L15 OR L16
L18          129 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L17 NOT PMS/CI
L21              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24              QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28              QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29              QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
```

```
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L53             QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54             QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L57             QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L58             QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L59          780 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L18
L63             QUE  SPE=ON  ABB=ON  PLU=ON  "DERMATOLOGICAL AGENTS"+PFT,
                OLD,NEW/CT
L64            3 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L59 AND L63
L126            STR
L128            SCR 1812 OR 1758
L130        1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131        1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143         173 SEA FILE=REGISTRY SSS FUL L141
L144         170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145         146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148         160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149         133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150        1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L151        1760 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L150
L152          11 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L151 AND L58
L153           8 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L151 AND L57
L154           9 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L151 AND (L55 OR L56)

L155          14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L152 OR L153 OR
                L154)
L156            QUE  SPE=ON  ABB=ON  PLU=ON  "SKIN, DISEASE"+PFT,OLD,NEW,
                NT/CT
L157          95 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L151 AND (L156 OR L64
                OR (L53 OR L54 OR L55 OR L56 OR L57))
L158         316 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L151 (L)(THU OR PKT
                OR PAC OR DMA OR BAC)/RL
L159          63 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L157 AND L158
L160            QUE  SPE=ON  ABB=ON  PLU=ON  DISEAS? OR DISORDER? OR SYND
                ROM? OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB
```

```
                ? OR DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
L161         18 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L159 AND ((L53 OR
                L54) (3A) L160)
L162         27 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L155 OR L161
L163         27 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L162 AND ((L53 OR L54
                OR L55 OR L56 OR L57 OR L58) OR L64)
L164         27 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  (L162 OR L163)
L165         14 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L164 AND (L21 OR L22
                OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
                OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
                OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
                OR L50 OR L51)


=> d his l213

     (FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:20:08 ON 25 SEP 2009)
L213          3 S L212 AND L21-L51

=> d que nos l213
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L126            STR
L128            SCR 1812 OR 1758
L130         1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131         1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
```

```
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L186            QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS
L204            QUE  SPE=ON  ABB=ON  PLU=ON  WILLAN (1A) LEPRA
L205            QUE  SPE=ON  ABB=ON  PLU=ON  PARAPSORIA?
L210        333 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L150 AND (USPATFULL
                OR USPAT2 OR USPATOLD)/LC
L211        409 SEA L210
L212          5 SEA L211 AND (L55/CLM OR L56/CLM OR L186/CLM OR L204/CLM OR
                L205/CLM)
L213          3 SEA L212 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
                L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
                L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
                L46 OR L47 OR L48 OR L49 OR L50 OR L51)


=> d que nos l175
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L58             QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L74             QUE  SPE=ON  ABB=ON  PLU=ON  (B14-N17C OR C14-N17C OR B12
                -A07 OR C12-A07)/MC
```

```
L126            STR
L128            SCR 1812 OR 1758
L141            STR
L169         82 SEA FILE=WPIX SSS FUL (L128 AND L126)
L171         15 SEA FILE=WPIX SSS FUL L141
L172         97 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L169 OR L171
L173        122 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (RABCOA/DCN OR RABCO3/DCN
                 OR RABCO8/DCN OR RABCO9/DCN OR RABNDP/DCN OR RABNDQ/DCN OR
                RAGHZJ/DCN OR RAGHZM/DCN OR RAHO0Q/DCN OR RAI7ME/DCN OR
                RAKQX2/DCN OR RALH0H/DCN OR RAL3SN/DCN OR RAL3SO/DCN OR
                RAL3SP/DCN OR RAL3SQ/DCN OR RAL3SR/DCN OR RAL3ST/DCN OR
                RANFVN/DCN OR RAN401/DCN OR RAN403/DCN OR RAPVAI/DCN OR
                RAPVAJ/DCN OR RAPVAK/DCN OR RAQW9I/DCN OR RAQW9P/DCN OR
                RAQW9R/DCN OR RAR1ZL/DCN OR RASW2T/DCN OR RASW2U/DCN OR
                RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW2Y/DCN OR
                RASW2Z/DCN OR RASW3A/DCN OR RASW3B/DCN OR RASW3C/DCN OR
                RASW3D/DCN OR RASW3E/DCN OR RASW3F/DCN OR RASW3G/DCN OR
                RASW3H/DCN OR RASW30/DCN OR RASW38/DCN OR RASW39/DCN OR
                RASW4A/DCN OR RASW50/DCN OR RASXL7/DCN OR RAUHHC/DCN OR
                RAUHHD/DCN OR RAUHHE/DCN OR RAUHHF/DCN OR RAUHHG/DCN OR
                RAUHHH/DCN OR RAUHH9/DCN OR RAUVSQ/DCN OR RAUVSR/DCN OR
                RAWFMV/DCN OR RAWUPX/DCN OR RAW47P/DCN OR RAW47Q/DCN OR
                RAW47R/DCN OR RAW47S/DCN OR RAW47T/DCN OR RAW47U/DCN OR
                RAXSIA/DCN OR RA0MNZ/DCN OR RA002O/DCN OR RA007X/DCN OR
                RA0083/DCN OR RA2NB0/DCN OR RA2Y7A/DCN OR RA3MBV/DCN OR
                RA4GNI/DCN OR RA4GOC/DCN OR RA4GOL/DCN OR RA4KMT/DCN OR
                RA4KMZ/DCN OR RA4KN3/DCN OR RA4KN4/DCN OR RA4NBT/DCN OR
                RA4NBW/DCN OR RA6Q5K/DCN OR RA63TX/DCN OR RA660M/DCN OR
                RA8AOM/DCN OR RA9JSH/DCN OR RA9JSI/DCN OR RA9XSQ/DCN OR
                RB0D0S/DCN OR RB0D0T/DCN OR RB0D0U/DCN OR RB0D0V/DCN OR
                R11693/DCN OR R11694/DCN OR R20556/DCN OR R21482/DCN) OR
                L172/DCR
L174         10 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L173 AND (L58 OR L74 OR
                (L55 OR L56))
L175          7 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L174 AND (L21 OR L22 OR
                L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
                L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR
                L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR
                L50 OR L51)


=> d que nos l189
L3  (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4              SEL  PLU=ON  L3 1- RN :      82 TERMS
L5           82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
```

```
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L179         28 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150
L180          7 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L150 AND MEDLINE/LC
L181        392 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L180
L182            SEL  PLU=ON  L179 1- NAME :      13 TERMS
L183         17 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L182
L184        399 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L181 OR L183
L185            QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L186            QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS
L187            QUE  SPE=ON  ABB=ON  PLU=ON  "SKIN DISEASES, PAPULOSQUAMO
                US"+PFT,OLD,NEW,NT/CT
L188          1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L184 AND ((L55 OR
                L56) OR L185 OR (L186 OR L187))
L189          1 SEA FILE=MEDLINE SPE=ON  ABB=ON  PLU=ON  L188 AND (L21 OR L22
                OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
                OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
                OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
                OR L50 OR L51)


=> d que nos l198
L3  (          5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4              SEL  PLU=ON  L3 1- RN :      82 TERMS
L5             82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
```

```
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L179         28 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150
L182            SEL  PLU=ON  L179 1- NAME :      13 TERMS
L186            QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS
L191          4 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L150 AND EMBASE/LC
L192        794 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L191
L193         69 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L182
L194        838 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  (L192 OR L193)
L195            QUE  SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L196            QUE  SPE=ON  ABB=ON  PLU=ON  "ERYTHEMATOSQUAMOUS SKIN DIS
                EASE"+PFT,OLD,NEW,NT/CT
L197          2 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L194 AND ((L55 OR L56)
                OR L186 OR (L195 OR L196))
L198          1 SEA FILE=EMBASE SPE=ON  ABB=ON  PLU=ON  L197 AND (L21 OR L22
                OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
                OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40
                OR L41 OR L42 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49
                OR L50 OR L51)
```

```
=> d his l208

     (FILE 'BIOSIS, BIOTECHNO, CABA, DRUGU, VETU' ENTERED AT 11:16:26 ON 25
     SEP 2009)
L208          0 S L207 AND L21-L51

=> d que nos l208
L3  (         5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4              SEL  PLU=ON  L3 1- RN :      82 TERMS
L5            82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4
L21             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23             QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24             QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27             QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28             QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29             QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32             QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33             QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34             QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37             QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38             QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
L53             QUE  SPE=ON  ABB=ON  PLU=ON  SKIN
L54             QUE  SPE=ON  ABB=ON  PLU=ON  ?DERM?
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L160            QUE  SPE=ON  ABB=ON  PLU=ON  DISEAS? OR DISORDER? OR SYND
                ROM? OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB
```

```
                ? OR DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
L179          28 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150
L182             SEL  PLU=ON  L179 1- NAME :      13 TERMS
L200          11 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L150 AND (BIOSIS OR
                BIOTECHNO OR CABA OR DRUGU OR VETU)/LC
L201         437 SEA L200
L202          45 SEA L182
L203         469 SEA (L201 OR L202)
L207           2 SEA L203 AND ((L53 OR L54) (5A) L160)
L208           0 SEA L207 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
                L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
                L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
                L46 OR L47 OR L48 OR L49 OR L50 OR L51)


=> d his l217

     (FILE 'HCAPLUS, WPIX, PASCAL, JAPIO, MEDLINE, BIOSIS, EMBASE, CABA,
     CEABA-VTB, LIFESCI, KOSMET, BIOENG, BIOTECHNO, BIOTECHDS, DRUGU, DRUGB,
     VETU, VETB, SCISEARCH, CONFSCI, DISSABS, RDISCLOSURE' ENTERED AT 11:29:03
     ON 25 SEP 2009)
L217          12 S L216 AND L21-L51

=> d que nos l217
L3  (          5)SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4               SEL  PLU=ON  L3 1- RN :      82 TERMS
L5            82 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L4
L21              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23              QUE  SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24              QUE  SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27              QUE  SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28              QUE  SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29              QUE  SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/A
                U,AUTH
L31              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32              QUE  SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33              QUE  SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34              QUE  SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37              QUE  SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38              QUE  SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
L40              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41              QUE  SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42              QUE  SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43              QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44              QUE  SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45              QUE  SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46              QUE  SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49              QUE  SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50              QUE  SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51              QUE  SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,
                PA
```

```
L55             QUE  SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE  SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
L58             QUE  SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC
L126            STR
L128            SCR 1812 OR 1758
L130       1799 SEA FILE=REGISTRY SSS FUL (L128 AND L126)
L131       1294 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L141            STR
L143        173 SEA FILE=REGISTRY SSS FUL L141
L144        170 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES
L146            STR
L148        160 SEA FILE=REGISTRY SUB=L143 SSS FUL L146
L149        133 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L131 OR L149
L179         28 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  L5 AND L150
L182            SEL  PLU=ON  L179 1- NAME :      13 TERMS
L186            QUE  SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS
L204            QUE  SPE=ON  ABB=ON  PLU=ON  WILLAN (1A) LEPRA
L205            QUE  SPE=ON  ABB=ON  PLU=ON  PARAPSORIA?
L215        425 SEA L182
L216         13 SEA L215 AND ((L55 OR L56) OR L186 OR (L204 OR L205) OR L58)
L217         12 SEA L216 AND (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR
                L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR
                L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR
                L46 OR L47 OR L48 OR L49 OR L50 OR L51)


=> dup rem l70 l122 l165 l213 l175 l189 l198 l208 l217
L208 HAS NO ANSWERS
DUPLICATE IS NOT AVAILABLE IN 'KOSMET, RDISCLOSURE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
FILE 'HCAPLUS' ENTERED AT 11:50:56 ON 25 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 11:50:56 ON 25 SEP 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 11:50:56 ON 25 SEP 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:50:56 ON 25 SEP 2009

FILE 'EMBASE' ENTERED AT 11:50:56 ON 25 SEP 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.
PROCESSING COMPLETED FOR L70
PROCESSING COMPLETED FOR L122
PROCESSING COMPLETED FOR L165
PROCESSING COMPLETED FOR L213
PROCESSING COMPLETED FOR L175
PROCESSING COMPLETED FOR L189
PROCESSING COMPLETED FOR L198
PROCESSING COMPLETED FOR L208
PROCESSING COMPLETED FOR L217
L220         22 DUP REM L70 L122 L165 L213 L175 L189 L198 L208 L217 (43 DUPLICATES
REMOVED)
                ANSWERS '1-15' FROM FILE HCAPLUS
                ANSWERS '16-19' FROM FILE WPIX
```

```
ANSWERS '20-21' FROM FILE USPATFULL
ANSWER '22' FROM FILE MEDLINE


=> file stnguide
FILE 'STNGUIDE' ENTERED AT 11:51:10 ON 25 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 18, 2009 (20090918/UP).
```

```
=> d ibib ed abs hitind hitstr 1-15
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' - CONTINUE?
(Y)/N:y



L220 ANSWER 1 OF 22  HCAPLUS  COPYRIGHT 2009 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2009:1018664  HCAPLUS  Full-text
DOCUMENT NUMBER:          151:272952
TITLE:                    Skin penetration enhancing systems for polar
                          drugs
INVENTOR(S):              Osborne, David W.; Sarpotdar, Pramod P.; Angel, Arturo
                          J.; Saenz De Tejada Gorman, Inigo; Cuevas
                          Sanchez, Pedro
PATENT ASSIGNEE(S):       USA
SOURCE:                   PCT Int. Appl., 51pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2009103069         A1    20090820    WO 2009-US34304         20090217
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       US 2008-29231P      P  20080215
ED   Entered STN:  21 Aug 2009
AB   The invention relates to pharmaceutical compns. and related methods for the
     topical administration of polar drugs.  In a particular embodiment, the
     invention relates to a pharmaceutical composition comprising an active
     pharmaceutical agent that is a polar drug, such as potassium 2,5-
     dihydroxybenzenesulfonate (I), at least one occlusive agent, and at least one
     stabilizer.  A formulation contains about 10 % I, about 20 % white petrolatum,
     about 20 % mineral oil, about 2.5 % stearyl alc., about 0.5 % cetyl alc.,
     about 1.0 % steareth-2, about 4.0 % steareth-21, about 0.5 % benzyl alc.,
     about 0.1 % sodium thiosulfate pentahydrate, about 0.05 % acetic acid, about
     0.02 % sodium acetate, and water to 100 %.
CC   63-6 (Pharmaceuticals)
ST   skin penetration enhancing system topical polar drug; topical
     potassium dobesilate occlusive agent stabilizer
IT   pH
        (adjuster for, penetration enhancing system further containing; occlusive
        agents and stabilizers in skin penetration enhancing systems
        for polar drugs)
IT   Hydrocarbon oils
     Hydrocarbon waxes
```

Paraffin oils
Petrolatum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as occlusive agent; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Emulsifying agents
Solubilizers
(as stabilizing agents; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Foams
(boosters of, as stabilizing agents; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Salts
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drugs in form of; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Polar molecules
(drugs; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Solubilizers
(hydrotopes, as stabilizing agents; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Ions
(mol., drugs in form of; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Permeation enhancers
Skin
Stabilizing agents
Topical drug delivery systems
(occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Polyoxyalkylenes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Antioxidants
Preservatives
Solvents
Surfactants
Thickening agents
(penetration enhancing system further containing; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Biological transport
(permeation; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Drugs
(polar; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Suspensions
(suspending agents, as stabilizing agents; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT Skin, disease
(treatment of, with topical potassium dobesilate; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT 123-31-9D, 1,4-Benzenediol, derivs., salts, solvates, isomers, prodrugs, biological studies 2624-44-4, Ethamsylate 20123-80-2, Calcium dobesilate 97225-83-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as drug; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT 9005-00-9, Steareth 12441-09-7, Sorbitan 12441-09-7D, Sorbitan, fatty acid esters, PEG derivs. 25322-68-3D, Polyethylene glycol, derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as emulsifying agent for stabilizer; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as polar drug; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT 57-55-6, Propylene glycol, biological studies 64-19-7, Acetic acid, biological studies 100-51-6, Benzyl alcohol, biological studies 112-92-5, Stearyl alcohol 127-09-3, Sodium acetate 1338-41-6, Span 60 7732-18-5, Water, biological studies 9005-67-8, Tween 60 10102-17-7, Sodium thiosulfate pentahydrate 36653-82-4, Cetyl alcohol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

IT 2624-44-4, Ethamsylate 20123-80-2, Calcium dobesilate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as drug; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)

RN 2624-44-4 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N

CM 2

CRN 88-46-0
CMF C6 H6 O5 S



RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

IT 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as polar drug; occlusive agents and stabilizers in skin penetration enhancing systems for polar drugs)
RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2009:521020 HCAPLUS Full-text
DOCUMENT NUMBER: 150:487712
TITLE: Methods of use 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro; Romero Garrido, Antonio; Gimenez Gallego, Guillermo; Valverde Lopez, Serafin; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: U.S. Pat. Appl. Publ., 32pp., Cont.-in-part of U.S. Ser. No. 588,166.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090111779	A1	20090430	US 2008-257854	20081024

ES 2238924 A1 20050901 ES 2004-371 20040217 <--
ES 2238924 B1 20061201
WO 2005077352 A1 20050825 WO 2005-ES70017 20050216 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 20070149618 A1 20070628 US 2006-506469 20060816
US 20080293816 A1 20081127 US 2008-588166 20080807 <--
PRIORITY APPLN. INFO.: ES 2004-371 A 20040217
WO 2005-ES70017 W 20050216
US 2006-506469 A3 20060816
US 2008-588166 A2 20080807
US 2006-588166 A2 20060802
OTHER SOURCE(S): MARPAT 150:487712
ED Entered STN: 30 Apr 2009
GI



I

AB Methods of use 2,5-dihydroxybenzene sulfonic acid compds. of formula I, where X is a hydrogen, an organic cation or an inorg. cation; n is an integer from 1 to 2; and m is an integer from 1 to 2, for the treatment of cancer, rosacea and psoriasis are disclosed. The invention describes compns. and methods of use for 2,5-dihydroxybenzene sulfonic acid compds. and pharmaceutically acceptable salts thereof. The invention provides methods for the treatment of skin cancer, organ cancer and leukemia. Method also involves in improving the efficacy of chemotherapy, radiation therapy and cancer immunotherapy. The invention also provides methods for the treatment of rosacea and psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one other therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compds. or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate.

INCL 514167000; 514576000; 514568000; 514171000
CC 1-6 (Pharmacology)
Section cross-reference(s): 2, 63
ST dihydroxybenzene sulfonate compd steroid combination therapy cancer rosacea psoriasis; antitumor antiinflammatory antioxidant combination chemotherapy potentiation dihydroxybenzene sulfonate compd
IT Animal cell line
(C-6; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for

treatment of cancer, rosacea and psoriasis)
IT Skin, neoplasm
(basal cell carcinoma; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT Carcinoma
(basal cell; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT Anti-inflammatory agents
Antimicrobial agents
Antioxidants
(codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT Retinoids
Steroids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT Antiproliferative agents
Antitumor agents
Brain, neoplasm
Combination chemotherapy
Erythema
Human
Leukemia
Melanoma
Neoplasm
Neuroglia, neoplasm
Pharmaceutical carriers
Pharmaceutical creams
Psoriasis
Skin, neoplasm
Telangiectasia
Topical drug delivery systems
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT Hydrocarbon oils
Petrolatum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT Drug interactions
(potentiation; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT Skin, disease
(rosacea, characterized by papules and pustules; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT Skin, disease
(rosacea; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT Neuroglia, neoplasm
(s.c.; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT 69-72-7, Salicylic acid, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)
IT 1406-16-2D, Vitamin D, analogs

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT 51-21-8, 5-FU 57-22-7, Vincristine 88-46-0, 2,5-Dihydroxybenzene sulfonic acid 2624-44-4, Diethylamine 2,5-dihydroxybenzenesulfonate 15663-27-1, Cisplatin 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 33069-62-4, Paclitaxel 97225-83-7, Magnesium 2,5-dihydroxybenzenesulfonate 97682-44-5, Irinotecan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT 112-92-5, Stearyl alcohol 36653-82-4, Cetyl alcohol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT 88-46-0, 2,5-Dihydroxybenzene sulfonic acid 2624-44-4, Diethylamine 2,5-dihydroxybenzenesulfonate 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 2624-44-4 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N

CM 2

CRN 88-46-0
CMF C6 H6 O5 S



RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)





RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



L220 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2008:1162068 HCAPLUS Full-text
DOCUMENT NUMBER: 149:402057
TITLE: Nitrosated derivatives of 2,5-dihydroxybenzene compounds and their preparation and use in the treatment of diseases
INVENTOR(S): Gimenez Gallego, Guillermo; Saenz De Tejada Gorman, Inigo; Cuevas Sanchez, Pedro; Angulo Frutos, Javier; Valverde Lopez, Serafin
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 147pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008113863	A2	20080925	WO 2008-EP53455	20080324 <--
WO 2008113863	A3	20081211		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: ES 2007-764 A 20070322
ES 2007-2037 A 20070720

OTHER SOURCE(S): CASREACT 149:402057; MARPAT 149:402057
ED Entered STN: 26 Sep 2008
GI



AB The invention relates to nitrosated derivs. of 2,5-dihydroxybenzene compds. of formula I that are useful in the preparation of medicinal products for the treatment of different diseases. The diseases in question are, in particular: cancer, rosacea, psoriasis, fibrosis, hemangiomas, ocular diseases, skin pigmentation and skin hyperpigmentation, diseases associated with amyloidosis, dermatitis , actinic and seborrheic keratosis, erectile dysfunction, female sexual dysfunction, arterial hypertension, atherosclerosis, inflammatory diseases in particular, arthritis, glomerulonephritis and asthma, intestinal inflammatory diseases in particular, ulcerative colitis and Crohn's disease, benign prostatic hyperplasia, Leishmaniasis, angiogenesis associated to chronic temporal lobe epilepsy, pain, hyperlipidemia and thrombosis. Compds. of formula I wherein R1 is (CH2)0-6SO3H and derivs., (CH2)0-6PO3H and derivs., (CH2)0-6CO2H and derivs., CH=CH(CH2)0-6SO3H and derivs., CH=CH(CH2)0-6PO3H and derivs., and CH=CH(CH2)0-6CO2H and derivs.; R9 and R9' are independently OH and derivs. and O-acyl, with the proviso that at least one of R9 and R9' is OH derivative; and their salts, isomers, prodrugs and solvates thereof, are claimed. Example compound II was prepared by esterification of 5-bromovaleric acid with 4-nitrophenol; the resulting 5-bromovaleric acid 4-nitrophenyl ester underwent nitrosation with silver nitrate to give 5-nitrooxyvaleric acid 4-nitrophenyl ester, which underwent sulfonylation and substitution to give

compound II. All the invention compds. were evaluated for their FGF-1 inhibitory activity (data given).

CC 25-13 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63

IT Skin, disease
(hyperpigmentation, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Skin, disease
(rosacea, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Arthritis
Asthma
Atherosclerosis
Crohn disease
Dermatitis
Eye, disease
Fibrosis
Glomerulonephritis
Hemangioma
Hyperlipidemia
Hypertension
Inflammation
Neuroglia, neoplasm
Pain
Pigmentation disorders
Psoriasis
Thrombosis
Ulcerative colitis
(treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds.
useful in treatment and prophylaxis of different diseases)

IT 100-02-7, 4-Nitrophenol, reactions 2067-33-6, 5-Bromovaleric acid
20123-80-2, Calcium dobesilate 21799-87-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT 20123-80-2, Calcium dobesilate 21799-87-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 21799-87-1 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



L220 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2008:223860 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276752
TITLE: Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of fibrosis
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Lozano Puerto, Rosa Maria; Romero Garrido, Antonio; Valverde Lopez, Serafin
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020040	A2	20080221	WO 2007-EP58454	20070815
WO 2008020040	A3	20080410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
ES 2315118	A1	20090316	ES 2006-2218	20060816 <--
US 20080113947	A1	20080515	US 2007-839515	20070815
US 20080113948	A1	20080515	US 2007-839520	20070815
US 20080114060	A1	20080515	US 2007-839522	20070815
US 20080125486	A1	20080529	US 2007-839525	20070815
PRIORITY APPLN. INFO.:			ES 2006-2218 A	20060816
			ES 2007-1856 A	20070702

OTHER SOURCE(S): MARPAT 148:276752

ED Entered STN: 22 Feb 2008
AB The invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in preparing a medicinal product for the treatment and/or prophylaxis of fibrosis.
CC 1-9 (Pharmacology)
IT Epidermal growth factor receptors
Fibroblast growth factor receptors
Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; use of hydroxybenzene compds. and derivs. for treatment of fibrosis)
IT Angiogenesis inhibitors
Anti-inflammatory agents
Antifibrotic agents
Antimicrobial agents
Antioxidants
Antitumor agents
Apoptosis
Buccal drug delivery systems
Burn
Chronic obstructive pulmonary disease
Emphysema
Endothelin receptor antagonists
Human
Immunomodulators
Inhalation drug delivery systems
Keloid
Lung, neoplasm
NMDA receptor antagonists
Neuroglia, neoplasm
Ophthalmic drug delivery systems
Oral drug delivery systems
Otic drug delivery systems
Parenteral drug delivery systems
Prodrugs
Prophylaxis
Prostate gland, neoplasm
Pulmonary fibrosis
Rectal drug delivery systems
Scleroderma
Topical drug delivery systems
Transdermal drug delivery systems
Vaginal drug delivery systems
(use of hydroxybenzene compds. and derivs. for treatment of fibrosis)
IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 80449-02-1 127464-60-2, Vascular endothelial growth factor 141436-78-4, Protein kinase C
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; use of hydroxybenzene compds. and derivs. for treatment of fibrosis)
IT 69-72-7, Salicylic acid, biological studies 88-46-0D, ester derivs. 123-31-9D, 1,4-Dihydroxybenzene, derivs. 490-79-9, Gentisic acid 636-01-1, 2,5-Dihydroxycinnamic acid 1084-96-4 5330-25-6 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5 59687-22-8 59687-73-9 60630-38-8 71761-06-3D, Vitamin D5, analogs 79122-68-2 79365-88-1 90447-15-7 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6 1007839-72-6D,

ester derivs. 1007839-87-3 1007839-89-5
1007839-91-9 1007839-93-1 1007839-94-2
1007839-96-4 1007840-02-9 1007840-05-2 1007840-08-5
1007840-09-6 1007840-11-0 1007840-12-1 1007840-13-2
1007840-16-5 1007840-17-6 1007840-18-7
1007840-19-8 1007840-20-1 1007840-21-2
1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene compds. and derivs. for treatment of fibrosis)

IT 88-46-0D, ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5 59687-22-8 60630-38-8 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene compds. and derivs. for treatment of fibrosis)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

L220 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2008:221345 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276712
TITLE: Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Lozano Puerto, Rosa Maria; Romero Garrido, Antonio; Valverde Lopez, Serafin
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020039	A2	20080221	WO 2007-EP58453	20070815
WO 2008020039	A3	20080918		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
ES 2315118	A1	20090316	ES 2006-2218	20060816 <--
US 20080113947	A1	20080515	US 2007-839515	20070815
US 20080113948	A1	20080515	US 2007-839520	20070815
US 20080114060	A1	20080515	US 2007-839522	20070815
US 20080125486	A1	20080529	US 2007-839525	20070815
EP 2061453	A2	20090527	EP 2007-802619	20070815
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:		
ES 2006-2218	A	20060816
ES 2007-1856	A	20070702
WO 2007-EP58453	W	20070815

OTHER SOURCE(S): MARPAT 148:276712
ED Entered STN: 21 Feb 2008
AB The present invention refers to the use of a 2,5-dihydroxybenzene derivative or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of hematol. dyscrasias, including myelodysplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a 2,5-dihydroxybenzene derivative in the manufacturing of a medicament for the treatment and/or prophylaxis of cancer of an organ.
CC 1-6 (Pharmacology)
IT Angiogenesis inhibitors
Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Antitumor agents
Apoptosis
Bladder, neoplasm
Brain, neoplasm
Buccal drug delivery systems
Cervix, neoplasm
Colon neoplasm
Endothelin receptor antagonists
Fibrosis
Human
Immunomodulators
Immunotherapy
Inhalation drug delivery systems
Kidney, neoplasm
Leukemia
Lung, neoplasm
Mammary gland, neoplasm
Metastasis
Myelodysplastic syndromes
NMDA receptor antagonists
Neoplasm
Neuroglia, neoplasm
Ophthalmic drug delivery systems
Oral drug delivery systems
Otic drug delivery systems
Ovary, neoplasm
Pancreas, neoplasm
Parenteral drug delivery systems
Prodrugs
Prophylaxis
Prostate gland, neoplasm
Radiotherapy
Rectal drug delivery systems
Rectal neoplasm
Sarcoma
Testis, neoplasm
Thyroid gland, neoplasm
Topical drug delivery systems
Transdermal drug delivery systems
Vaginal drug delivery systems
(use of hydroxybenzene compds. and derivs. for treatment of hematol. dyscrasias and cancer)
IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(antagonists; use of hydroxybenzene compds. and derivs. for treatment of hematol. dyscrasias and cancer)

IT 69-72-7, Salicylic acid, biological studies 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs. 123-31-9D, 1,4-Dihydroxybenzene, derivs. 451-13-8, Homogentisic acid 490-79-9, Gentisic acid 636-01-1, 2,5-Dihydroxycinnamic acid 1084-96-4 1406-16-2D, Vitamin D, analogs 5330-25-6 16094-44-3 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5 59687-22-8 59687-73-9 60630-38-8 67127-91-7 79122-68-2 79365-88-1 79755-47-8 90447-15-7 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 814262-90-3 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-02-9 1007840-05-2 1007840-08-5 1007840-09-6 1007840-11-0 1007840-12-1 1007840-13-2 1007840-14-3 1007840-15-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of hydroxybenzene compds. and derivs. for treatment of hematol. dyscrasias and cancer)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5 59687-22-8 60630-38-8 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of hydroxybenzene compds. and derivs. for treatment of hematol. dyscrasias and cancer)

RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

L220 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2008:221788 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276732
TITLE: Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Lozano Puerto, Rosa Maria; Romero Garrido, Antonio; Valverde Lopez, Serafin
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 134pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020033	A1	20080221	WO 2007-EP58446	20070815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2315117	A1	20090316	ES 2006-2217	20060816
US 20080114063	A1	20080515	US 2007-839529	20070815
EP 2054045	A1	20090506	EP 2007-788431	20070815
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:			
ES 2006-2217	A	20060816	
ES 2007-1855	A	20070702	
WO 2007-EP58446	W	20070815	

OTHER SOURCE(S): MARPAT 148:276732
ED Entered STN: 21 Feb 2008
AB The present invention relates to the use of 2,5-dihydroxybenzene derivs. or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the

manufacturing of a medicament for the treatment and/or prophylaxis of arthritis and pain.

CC 1-7 (Pharmacology)
Section cross-reference(s): 63

IT Arthritis
(lupus-related, psoriasis-related, infectious, viral, parasitic, bacterial; use of hydroxybenzene derivs. for treatment of arthritis and pain)

IT Analgesics
Anesthetics
Angiogenesis inhibitors
Anti-inflammatory agents
Antiandrogens
Antiarthritics
Antiasthmatics
Antibiotics
Antioxidants
Antirheumatic agents
Antitumor agents
Asthma
Buccal drug delivery systems
Cholinergic antagonists
Crohn disease
Endometriosis
Gastroenteritis
Gout
Hemangioma
Human
Immunomodulators
Immunosuppressants
Inhalation drug delivery systems
Leishmaniasis
Neuroglia, neoplasm
Nonsteroidal anti-inflammatory drugs
Ophthalmic drug delivery systems
Oral drug delivery systems
Osteoarthritis
Otic drug delivery systems
Pain
Parasiticides
Parenteral drug delivery systems
Pharmaceutical creams
Pharmaceutical gels
Pharmaceutical solids
Pharmaceutical solutions
Prodrugs
Prophylaxis
Rectal drug delivery systems
Rheumatoid arthritis
Topical drug delivery systems
Transdermal drug delivery systems
Ulcerative colitis
Vaginal drug delivery systems
α-Adrenoceptor antagonists
β-Adrenoceptor agonists
(use of hydroxybenzene derivs. for treatment of arthritis and pain)

IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; use of hydroxybenzene derivs. for treatment of arthritis

and pain)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, 2,5-Dihydroxybenzenesulfonic acid, ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 28088-64-4D, Aminosalicylic acid, derivs. 51579-69-2 57775-26-5 59687-22-8 60630-38-8 63177-57-1 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treatment of arthritis and pain)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, 2,5-Dihydroxybenzenesulfonic acid, ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5 59687-22-8 60630-38-8 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treatment of arthritis and pain)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]-

(CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2008:223400 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276783
TITLE: 2,5-Dihydroxybenzene for the treatment of psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain

SOURCE: PCT Int. Appl., 66pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020030	A1	20080221	WO 2007-EP58443	20070815 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2315118	A1	20090316	ES 2006-2218	20060816 <--
US 20080113947	A1	20080515	US 2007-839515	20070815
US 20080113948	A1	20080515	US 2007-839520	20070815
US 20080114060	A1	20080515	US 2007-839522	20070815
US 20080125486	A1	20080529	US 2007-839525	20070815
EP 2056814	A1	20090513	EP 2007-788429	20070815 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:			
	ES 2006-2218	A	20060816
	ES 2007-1856	A	20070702
	WO 2007-EP58443	W	20070815

OTHER SOURCE(S): MARPAT 148:276783
ED Entered STN: 22 Feb 2008
AB The invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in preparing a medicinal product for the treatment and/or prophylaxis of psoriasis.
CC 1-12 (Pharmacology)
ST hydroxybenzene deriv psoriasis therapy
IT Epidermal growth factor receptors
Fibroblast growth factor receptors
Hepatocyte growth factor
Hepatocyte growth factor receptors
Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; hydroxybenzene derivs. for treatment of psoriasis
)
IT Therapy
(coadjuvant; hydroxybenzene derivs. for treatment of psoriasis
)
IT Angiogenesis inhibitors
Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Antitumor agents
Apoptosis
Buccal drug delivery systems

Endothelin receptor antagonists
Fibrosis
Human
Immunomodulators
Lung, neoplasm
Neuroglia, neoplasm
Oral drug delivery systems
Otic drug delivery systems
Parenteral drug delivery systems
Photodynamic therapy
Phototherapy
Prodrugs
Prophylaxis
Prostate gland, neoplasm
Psoriasis
Rectal drug delivery systems
Topical drug delivery systems
Transdermal drug delivery systems
(hydroxybenzene derivs. for treatment of psoriasis)

IT Corticosteroids, biological studies
Retinoids
Steroids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxybenzene derivs. for treatment of psoriasis)

IT Fibroblast
(mitogenesis; hydroxybenzene derivs. for treatment of psoriasis)

IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; hydroxybenzene derivs. for treatment of psoriasis)

IT 106096-92-8, FGF-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydroxybenzene derivs. for treatment of psoriasis)

IT 59-05-2, Methotrexate 69-72-7, Salicylic acid, biological studies
88-46-0, 2,5-Dihydroxybenzenesulfonic acid 110-17-8D, 2-Butenedioic acid (2E)-, derivs. 123-31-9D, 1,4-Dihydroxybenzene, derivs. 490-79-9, Gentisic acid 636-01-1, 2,5-Dihydroxycinnamic acid 1406-16-2D, Vitamin D, analogs
21799-87-1, Potassium 2,5-Dihydroxybenzenesulfonate
21799-87-1D, ester derivs. 51579-69-2
57775-26-5 59687-22-8 59865-13-3, Cyclosporin
60630-38-8 79122-68-2 159252-66-1
159252-66-1D, ester derivs. 170277-31-3, Infliximab
185243-69-0, Etanercept 214745-43-4, Efalizumab 222535-22-0, Alefacept
331731-18-1, Adalimumab 748106-93-6 1007839-71-5
1007839-72-6D, ester derivs. 1007839-87-3
1007839-89-5 1007839-91-9 1007839-93-1
1007839-94-2 1007839-96-4 1007840-16-5
1007840-17-6 1007840-18-7 1007840-19-8
1007840-20-1 1007840-21-2 1007840-22-3
1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxybenzene derivs. for treatment of psoriasis)

IT 80449-02-1, Protein tyrosine kinase 141436-78-4, Protein kinase C
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; hydroxybenzene derivs. for treatment of psoriasis

)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 636-01-1, 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium 2,5-Dihydroxybenzenesulfonate 21799-87-1D, ester derivs. 51579-69-2 57775-26-5 59687-22-8 60630-38-8 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxybenzene derivs. for treatment of psoriasis)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



1/2 Ca

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 8
ACCESSION NUMBER: 2008:223941 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276785
TITLE: 2,5-Dihydroxybenzene compounds for the treatment of Rosacea
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 67pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020028	A1	20080221	WO 2007-EP58441	20070815

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,

KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

ES 2315118	A1	20090316	ES 2006-2218	20060816 <--
US 20080113947	A1	20080515	US 2007-839515	20070815
US 20080113948	A1	20080515	US 2007-839520	20070815
US 20080114060	A1	20080515	US 2007-839522	20070815
US 20080125486	A1	20080529	US 2007-839525	20070815
EP 2056813	A1	20090513	EP 2007-788428	20070815

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.:	ES 2006-2218	A	20060816
	ES 2007-1856	A	20070702
	WO 2007-EP58441	W	20070815

OTHER SOURCE(S): MARPAT 148:276785
ED Entered STN: 22 Feb 2008
AB The invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in preparing a medicinal product for the treatment and/or prophylaxis of rosacea.
CC 1-12 (Pharmacology)
IT Epidermal growth factor receptors
Fibroblast growth factor receptors
Hepatocyte growth factor
Hepatocyte growth factor receptors
Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; hydroxybenzene compds. for treatment of Rosacea)
IT Angiogenesis inhibitors
Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Antitumor agents
Apoptosis
Buccal drug delivery systems
Endothelin receptor antagonists
Fibrosis
Human
Immunomodulators
Inhalation drug delivery systems
Lung, neoplasm
Neuroglia, neoplasm
Ophthalmic drug delivery systems
Oral drug delivery systems
Otic drug delivery systems
Parenteral drug delivery systems
Prodrugs
Prophylaxis
Prostate gland, neoplasm
Rectal drug delivery systems
Topical drug delivery systems
Transdermal drug delivery systems
Vasoconstrictors
(hydroxybenzene compds. for treatment of Rosacea)

IT Skin, disease
(rosacea, erythematotelangiectatic, papulopustular, phymatous, ocular; hydroxybenzene compds. for treatment of Rosacea)
IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; hydroxybenzene compds. for treatment of Rosacea)
IT 69-72-7, Salicylic acid, biological studies 80-08-0, Dapsone 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs. 123-31-9D, 1,4-Dihydroxybenzene, derivs. 443-48-1, Metronidazole 490-79-9, Gentisic acid 636-01-1, 2,5-Dihydroxycinnamic acid 1406-16-2D, Vitamin D, analogs 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5 59687-22-8 60630-38-8 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxybenzene compds. for treatment of Rosacea)
IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5 59687-22-8 60630-38-8 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxybenzene compds. for treatment of Rosacea)
RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 9
ACCESSION NUMBER: 2008:223605 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276717
TITLE: Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020027	A2	20080221	WO 2007-EP58440	20070815
WO 2008020027	A3	20080410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
ES 2315118	A1	20090316	ES 2006-2218	20060816 <--
US 20080113947	A1	20080515	US 2007-839515	20070815
US 20080113948	A1	20080515	US 2007-839520	20070815
US 20080114060	A1	20080515	US 2007-839522	20070815
US 20080125486	A1	20080529	US 2007-839525	20070815

PRIORITY APPLN. INFO.: ES 2006-2218 A 20060816
ES 2007-1856 A 20070702

OTHER SOURCE(S): MARPAT 148:276717
ED Entered STN: 22 Feb 2008
AB The invention relates to the use of a 2,5-dihydroxybenzene derivative or pharmaceutically acceptable salts or solvates, isomers or prodrugs thereof in

the manufacture of a medicament for the therapeutic and/or prophylactic treatment of skin cancer.

CC 1-6 (Pharmacology)

ST antitumor hydroxybenzene deriv skin cancer therapy

IT Carcinoma
(Merkel cell, sweat gland, sebaceous gland; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Epidermal growth factor receptors
Fibroblast growth factor receptors
Hepatocyte growth factor
Hepatocyte growth factor receptors
Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Skin, neoplasm
(basal cell carcinoma; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Carcinoma
(basal cell; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Sebaceous gland
(carcinoma; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Therapy
(cryotherapy, curettage and coadjuvant; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Tyrosine kinase receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Skin, neoplasm
(keratoacanthoma; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Disease, animal
(lentigo maligna; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Fibroblast
(mitogenesis; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Leukotrienes
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modifiers; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Interleukin receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solubilized; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Carcinoma
(squamous cell; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Analgesics
Anesthetics
Angiogenesis inhibitors
Antibiotics
Antitumor agents
Apoptosis
Buccal drug delivery systems
Cutaneous T-cell lymphoma

Fibrosis
Hemangiosarcoma
Human
Immunomodulators
Inhalation drug delivery systems
Lung, neoplasm
Melanoma
Neuroglia, neoplasm
Nonsteroidal anti-inflammatory drugs
Ophthalmic drug delivery systems
Oral drug delivery systems
Otic drug delivery systems
Parenteral drug delivery systems
Photodynamic therapy
Prodrugs
Prophylaxis
Prostate gland, neoplasm
Rectal drug delivery systems
Sarcoma
Skin, neoplasm
Surgery
Topical drug delivery systems
Transdermal drug delivery systems
Vaginal drug delivery systems
(use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT Corticosteroids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT 141436-78-4, Protein kinase C
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT 51-21-8, 5-Fluorouracil 64-86-8, Colchicine 76-03-9, Trichloroacetic acid, biological studies 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs. 106-60-5, 5-Aminolevulinic acid 123-31-9D, 1,4-Dihydroxybenzene, derivs. 490-79-9, Gentisic acid 503-11-7, Glycidic acid 548-04-9, Hypericin 636-01-1, 2,5-Dihydroxycinnamic acid 4759-48-2, Isotretinoin 15307-86-5, Diclofenac 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 28088-64-4D, Aminosalicylic acid, derivs. 33320-16-0, Methyl aminolevulinate 51579-69-2 52227-85-7, T4 Endonuclease V 55079-83-9, Acitretin 57775-26-5 59687-22-8 60630-38-8 79122-68-2 99011-02-6, Imiquimod 113852-37-2, Cidofovir 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5 59687-22-8 60630-38-8 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene compds. and derivs. for treatment of skin cancer)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS

CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

L220 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 10
ACCESSION NUMBER: 2008:221418 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276779
TITLE: Use of 2,5-dihydroxybenzene derivatives for treating dermatitis
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 59pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020026	A1	20080221	WO 2007-EP58439	20070815

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,

PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

ES 2315119	A1	20090316	ES 2006-2219	20060816
US 20080114075	A1	20080515	US 2007-839512	20070815
EP 2056815	A1	20090513	EP 2007-788426	20070815

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.:	ES 2006-2219	A	20060816
	ES 2007-1857	A	20070702
	WO 2007-EP58439	W	20070815

OTHER SOURCE(S): MARPAT 148:276779
ED Entered STN: 21 Feb 2008
AB The present invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate thereof, isomer or prodrug thereof to prepare a medicament for the therapeutic and/or prophylactic treatment of dermatitis.
CC 1-12 (Pharmacology)
ST antiinflammatory hydroxybenzene deriv treating dermatitis therapy
IT Dermatitis
(actinic, carcinomatous, diaper, stasis, radiation-induced; use of hydroxybenzene derivs. for treating dermatitis)
IT Allergy
(allergic contact dermatitis; use of hydroxybenzene derivs. for treating dermatitis)
IT Dermatitis
(allergic contact; use of hydroxybenzene derivs. for treating dermatitis)
IT Epidermal growth factor receptors
Fibroblast growth factor receptors
Hepatocyte growth factor receptors
Tyrosine kinase receptors
Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; use of hydroxybenzene derivs. for treating dermatitis)
IT Dermatitis
(atopic; use of hydroxybenzene derivs. for treating dermatitis)
IT Dermatitis
(contact; use of hydroxybenzene derivs. for treating dermatitis)
IT Leukotrienes
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modifiers; use of hydroxybenzene derivs. for treating dermatitis)
IT Immunomodulators
(oral and topical; use of hydroxybenzene derivs. for treating dermatitis)
IT Interleukin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(solubilized; use of hydroxybenzene derivs. for treating dermatitis)
IT Analgesics

Anesthetics
Angiogenesis inhibitors
Anti-inflammatory agents
Antibiotics
Buccal drug delivery systems
Cell infiltration
Dermatomyositis
Edema
Immunosuppressants
Inhalation drug delivery systems
Leukocyte
Neurodermatitis
Nonsteroidal anti-inflammatory drugs
Oral drug delivery systems
Otic drug delivery systems
Parenteral drug delivery systems
Prodrugs
Prophylaxis
Topical drug delivery systems
Transdermal drug delivery systems
(use of hydroxybenzene derivs. for treating dermatitis)

IT Corticosteroids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treating dermatitis)

IT 141436-78-4, Protein kinase C
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; use of hydroxybenzene derivs. for treating dermatitis)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 636-01-1, 2,5-Dihydroxycinnamic acid 4759-48-2, Isotretinoin 15307-86-5, Diclofenac 28088-64-4D, Aminosalicylic acid, derivs. 51579-69-2 52227-85-7, T4 Endonuclease V 55079-83-9, Acitretin 57775-26-5 59687-22-8 60630-38-8 104987-11-3, Tacrolimus 113852-37-2, Cidofovir 137071-32-0, Pimecrolimus 159252-66-1 748106-93-6 1007839-71-5 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treating dermatitis)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 636-01-1, 2,5-Dihydroxycinnamic acid 51579-69-2 57775-26-5 59687-22-8 60630-38-8 159252-66-1 748106-93-6 1007839-71-5 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treating dermatitis)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 11
ACCESSION NUMBER: 2008:223283 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276782
TITLE: Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain

SOURCE: PCT Int. Appl., 79pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020025	A1	20080221	WO 2007-EP58438	20070815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2315119	A1	20090316	ES 2006-2219	20060816
US 20080114075	A1	20080515	US 2007-839512	20070815
EP 2054051	A1	20090506	EP 2007-788425	20070815
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:

ES 2006-2219	A	20060816
ES 2007-1857	A	20070702
WO 2007-EP58438	W	20070815

OTHER SOURCE(S): MARPAT 148:276782
ED Entered STN: 22 Feb 2008
AB The present invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate thereof, isomer or prodrug thereof to prepare a medicament for the therapeutic and/or prophylactic treatment of actinic keratosis.
CC 1-12 (Pharmacology)
Section cross-reference(s): 63
IT Skin, disease
(photoaging; use of hydroxybenzene derivs. for treating actinic keratosis)
IT Skin, disease
(solar lentigos; use of hydroxybenzene derivs. for treating actinic keratosis)
IT Adipogenesis
Analgesics
Anesthetics
Antibiotics
Antitumor agents
Buccal drug delivery systems
Dermatological agents
Hair growth inhibitors
Human
Immunomodulators
Immunosuppressants
Inhalation drug delivery systems
Neuroglia, neoplasm
Nonsteroidal anti-inflammatory drugs
Obesity

Parenteral drug delivery systems
Pharmaceutical creams
Pharmaceutical emulsions
Photodynamic therapy
Prodrugs
Prophylaxis
Rectal drug delivery systems
Surgery
Topical drug delivery systems
Transdermal drug delivery systems
(use of hydroxybenzene derivs. for treating actinic keratosis)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Dobesilate; use of hydroxybenzene derivs. for treating actinic keratosis)

IT 51-21-8, 5-Fluorouracil 64-86-8, Colchicine 76-03-9, Trichloroacetic acid, biological studies 88-46-0D, 2,5-Dihydroxybenzenesulfonic acid, monoesters 106-60-5, 5-Aminolevulinic acid 123-31-9D, 1,4-Dihydroxybenzene, derivs. 451-13-8, Homogentisic acid 490-79-9, Gentisic acid 503-11-7, Glycidic acid 548-04-9, Hypericin 636-01-1, 2,5-Dihydroxycinnamic acid 1084-96-4 2624-44-4, Ethamsylate 4759-48-2, Isotretinoin 5330-25-6 15307-86-5, Diclofenac 16094-44-3 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 28088-64-4D, Aminosalicylic acid, derivs. 33320-16-0, Methyl aminolevulinate 51579-69-2 52227-85-7, T4 Endonuclease V 55079-83-9, Acitretin 57775-26-5 59687-22-8 59687-73-9 60630-38-8 67127-91-7 79122-68-2, Potassium 2,5-diacetoxybenzenesulfonate 79365-88-1 79755-47-8 90447-15-7 97225-83-7, Magnesium 2,5-dihydroxybenzenesulfonate 99011-02-6, Imiquimod 113852-37-2, Cidofovir 159252-66-1 159252-66-1D, monoesters 748106-93-6 814262-90-3 1007839-71-5 1007839-72-6D, monoesters 1007839-80-6 1007839-81-7 1007839-83-9 1007839-85-1 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007839-97-5 1007839-99-7 1007840-01-8 1007840-02-9 1007840-05-2 1007840-08-5 1007840-09-6 1007840-11-0 1007840-12-1 1007840-13-2 1007840-14-3 1007840-15-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treating actinic keratosis)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Dobesilate; use of hydroxybenzene derivs. for treating actinic keratosis)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



IT 88-46-0D, 2,5-Dihydroxybenzenesulfonic acid, monoesters
636-01-1, 2,5-Dihydroxycinnamic acid 2624-44-4,
Ethamsylate 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate
21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
51579-69-2 57775-26-5 59687-22-8
60630-38-8 79122-68-2, Potassium
2,5-diacetoxybenzenesulfonate 159252-66-1
159252-66-1D, monoesters 748106-93-6
1007839-71-5 1007839-72-6D, monoesters
1007839-87-3 1007839-89-5 1007839-91-9
1007839-93-1 1007839-94-2 1007839-96-4
1007840-16-5 1007840-17-6 1007840-18-7
1007840-19-8 1007840-20-1 1007840-21-2
1007840-22-3 1007840-23-4 1007840-24-5
1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treating actinic keratosis)
RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 2624-44-4 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)
(CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N

CM 2

CRN 88-46-0
CMF C6 H6 O5 S



RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)





RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 12
ACCESSION NUMBER: 2008:646739 HCAPLUS Full-text
DOCUMENT NUMBER: 149:1511
TITLE: 2,5-dihydroxybenzene derivatives for treating actinic keratosis
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz De Tejada Morgan, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, Spain
SOURCE: U.S. Pat. Appl. Publ., 43pp., Cont.-in-part of U.S. Ser. No. 506,469.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080125485	A1	20080529	US 2007-839508	20070815
ES 2238924	A1	20050901	ES 2004-371	20040217 <--
ES 2238924	B1	20061201		
WO 2005077352	A1	20050825	WO 2005-ES70017	20050216 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070149618	A1	20070628	US 2006-506469	20060816

ES 2315119 A1 20090316 ES 2006-2219 20060816
PRIORITY APPLN. INFO.: ES 2004-371 A 20040217
WO 2005-ES70017 W 20050216
US 2006-588166 A2 20060802
ES 2006-2219 A 20060816
US 2006-506469 A2 20060816
ES 2007-1857 A 20070702
OTHER SOURCE(S): MARPAT 149:1511
ED Entered STN: 30 May 2008
GI



I

AB The invention relates to the use of a 2,5-dihydroxybenzene derivative (I) [R1 = (CH2)aY, CH=CH(CH2)pY; a, p = 0-6; Y = SO3H, CO2H, etc.; R9, R9' = (un)substituted OH], or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof, for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.

INCL 514546000; 514553000; 514568000; 514548000
CC 1-12 (Pharmacology)
Section cross-reference(s): 63

IT Adipogenesis
Analgesics
Anesthetics
Angiogenesis inhibitors
Antiaging cosmetics
Antibiotics
Antiobesity agents
Antitumor agents
Buccal drug delivery systems
Combination chemotherapy
Cosmetic creams
Cytotoxic agents
Dermatological agents
Hair
Hair growth inhibitors
Immunomodulators
Immunosuppressants
Inhalation drug delivery systems
Neuroglia, neoplasm
Nonsteroidal anti-inflammatory drugs
Obesity
Ophthalmic drug delivery systems
Oral drug delivery systems
Pharmaceutical creams
Pharmaceutical emulsions
Photodynamic therapy
Prodrugs
Prophylaxis
Rectal drug delivery systems
Skin-lightening cosmetics
Surgery

Topical drug delivery systems
Transdermal drug delivery systems
Vaginal drug delivery systems
Wrinkle-preventing cosmetics
(2,5-dihydroxybenzene derivs. for treating actinic keratosis)

IT Skin, disease
(photoaging; 2,5-dihydroxybenzene derivs. for treating actinic keratosis)

IT Skin, disease
(solar lentigos; 2,5-dihydroxybenzene derivs. for treating actinic keratosis)

IT 21799-87-1
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene derivs. for treating actinic keratosis)

IT 51-21-8, 5-Fluorouracil 64-86-8, Colchicine 69-72-7D, Salicylic acid, derivs 76-03-9, Trichloroacetic acid, biological studies 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, magnesium complexes 106-60-5, 5-Aminolevulinic acid 123-31-9D, 1,4-Benzenediol, derivs., derivs., salts, or solvates, biological studies 451-13-8 451-13-8D, salts or solvates 490-79-9, 2,5-Dihydroxybenzoic acid 490-79-9D, salts or solvates 503-11-7, Glycidic acid 548-04-9, Hypericin 636-01-1 636-01-1D, salts or solvates 1084-96-4 1084-96-4D, salts or solvates 2624-44-4 4759-48-2, Isotretinoin 5330-25-6 5330-25-6D, salts or solvates 15307-86-5, Diclofenac 16094-44-3 16094-44-3D, salts or solvates 33320-16-0, Methyl aminolevulinate 37217-32-6, Bacteriophage T4 UV-endonuclease 51579-69-2 51579-69-2D, salts or solvates 55079-83-9, Acitretin 57775-26-5 57775-26-5D, salts or solvates 59687-22-8 59687-22-8D, complexes with FGF-1 59687-22-8D, salts or solvates 59687-73-9 59687-73-9D, salts or solvates 60630-38-8 60630-38-8D, salts or solvates 67127-91-7 67127-91-7D, salts or solvates 68864-98-2, 2,5-Dihydroxybenzenesulfonate 68864-98-2D, 2,5-Dihydroxybenzenesulfonate, esters; complexes with FGF-1 70790-72-6 79365-88-1 79365-88-1D, salts or solvates 79755-47-8 79755-47-8D, salts or solvates 90447-15-7 90447-15-7D, salts or solvates 99011-02-6, Imiquimod 106096-92-8D, Fibroblast growth factor-1, complexes with 2,5-dihydroxybenzenesulfonate esters 113852-37-2, Cidofovir 159252-66-1 748106-93-6 748106-93-6D, complexes with FGF-1 748106-93-6D, salts or solvates 814262-90-3 814262-90-3D, salts or solvates 1007839-71-5 1007839-71-5D, complexes with FGF-1 1007839-71-5D, salts or solvates 1007839-72-6 1007839-80-6 1007839-80-6D, salts or solvates 1007839-81-7 1007839-81-7D, salts or solvates 1007839-83-9 1007839-83-9D, salts or solvates 1007839-85-1 1007839-85-1D, salts or solvates 1007839-87-3 1007839-87-3D, salts or solvates 1007839-89-5 1007839-89-5D, salts or solvates 1007839-91-9 1007839-91-9D, salts or solvates 1007839-93-1 1007839-93-1D, salts or solvates 1007839-94-2 1007839-94-2D, salts or solvates 1007839-96-4 1007839-96-4D, salts or solvates 1007839-97-5 1007839-97-5D, salts or solvates 1007839-99-7 1007839-99-7D, salts or solvates 1007840-01-8 1007840-01-8D, salts or solvates 1007840-02-9 1007840-02-9D, salts or solvates 1007840-05-2 1007840-05-2D, salts or solvates 1007840-08-5 1007840-08-5D, salts or solvates 1007840-09-6 1007840-09-6D, salts or solvates 1007840-11-0 1007840-11-0D, salts or solvates 1007840-12-1 1007840-12-1D, salts or solvates 1007840-13-2 1007840-13-2D, salts or solvates 1007840-14-3

1007840-14-3D, salts or solvates 1007840-15-4 1007840-15-4D, salts or solvates 1007840-16-5 1007840-16-5D, salts or solvates 1007840-17-6 1007840-17-6D, salts or solvates 1007840-18-7 1007840-18-7D, salts or solvates 1007840-19-8 1007840-19-8D, salts or solvates 1007840-20-1 1007840-20-1D, salts or solvates 1007840-21-2 1007840-21-2D, salts or solvates 1007840-22-3 1007840-22-3D, salts or solvates 1007840-23-4 1007840-23-4D, salts or solvates 1007840-24-5 1007840-24-5D, salts or solvates

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene derivs. for treating actinic keratosis)

IT 21799-87-1

RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene derivs. for treating actinic keratosis)

RN 21799-87-1 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, magnesium complexes 636-01-1 636-01-1D, salts or solvates 2624-44-4 51579-69-2 51579-69-2D, salts or solvates 57775-26-5 57775-26-5D, salts or solvates 59687-22-8 59687-22-8D, complexes with FGF-1 60630-38-8 60630-38-8D, salts or solvates 70790-72-6 159252-66-1 748106-93-6 748106-93-6D, complexes with FGF-1 1007839-71-5 1007839-71-5D, complexes with FGF-1 1007839-72-6 1007839-87-3 1007839-87-3D, salts or solvates 1007839-89-5 1007839-89-5D, salts or solvates 1007839-91-9 1007839-91-9D, salts or solvates 1007839-93-1 1007839-93-1D, salts or solvates 1007839-94-2 1007839-94-2D, salts or solvates 1007839-96-4 1007839-96-4D, salts or solvates 1007840-16-5 1007840-16-5D, salts or solvates 1007840-17-6 1007840-17-6D, salts or solvates 1007840-18-7 1007840-18-7D, salts or solvates 1007840-19-8 1007840-19-8D, salts or solvates 1007840-20-1 1007840-20-1D, salts or solvates 1007840-21-2 1007840-21-2D, salts or solvates 1007840-22-3 1007840-22-3D, salts or solvates 1007840-23-4 1007840-23-4D, salts or solvates 1007840-24-5

1007840-24-5D, salts or solvates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene derivs. for treating actinic keratosis)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 2624-44-4 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1)

(CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N



CM 2

CRN 88-46-0
CMF C6 H6 O5 S



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA

INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 70790-72-6 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (1:?) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



L220 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 13
ACCESSION NUMBER: 2008:221722 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276759
TITLE: Use of 2,5-dihydroxybenzene derivatives for treating obesity, hirsutism, hypertricosis and viral warts
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Lozano Puerto, Rosa Maria; Romero Garrido, Antonio; Valverde Lopez, Serafin; Garcia Gomez, Ignacio
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 77pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020037	A1	20080221	WO 2007-EP58451	20070815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2315119	A1	20090316	ES 2006-2219	20060816
US 20080114075	A1	20080515	US 2007-839512	20070815
PRIORITY APPLN. INFO.:			ES 2006-2219 A	20060816
			ES 2007-1857 A	20070702

OTHER SOURCE(S): MARPAT 148:276759
ED Entered STN: 21 Feb 2008
AB The present invention relates to the use of a 2,5-dihydroxybenzene derivative or a pharmaceutically acceptable salt or solvate thereof, isomer or prodrug thereof to prepare a medicament for the therapeutic and/or prophylactic treatment of a disease selected from obesity, hirsutism, hypertricosis and viral warts.
CC 1-10 (Pharmacology)
IT Keratosis
(actinic; use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertricosis and viral warts)
IT Wart

(acuminate; use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertricosis and viral warts)

IT Skin, disease
(photoaging; use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertricosis and viral warts)

IT Keratosis
(seborrheic; use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertricosis and viral warts)

IT Adipogenesis
Antiobesity agents
Antitumor agents
Buccal drug delivery systems
Hair growth inhibitors
Hirsutism
Human
Hypolipemic agents
Inhalation drug delivery systems
Neuroglia, neoplasm
Obesity
Oral drug delivery systems
Parenteral drug delivery systems
Pharmaceutical creams
Pharmaceutical emulsions
Prophylaxis
Rectal drug delivery systems
Topical drug delivery systems
Transdermal drug delivery systems
(use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertricosis and viral warts)

IT 51-21-8, 5-Fluorouracil 64-86-8, Colchicine 76-03-9, Trichloroacetic acid, biological studies 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs. 123-31-9D, 1,4-Dihydroxybenzene, derivs. 451-13-8, Homogentisic acid 490-79-9, Gentisic acid 503-11-7, Glycidic acid 636-01-1, 2,5-Dihydroxycinnamic acid 1084-96-4 2624-44-4, Ethamsylate 4759-48-2, Isotretinoin 5330-25-6 15307-86-5, Diclofenac 16094-44-3 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 52227-85-7, T4 Endonuclease V 55079-83-9, Acitretin 57775-26-5 59687-22-8 59687-73-9 60630-38-8 67127-91-7 79122-68-2 79365-88-1 79755-47-8 90447-15-7 97225-83-7, Magnesium 2,5-dihydroxybenzenesulfonate 99011-02-6, Imiquimod 113852-37-2, Cidofovir 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 814262-90-3 1007839-71-5 1007839-72-6D, ester derivs. 1007839-80-6 1007839-81-7 1007839-83-9 1007839-85-1 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007839-97-5 1007839-99-7 1007840-01-8 1007840-02-9 1007840-05-2 1007840-08-5 1007840-09-6 1007840-11-0 1007840-12-1 1007840-13-2 1007840-14-3 1007840-15-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertricosis and viral warts)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid 2624-44-4, Ethamsylate 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5 59687-22-8 60630-38-8 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-80-6 1007839-81-7 1007839-83-9 1007839-85-1 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007839-97-5 1007839-99-7 1007840-01-8 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treating obesity, hirsutism, hypertricosis and viral warts)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 HCAPLUS
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 2624-44-4 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N

CM 2

CRN 88-46-0
CMF C6 H6 O5 S



RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)





RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 51579-69-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 HCAPLUS
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-80-6 HCAPLUS
CN Benzenesulfonic acid, 5-hydroxy-2-(phenylmethoxy)- (CA INDEX NAME)



RN 1007839-81-7 HCAPLUS
CN Benzenesulfonic acid, 2-hydroxy-5-(phenylmethoxy)- (CA INDEX NAME)



RN 1007839-83-9 HCAPLUS
CN Benzenesulfonic acid, 2,5-bis(phenylmethoxy)- (CA INDEX NAME)



RN 1007839-85-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 1007839-87-3 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)



RN 1007839-89-5 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]-
(CA INDEX NAME)



RN 1007839-91-9 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 HCAPLUS
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 HCAPLUS
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007839-97-5 HCAPLUS
CN Benzenemethanesulfonic acid, 5-hydroxy-2-(phenylmethoxy)- (CA INDEX NAME)



RN 1007839-99-7 HCAPLUS
CN Benzenemethanesulfonic acid, 2-hydroxy-5-(phenylmethoxy)- (CA INDEX NAME)



RN 1007840-01-8 HCAPLUS
CN Benzenemethanesulfonic acid, 2,5-bis(phenylmethoxy)- (CA INDEX NAME)



RN 1007840-16-5 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-17-6 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-18-7 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 HCAPLUS
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 HCAPLUS
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 HCAPLUS
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 HCAPLUS
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 HCAPLUS
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 HCAPLUS
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L220 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 14
ACCESSION NUMBER: 2007:705929 HCAPLUS Full-text
DOCUMENT NUMBER: 147:87646
TITLE: 2,5-Dihydroxybenzene sulfonate compounds for treatment of cancer, rosacea, and psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro; Romero Garrido, Antonio; Gimenez Gallego, Guillermo; Valverde Lopez, Serafin; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of U.S. Ser. No. 588,166.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070149618	A1	20070628	US 2006-506469	20060816
ES 2238924	A1	20050901	ES 2004-371	20040217 <--
ES 2238924	B1	20061201		
WO 2005077352	A1	20050825	WO 2005-ES70017	20050216 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20080125485	A1	20080529	US 2007-839508	20070815
US 20090111779	A1	20090430	US 2008-257854	20081024

PRIORITY APPLN. INFO.:

ES 2004-371	A	20040217
WO 2005-ES70017	W	20050216
US 2006-588166	A2	20060802
ES 2006-2219	A	20060816
US 2006-506469	A2	20060816
ES 2007-1857	A	20070702
US 2008-588166	A2	20080807

ED Entered STN: 29 Jun 2007

AB The invention describes compns. and methods of use for 2,5-dihydroxybenzene sulfonic acid compds. and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compns. comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compds. or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate. Administration of 2,5-dihydroxybenzene sulfonate combined with irinotecan reduced the tumor progression of gliomas in rats to a greater degree than treatment of either agent alone.

INCL 514553000; 514171000; 514559000; 514167000; 514159000

CC 1-6 (Pharmacology)

ST dihydroxybenzene sulfonate cancer rosacea psoriasis therapy; glioma irinotecan dihydroxybenzene sulfonate antitumor combination

IT Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Buccal drug delivery systems
Chemosensitizers, pharmaceutical
Chemotherapy
Combination chemotherapy
Cytotoxic agents
Dermatological agents
Immunomodulators
Inhalation drug delivery systems
Leukemia
Melanoma
NMDA receptor antagonists
Neuroglia, neoplasm
Oral drug delivery systems
Parenteral drug delivery systems
Pharmaceutical carriers
Pharmaceutical creams
Proliferation inhibition
Psoriasis
Rectal drug delivery systems
Skin, neoplasm
Topical drug delivery systems
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Retinoids
Steroids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Petrolatum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Carcinoma
Skin, neoplasm

(Bowen's disease, verrucae; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Keratosis
(actinic; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Apoptosis
(basal cell carcinoma cells; 2,5-dihydroxybenzenesulfonate-induced; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, neoplasm
(basal cell carcinoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Carcinoma
(basal cell; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Carcinoma
(cutaneous squamous cell; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Antitumor agents
Immunotherapy
Radiotherapy
(efficacy; agents improving; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, neoplasm
(keratoacanthoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Sarcoma
(orangiosarcoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Drug interactions
(pharmacodynamic, potentiation; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, disease
(rosacea; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Neoplasm
(solid; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, neoplasm
(squamous cell carcinoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Paraffin waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(white soft; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT 51-21-8, 5-Fluorouracil 57-22-7, Vincristine 69-72-7, Salicylic acid, biological studies 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 1406-16-2D, Vitamin D, analog 2624-44-4, Diethylamine 2,5-dihydroxybenzenesulfonate 15663-27-1, Cisplatin 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 33069-62-4, Paclitaxel 68864-98-2, 2,5-Dihydroxybenzenesulfonate 97225-83-7, Magnesium 2,5-dihydroxybenzenesulfonate 97682-44-5, Irinotecan 100286-90-6, Campto
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT 112-92-5, Stearic alcohol 7732-18-5, Water, biological studies 36653-82-4, Cetylic alcohol 942134-54-5, Sorbinate deato

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT 116243-73-3, Endothelin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonist; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 2624-44-4, Diethylamine 2,5-dihydroxybenzenesulfonate 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 2624-44-4 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N

CM 2

CRN 88-46-0
CMF C6 H6 O5 S



RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

L220 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 15
ACCESSION NUMBER: 2005:888919 HCAPLUS Full-text
DOCUMENT NUMBER: 143:216719
TITLE: Use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases such as cancer and psoriasis
INVENTOR(S): Cuevas, Sanchez Pedro
PATENT ASSIGNEE(S): Investread Europa, S.L., Spain
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077352	A1	20050825	WO 2005-ES70017	20050216 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

ES 2238924	A1	20050901	ES 2004-371	20040217	<--
ES 2238924	B1	20061201			
AU 2005211956	A1	20050825	AU 2005-211956	20050216	<--
CA 2555248	A1	20050825	CA 2005-2555248	20050216	<--
EP 1719509	A1	20061108	EP 2005-708114	20050216	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, IS, YU					
CN 101014330	A	20070808	CN 2005-80005187	20050216	<--
JP 2007522256	T	20070809	JP 2006-553602	20050216	<--
IN 2006DN04546	A	20070810	IN 2006-DN4546	20060807	
KR 2007007783	A	20070116	KR 2006-716184	20060811	
MX 2006009295	A	20070323	MX 2006-9295	20060816	<--
US 20070149618	A1	20070628	US 2006-506469	20060816	
US 20080125485	A1	20080529	US 2007-839508	20070815	
US 20080293816	A1	20081127	US 2008-588166	20080807	<--
US 20090111779	A1	20090430	US 2008-257854	20081024	

PRIORITY APPLN. INFO.:	ES 2004-371	A	20040217
	WO 2005-ES70017	W	20050216
	US 2006-588166	A2	20060802
	ES 2006-2219	A	20060816
	US 2006-506469	A2	20060816
	ES 2007-1857	A	20070702
	US 2008-588166	A2	20080807

ED Entered STN: 25 Aug 2005

AB The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforementioned compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases which present a reduction in apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compds. in non-quiescent cells. In addition, the invention details the potentiating effect of said compds. on known cytostatic medicines in the treatment of tumors and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compds., based on the combined antiproliferative, antiangiogenic and proapoptotic capacities thereof, in the treatment of chronic psoriatic plaques.

IC ICM A61K031-185
ICS A61P035-00; A61P017-06

CC 63-6 (Pharmaceuticals)

IT Neoplasm
Psoriasis
(use of dihydroxybenzenesulfonic acid in drugs for treatment of angiodependent diseases)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 20123-80-2
, 2,5-Dihydroxybenzenesulfonic acid calcium salt 862162-74-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of dihydroxybenzenesulfonic acid in drugs for treatment of angiodependent diseases)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 20123-80-2
, 2,5-Dihydroxybenzenesulfonic acid calcium salt 862162-74-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of dihydroxybenzenesulfonic acid in drugs for treatment of angiodependent diseases)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 862162-74-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:?) (CA INDEX NAME)



●x K

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d iall abeq tech abex hitstr 16-19
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' - CONTINUE? (Y)/N:y

L220 ANSWER 16 OF 22 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-L13777 [65] WPIX
CROSS REFERENCE: 2008-D99595; 2008-E49165; 2008-E61270; 2008-G33820
DOC. NO. CPI: C2008-323605 [65]
TITLE: Use of dihydroxybenzene compound to treat e.g. benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis, leishmaniasis, hemangiomas and hemangioblastomas
DERWENT CLASS: B05
INVENTOR: ANGULO FRUTOS J; CUEVAS SANCHEZ F; FERNANDEZ JAEN T F; GIMENEZ GALLEGO G; LOZANO FUERTO R M; MORENO NUNCIO F J; RIVAS LOPEZ L I; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I; VALVERDE LOPEZ S
PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL
COUNTRY COUNT: 121

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020042	A1	20080221	(200865)*	EN	103[22]	
EP 2056805	A1	20090513	(200933)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020042	A1	WO 2007-EP58456	20070815
EP 2056805	A1	EP 2007-788436	20070815
EP 2056805	A1 PCT Application	WO 2007-EP58456	20070815

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 2056805	A1	Based on	WO 2008020042	A

PRIORITY APPLN. INFO: ES 2007-1855 20070702
ES 2006-2217 20060816
INT. PATENT CLASSIF.:
IPC ORIGINAL: A61K0031-095 [I,C]; A61K0031-095 [I,C]; A61K0031-10 [I,A]; A61K0031-185 [I,C]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]; A61K0031-60 [I,C]; A61K0031-618 [I,A]; A61P0011-00 [I,C]; A61P0011-00 [I,C]; A61P0011-06 [I,A]
ECLA: A61K0031-10; A61K0031-192; A61K0031-60; A61K0031-618
BASIC ABSTRACT:

WO 2008020042 A1 UPAB: 20090527

NOVELTY - Use of a dihydroxybenzene compound (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of diseases of benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis and leishmaniasis, is claimed.

DETAILED DESCRIPTION - Use of a dihydroxybenzene compound of formula (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of diseases of benign

prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis and leishmaniasis, is claimed.

R1 = -(CH2)aY1 or -CH=CH-(CH2)pY1;

Y1 = -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3, -CO2H, -CO2-.X+ or -CO2R3;

X+ = organic cation or inorganic cation such that the general charge of (I) is neutral;

R9, R9a = -OH or -OR2;

R2 = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl;

R3 = alkyl or aryl; and

a, p = 0-6.

Provided that when R9, R9a are both -OR2, then R9 and R9a can be the same or different.

ACTIVITY - Cytostatic; Gastrointestinal-Gen; Antiinflammatory; Antiasthmatic; Muscular-Gen; Osteopathic; Protozoacide; Antiulcer. Gastrointestinal-Gen.

MECHANISM OF ACTION - None given.

USE - (I) is useful for treating/preventing benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, leishmaniasis, ulcerative colitis (claimed) (proctitis, proctosigmoiditis, pancolitis), hemangiomas and hemangioblastomas. The ability of (I) to treat muscle lesion was tested in a patient. The result showed that the patient (taken 500 mg of 2,5-dihydroxybezenesulfonic acid for two weeks) recovered from the lesion in the quadriceps and the hematoma was not observed.

ADVANTAGE - (I) is safe and effective for treating leishmaniasis. (I) exhibits pharmacological properties. MANUAL CODE: CPI: B05-B01F; B10-A09B; B10-B02A; B10-C04B; B10-C04C;
B14-A03F; B14-E08; B14-E10C1; B14-H01B; B14-H05; B14-J05; B14-K01A; B14-N07; B14-S14

TECH

PHARMACEUTICALS - Preferred Components: The medicament comprises at least one additional therapeutic agent such as a chemotherapeutic agent, corticosteroid, antibiotic, analgesic, alpha-adrenergic blocker, beta-adrenergic agonist, anticholinergic, inhibitor of 5-alpha-reductase, antiandrogen, oral contraceptive, immunomodulator, immunosuppressant, anti-angiogenic, bronchodilator, leukotriene modifier, aminosalicylate, anesthetic, non-steroidal anti-inflammatory, antiparasitic, proton pump inhibitor, hydrogen-receptor antagonist, therapy of the solubilized interleukin receptor, intramuscular gold, cytotoxic and\or antioxidant. (I) is in the form of esters at position 1, preferably methyl and ethyl esters.

ABEX DEFINITIONS - Preferred Definitions: - Y1 = -SO3H, -SO3-.X+, -SO3R3, -CO2H, -CO2-.X+ or -CO2R3; - R9 and R9a = alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted); and - R2 = methylcarbonyl, phenylsulfonyl, 4-methylphenylsulfonyl, benzylsulfonyl, benzyl or phenyl.

ADMINISTRATION - Administration of (I) is topical, oral, buccal, transdermal, parenteral or rectal (claimed). Dosage of (I) is 0.05-50 (preferably 1-1.5) g/day.

SPECIFIC COMPOUNDS - The use of 53 compounds (I) is specifically claimed e.g. 5-hydroxy-2-(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2-hydroxy-5-(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2,5-bis(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid and 2,5-dihydroxybezenesulfonic acid (dobesilate) of formula (Ia).

AN.S DCR-1595300

CN.S Acetic acid 4-acetoxy-3-sulfo-phenyl ester

SDCN RASW2X



AN.S DCR-1669099
CN.S Toluene-4-sulfonic acid 4-hydroxy-2-sulfomethyl-phenyl ester
SDCN RAUHHC



AN.S DCR-1669100
CN.S Toluene-4-sulfonic acid 4-hydroxy-3-sulfomethyl-phenyl ester
SDCN RAUHHD



AN.S DCR-1669101
SDCN RAUHHE



AN.S DCR-1669102
CN.S Acetic acid 4-hydroxy-2-sulfomethyl-phenyl ester
SDCN RAUHHF



AN.S DCR-1669103
CN.S Acetic acid 4-hydroxy-3-sulfomethyl-phenyl ester
SDCN RAUHHG



AN.S DCR-1669104

CN.S Acetic acid 4-acetoxy-3-sulfomethyl-phenyl ester
SDCN RAUHHH



AN.S DCR-1595313
CN.S (E)-3-[2-Hydroxy-5-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid
SDCN RASW3A



AN.S DCR-1595315
CN.S (E)-3-(2-Acetoxy-5-hydroxy-phenyl)-acrylic acid
SDCN RASW3C



AN.S DCR-1595316
CN.S (E)-3-(5-Acetoxy-2-hydroxy-phenyl)-acrylic acid

SDCN RASW3D



AN.S DCR-1595317
CN.S (E)-3-(2,5-Diacetoxy-phenyl)-acrylic acid
SDCN RASW3E



AN.S DCR-1595318
CN.S (E)-3-(2-Benzyloxy-5-hydroxy-phenyl)-acrylic acid
SDCN RASW3F



AN.S DCR-1595319
CN.S (E)-3-(5-Benzyloxy-2-hydroxy-phenyl)-acrylic acid
SDCN RASW3G



AN.S DCR-1595320
CN.S (E)-3-(2,5-Bis-benzyloxy-phenyl)-acrylic acid
SDCN RASW3H



AN.S DCR-1595296
CN.S 5-Hydroxy-2-(toluene-4-sulfonyloxy)-benzenesulfonic acid
SDCN RASW2T



AN.S DCR-108109
CN.P SULTOSILATE
SDCN RA2Y7A



AN.S DCR-1595297
CN.S 2,5-Bis-(toluene-4-sulfonyloxy)-benzenesulfonic acid
SDCN RASW2U



AN.S DCR-1595298
CN.S Acetic acid 4-hydroxy-2-sulfo-phenyl ester
SDCN RASW2V



AN.S DCR-1595299
CN.S Acetic acid 4-hydroxy-3-sulfo-phenyl ester
SDCN RASW2W



L220 ANSWER 17 OF 22 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-D99595 [28] WPIX
CROSS REFERENCE: 2008-E49165; 2008-E61270; 2008-G33820; 2008-L13777
DOC. NO. CPI: C2008-131560 [28]
TITLE: Use of dihydroxybenzene compound to treat e.g. hemangiomas, hemangioblastomas, benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis and leishmaniasis
DERWENT CLASS: B05
INVENTOR: ANGULO FRUTOS J; CUEVAS SANCHEZ P; GIMENEZ GALLEGO G; LOZANO PUERTO R M; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I; VALVERDE LOPEZ S; LOPEZ S V; FERNANDEZ JAEN T F; FRUTOS J A; MORENO NUNCIO F J; RIVAS LOPEZ L I; SANCHEZ P C
PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL
COUNTRY COUNT: 120

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020034	A1	20080221	(200828)*	EN	101[22]	
US 20080114063	A1	20080515	(200835)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020034	A1	WO 2007-EP58447	20070815
US 20080114063	A1	US 2007-839529	20070815

PRIORITY APPLN. INFO: ES 2007-1855 20070702
ES 2006-2217 20060816
INT. PATENT CLASSIF.:
IPC ORIGINAL: A61K0031-095 [I,C]; A61K0031-10 [I,A]; A61K0031-185 [I,C]; A61K0031-185 [I,A]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-21 [I,C]; A61K0031-22 [I,A]; A61K0031-225 [I,A]; A61K0031-60 [I,A]; A61K0031-60 [I,C]; A61K0031-618 [I,A]; A61P0035-00 [I,A]; A61P0035-00 [I,C]
ECLA: A61K0031-10; A61K0031-192; A61K0031-60; A61K0031-618

USCLASS NCLM: 514/546.000
NCLS: 514/548.000; 514/553.000
BASIC ABSTRACT:
WO 2008020034 A1 UPAB: 20080501
NOVELTY - Use of a 2,5-dihydroxybenzene compound (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of a disease of hemangiomas and hemangioblastomas, is claimed.
DETAILED DESCRIPTION - Use of a 2,5-dihydroxybenzene compound of formula (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of a disease of hemangiomas and hemangioblastomas, is claimed.
R1 = -(CH2)aY1 or -CH=CH-(CH2)pY1;
Y1 = -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3, -CO2H, -CO2-.X+ or -CO2R3;
X+ = organic cation or inorganic cation such that general charge of (I) is neutral;
R9, R9a = -OH or -OR2;
R2 = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl (all optionally substituted);
R3 = alkyl or aryl (both optionally substituted); and
a, p = 0-6.
ACTIVITY - Cytostatic; Gastrointestinal-Gen; Antiinflammatory; Antiasthmatic; Muscular-Gen; Osteopathic; Antiulcer; Protozoacide; Analgesic; Antiarthritic.
MECHANISM OF ACTION - None given.
USE - (I) is useful for treating/preventing a disease of hemangiomas and hemangioblastomas (claimed), benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis (proctitis, proctosigmoiditis and pancolitis), leishmaniasis, pain and arthritis. The ability of (I) to treat muscle lesion was tested in a patient. The result showed that the patient (taken 500 mg of 2,5-dihydroxybenzene sulfonic acid for two weeks) recovered from the lesion in the quadriceps and the hematoma was not observed.
ADVANTAGE - (I) is safe and effective for treating leishmaniasis. (I) exhibits pharmacological properties. MANUAL CODE: CPI: B02-Z; B05-A01B; B05-B01N; B10-A09B; B10-C03;
B10-E02; B10-G02; B14-A03F; B14-C01; B14-C03; B14-C07; B14-C09; B14-D06C; B14-E08; B14-E10A; B14-E10C1; B14-F02F2; B14-G02; B14-G03; B14-H01; B14-H01E2; B14-H05; B14-J05; B14-K01A; B14-L06; B14-N01; B14-S08; B14-S16
TECH
PHARMACEUTICALS - Preferred Components: The medicament comprises at least one additional therapeutic agent (such as chemotherapeutic agent, corticosteroid, antibiotic, analgesic, antiandrogen, immunomodulator, anti-angiogenic including anti-vascular endothelial growth factor, anti-fibroblast growth factor, anti-epidermal growth factor and anti-hepatocyte growth factor), inhibitors of tyrosin-kinase receptors, protein kinase C inhibitors, non-steroidal anti-inflammatory, a therapy of the solubilized interleukin receptor, a cytotoxic and/or antioxidant. (I) is in the form of esters at position 1, preferably methyl and ethyl esters.
ABEX DEFINITIONS - Preferred Definitions: - Y1 = -SO3H, -SO3-X+, -SO3R3, -CO2H, -CO2-.X+ or -CO2R3; - R9, R9a = alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted); and - R2 = methylcarbonyl, phenylsulfonyl, 4-methylphenylsulfonyl, benzylsulfonyl, benzyl or phenyl.
ADMINISTRATION - Administration of (I) is oral, buccal, parenteral, rectal, intravaginal, intraocular, transdermal, topical or via inhalation (claimed). Dosage of (I) is 0.05-50 (preferably 1-1.5) g/day.

SPECIFIC COMPOUNDS - The use of 54 compounds (I) is specifically claimed e.g. 5-hydroxy-2-(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2-hydroxy-5-(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2,5-bis(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid and 2,5-dihydroxybezenesulfonic acid (dobesilate) of formula (Ia).

AN.S DCR-1595296
CN.S 5-Hydroxy-2-(toluene-4-sulfonyloxy)-benzenesulfonic acid
SDCN RASW2T



AN.S DCR-108109
CN.P SULTOSILATE
SDCN RA2Y7A



AN.S DCR-1595297
CN.S 2,5-Bis-(toluene-4-sulfonyloxy)-benzenesulfonic acid
SDCN RASW2U



AN.S DCR-1595298
CN.S Acetic acid 4-hydroxy-2-sulfo-phenyl ester
SDCN RASW2V



AN.S DCR-1595299
CN.S Acetic acid 4-hydroxy-3-sulfo-phenyl ester
SDCN RASW2W



AN.S DCR-1595300
CN.S Acetic acid 4-acetoxy-3-sulfo-phenyl ester
SDCN RASW2X



AN.S DCR-1595312
CN.S (E)-3-[5-Hydroxy-2-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid
SDCN RASW39



AN.S DCR-1595313
CN.S (E)-3-[2-Hydroxy-5-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid
SDCN RASW3A



AN.S DCR-1595314
CN.S (E)-3-[2,5-Bis-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid

SDCN RASW3B



AN.S DCR-1595315
CN.S (E)-3-(2-Acetoxy-5-hydroxy-phenyl)-acrylic acid
SDCN RASW3C



AN.S DCR-1595316
CN.S (E)-3-(5-Acetoxy-2-hydroxy-phenyl)-acrylic acid
SDCN RASW3D



AN.S DCR-1595317
CN.S (E)-3-(2,5-Diacetoxy-phenyl)-acrylic acid
SDCN RASW3E



AN.S DCR-1595318
CN.S (E)-3-(2-Benzyloxy-5-hydroxy-phenyl)-acrylic acid
SDCN RASW3F



AN.S DCR-1595319
CN.S (E)-3-(5-Benzyloxy-2-hydroxy-phenyl)-acrylic acid
SDCN RASW3G



L220 ANSWER 18 OF 22 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-E61270 [31] WPIX
CROSS REFERENCE: 2008-D99595; 2008-E49165; 2008-G33820; 2008-L13777
DOC. NO. CPI: C2008-153460 [31]
TITLE: Use of substituted phenyl compounds in the manufacturing of a medicament for the treatment and/or prophylaxis of e.g. macular degeneration, corneal neovascularization or angiogenesis and diabetic proliferative retinopathy
DERWENT CLASS: B05
INVENTOR: ANGULO FRUTOS J; CUEVAS SANCHEZ P; GIMENEZ GALLEGO G; LOZANO PUERTO R M; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I; VALVERDE LOPEZ S
PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL
COUNTRY COUNT: 121

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020032	A1	20080221	(200831)*	EN	133[29]	
WO 2008020032	A8	20080417	(200831)	EN		
EP 2056804	A1	20090513	(200933)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020032	A1	WO 2007-EP58445	20070815
EP 2056804	A1	EP 2007-802616	20070815
EP 2056804	A1 PCT Application	WO 2007-EP58445	20070815

FILING DETAILS:

PATENT NO	KIND		PATENT NO
EP 2056804	A1	Based on	WO 2008020032 A

PRIORITY APPLN. INFO: ES 2007-1855 20070702
ES 2006-2217 20060816
INT. PATENT CLASSIF.:
IPC ORIGINAL: A61K0031-095 [I,C]; A61K0031-095 [I,C]; A61K0031-10 [I,A]; A61K0031-185 [I,C]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]; A61K0031-60 [I,C]; A61K0031-618 [I,A]; A61P0027-00 [I,C]; A61P0027-00 [I,C]; A61P0027-02 [I,A]

ECLA: A61K0031-10; A61K0031-192; A61K0031-60; A61K0031-618
BASIC ABSTRACT:
WO 2008020032 A1 UPAB: 20090527
NOVELTY - Use of substituted phenyl compounds (I) or their salts, solvates, isomers or prodrugs in the manufacturing of a medicament for the treatment and/or prophylaxis of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy, is claimed
DETAILED DESCRIPTION - Use of substituted phenyl compounds of formula (I) or their salts, solvates, isomers or prodrugs in the manufacturing of a medicament for the treatment and/or prophylaxis of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy, is claimed.
R1 = -(CH2)aY1 or -CH=CH-(CH2)pY1;
Y1 = -SO3H, -SO3-X+, -SO3R3, -PO3H, -PO3-X+, -PO3R3, -CO2H, -CO2-X+ or -CO2R3;
X+ = an organic cation or an inorganic cation, such that the general charge of (I) is neutral;
R9, R9a = -OH or -OR2;
R2 = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl (all optionally substituted);
R3 = alkyl or aryl (both optionally substituted); and
a, p = 0-6.
When R9 and R9a are both -OR2, then the R9 and R9a can be the same or different; when Y1 is -SO3H, -SO3-X+ or -SO3R3, then R9 and R9a are -OH and -OR2; and at least one of R9 and R9a is alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted).
ACTIVITY - Antibacterial; Ophthalmological; Gynecological; Nephrotropic; Cytostatic; Gastrointestinal-Gen.; Antiinflammatory; Antiasthmatic; Antiulcer; Protozoacide; Analgesic; Antiarthritic; Angiogenesis inhibitor.
MECHANISM OF ACTION - Fibroblast mitogenesis inhibitor.
USE - (I) are useful for the treatment and/or prophylaxis of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy (claimed). (I) are useful for the treatment and/or prophylaxis of hemangiomas, hemangioblastomas, benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Barrett's disease, Crohn's disease, ulcerative colitis (proctitis, proctosigmoiditis, pancolitis), leishmaniasis, Helicobacter pylori infection, pterygium, endometriosis, ovarian hyperstimulation syndrome, polycystic kidney disease, pain, arthritis. (I) were tested for their ability to reduce the proliferation capacity of human retinal endothelial cells (HREC). The results showed that 2,5-dihydroxycinnamic acid methyl ester significantly inhibited HREC proliferation at 50-100 mu M.
ADVANTAGE - (I) are effective for the treatment of e.g. hemangiomas, leishmaniasis, polycystic kidney disease, ovarian hyperstimulation syndrome, endometrosis and benign prostatic hyperplasia. MANUAL CODE: CPI: B05-A01B; B05-B01N; B10-A09B; B10-C03; B10-E02;
B10-G02; B14-A01A; B14-A03F; B14-B02; B14-C01; B14-C03; B14-C07; B14-C09; B14-E08; B14-E10A; B14-E10C1; B14-F02F2; B14-G02; B14-G03; B14-H01E2; B14-H05; B14-J02C1; B14-J02D1; B14-J05; B14-K01A; B14-L06; B14-N03; B14-N07; B14-N10; B14-P01; B14-S08; B14-S16
TECH
PHARMACEUTICALS - Preferred Components: (I) are in the form of esters at

position 1, particularly methyl or ethyl esters. The medicament comprises an additional therapeutic agent such as a chemotherapeutic agent, corticosteroid, antibiotic, analgesic, alpha-adrenergic blocker, beta-adrenergic agonist, anticholinergic, inhibitor of 5-alpha-reductase, antiandrogen, oral contraceptive, immunomodulator, immunosuppressant, anti-angiogenic, bronchodilator, leukotriene modifier, aminosalicylate, anesthetic, non-steroidal anti-inflammatory, antiparasitic, proton pump inhibitor, hydrogen-receptor antagonist, therapy of the solubilized interleukin receptor, intramuscular gold, cytotoxic and/or an antioxidant.

ABEX DEFINITIONS - Preferred Definitions: - Y1 = -SO3H, -SO3-X+, -SO3R3, -CO2H, -CO2-X+ or -CO2R3; and - R2 = methylcarbonyl, phenylsulfonyl, 4-methylphenylsulfonyl, benzylsulfonyl, benzyl or phenyl. - At least one of R9 and R9a are alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted).

ADMINISTRATION - Administration of (I) is topical, transdermal, oral, buccal, parenteral, intradermal, rectal, intravaginal, intraocular or by inhalation (claimed). Dosage of (I) is 0.05-50 (preferably 0.1, 0.25, 0.5, 0.75, 1, 5, 10, 25 or 50) g/day.

SPECIFIC COMPOUNDS - The use of 42 compounds (I) is specifically claimed e.g. 5-hydroxy-2-(((4-methylphenyl)sulfonyl)oxy)benzenesulfonic acid (Ia), 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, 5-(acetyloxy)-2-hydroxybenzenesulfonic acid, 2,5-bis(acetyloxy)benzenesulfonic acid and 2,5-bis(benzyloxy)benzoic acid.

AN.S DCR-1595312
CN.S (E)-3-[5-Hydroxy-2-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid
SDCN RASW39



AN.S DCR-1595313
CN.S (E)-3-[2-Hydroxy-5-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid
SDCN RASW3A



AN.S DCR-1595314
CN.S (E)-3-[2,5-Bis-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid
SDCN RASW3B



AN.S DCR-1595315
CN.S (E)-3-(2-Acetoxy-5-hydroxy-phenyl)-acrylic acid
SDCN RASW3C



AN.S DCR-1595316
CN.S (E)-3-(5-Acetoxy-2-hydroxy-phenyl)-acrylic acid
SDCN RASW3D



AN.S DCR-1595317
CN.S (E)-3-(2,5-Diacetoxy-phenyl)-acrylic acid
SDCN RASW3E



AN.S DCR-1595318
CN.S (E)-3-(2-Benzyloxy-5-hydroxy-phenyl)-acrylic acid
SDCN RASW3F



AN.S DCR-1595319
CN.S (E)-3-(5-Benzyloxy-2-hydroxy-phenyl)-acrylic acid
SDCN RASW3G



AN.S DCR-1595320
CN.S (E)-3-(2,5-Bis-benzyloxy-phenyl)-acrylic acid
SDCN RASW3H



AN.S DCR-108109
CN.P SULTOSILATE
SDCN RA2Y7A



AN.S DCR-1595297
CN.S 2,5-Bis-(toluene-4-sulfonyloxy)-benzenesulfonic acid
SDCN RASW2U



AN.S DCR-1595298
CN.S Acetic acid 4-hydroxy-2-sulfo-phenyl ester
SDCN RASW2V



AN.S DCR-1595299
CN.S Acetic acid 4-hydroxy-3-sulfo-phenyl ester
SDCN RASW2W



AN.S DCR-1595300
CN.S Acetic acid 4-acetoxy-3-sulfo-phenyl ester
SDCN RASW2X



AN.S DCR-1595296
CN.S 5-Hydroxy-2-(toluene-4-sulfonyloxy)-benzenesulfonic acid
SDCN RASW2T



L220 ANSWER 19 OF 22 WPIX COPYRIGHT 2009 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-E49165 [30] WPIX
CROSS REFERENCE: 2008-D99595; 2008-E61270; 2008-G33820; 2008-L13777
DOC. NO. CPI: C2008-149386 [30]

TITLE: Use of substituted phenyl compounds in the manufacturing of a medicament for the treatment and/or prophylaxis of e.g. pterygium, endometrosis, ovarian hyperstimulation syndrome and polycystic kidney disease

DERWENT CLASS: B05

INVENTOR: ANGULO FRUTOS J; CUEVAS SANCHEZ F; GIMENEZ GALLEGO G; LOZANO PUERTO R M; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I; VALVERDE LOPEZ S

PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL

COUNTRY COUNT: 120

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020031	A1	20080221	(200830)*	EN	135[29]	
ES 2315117	A1	20090316	(200922)	ES		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020031	A1	WO 2007-EP58444	20070815
ES 2315117	A1	ES 2006-2217	20060816

PRIORITY APPLN. INFO: ES 2007-1855 20070702
ES 2006-2217 20060816

INT. PATENT CLASSIF.:
IPC ORIGINAL: A61K0031-095 [I,C]; A61K0031-10 [I,A]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-60 [I,A]; A61K0031-60 [I,C]; A61K0031-618 [I,A]; A61P0015-00 [I,A]; A61P0015-00 [I,C]; A61K0031-185 [I,A]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61P0011-00 [I,C]; A61P0011-06 [I,A]

ECLA: A61K0031-10; A61K0031-192; A61K0031-60; A61K0031-618

BASIC ABSTRACT:

WO 2008020031 A1 UPAB: 20090407

NOVELTY - Use of substituted phenyl compounds (I) or their salts, solvates, isomers or prodrugs in the manufacturing of a medicament for the treatment and/or prophylaxis of diseases associated to Helicobacter pylori infection, pterygium, endometrosis, ovarian hyperstimulation syndrome and/or polycystic kidney disease, is claimed

DETAILED DESCRIPTION - Use of substituted phenyl compounds of formula (I) or their salts, solvates, isomers or prodrugs in the manufacturing of a medicament for the treatment and/or prophylaxis of diseases associated to Helicobacter pylori infection, pterygium, endometrosis, ovarian hyperstimulation syndrome and/or polycystic kidney disease, is claimed.

R1 = -(CH2)aY1 or -CH=CH-(CH2)pY1;

Y1 = -SO3H, -SO3-X+, -SO3R3, -PO3H, -PO3-X+, -PO3R3, -CO2H, -CO2-X+ or -CO2R3;

X+ = an organic cation or an inorganic cation, such that the general charge of (I) is neutral;

R9, R9a = -OH or -OR2;

R2 = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl (all optionally substituted);

R3 = alkyl or aryl (both optionally substituted); and

a, p = 0-6.

When R9 and R9a are both -OR2, then the R9 and R9a can be the same or different; when Y1 is -SO3H, -SO3-X+ or -SO3R3, then R9 and R9a are -OH and -

OR2; and at least one of R9 and R9a is alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted).

ACTIVITY - Antibacterial; Ophthalmological; Gynecological; Nephrotropic; Cytostatic; Gastrointestinal-Gen.; Antiinflammatory; Antiasthmatic; Antiulcer; Protozoacide; Analgesic; Antiarthritic; Angiogenesis inhibitor.

MECHANISM OF ACTION - Fibroblast mitogenesis inhibitor.

USE - (I) are useful for the treatment and/or prophylaxis of diseases associated to Helicobacter pylori infection, pterygium, endometrosis, ovarian hyperstimulation syndrome and/or polycystic kidney disease (claimed). (I) are useful for the treatment and/or prophylaxis of hemangiomas, hemangioblastomas, benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis (proctitis, proctosigmoiditis, pancolitis), leishmaniasis, pain, arthritis, macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy. (I) were tested for their ability to reduce the proliferation capacity of human retinal endothelial cells (HREC). The results showed that 2,5-dihydroxycinnamic acid methyl ester significantly inhibited HREC proliferation at 50-100 mu M.

ADVANTAGE - (I) are effective for the treatment of e.g. hemangiomas, leishmaniasis, polycystic kidney disease, ovarian hyperstimulation syndrome, endometrosis and benign prostatic hyperplasia. MANUAL CODE: CPI: B02-Z; B05-A01B; B05-B01N; B10-A09B; B10-C03;
B10-E02; B10-G02; B14-A01A; B14-A03F; B14-B02; B14-C01; B14-C03; B14-C07; B14-C09; B14-E08; B14-E10A; B14-E10C1; B14-F02F2; B14-G02; B14-G03; B14-H05; B14-J02C1; B14-J02D1; B14-J05; B14-K01A; B14-L01; B14-L06; B14-L12; B14-N03; B14-N07; B14-N10; B14-P01; B14-S08

TECH

PHARMACEUTICALS - Preferred Components: (I) are in the form of esters at position 1, particularly methyl or ethyl esters. The medicament comprises an additional therapeutic agent such as a chemotherapeutic agent, corticosteroid, antibiotic, analgesic, alpha-adrenergic blocker, beta-adrenergic agonist, anticholinergic, inhibitor of 5-alpha-reductase, antiandrogen, oral contraceptive, immunomodulator, immunosuppressant, anti-angiogenic, bronchodilator, leukotriene modifier, aminosalicylate, anesthetic, non-steroidal anti-inflammatory, antiparasitic, proton pump inhibitor, hydrogen-receptor antagonist, therapy of the solubilized interleukin receptor, intramuscular gold, cytotoxic and/or an antioxidant.

ABEX DEFINITIONS - Preferred Definitions: - Y1 = -SO3H, -SO3-X+, -SO3R3, -CO2H, -CO2-X+ or -CO2R3; and - R2 = methylcarbonyl, phenylsulfonyl, 4-methylphenylsulfonyl, benzylsulfonyl, benzyl or phenyl. - At least one of R9 and R9a are alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted).

ADMINISTRATION - Administration of (I) is topical, transdermal, oral, buccal, parenteral, intradermal, rectal, intravaginal, intraocular or by inhalation (claimed). Dosage of (I) is 0.05-50 (preferably 0.1, 0.25, 0.5, 0.75, 1, 5, 10, 25 or 50) g/day.

SPECIFIC COMPOUNDS - The use of 42 compounds (I) is specifically claimed e.g. 5-(acetyloxy)-2-hydroxyhomobenzoic acid (Ia), 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, 5-(acetyloxy)-2-hydroxybenzenesulfonic acid, 2,5-bis(acetyloxy)benzenesulfonic acid and 2,5-bis(benzyloxy)homobenzoic acid.

AN.S DCR-1595296

CN.S 5-Hydroxy-2-(toluene-4-sulfonyloxy)-benzenesulfonic acid

SDCN RASW2T



AN.S DCR-108109
CN.P SULTOSILATE
SDCN RA2Y7A



AN.S DCR-1595297
CN.S 2,5-Bis-(toluene-4-sulfonyloxy)-benzenesulfonic acid
SDCN RASW2U



AN.S DCR-1595298
CN.S Acetic acid 4-hydroxy-2-sulfo-phenyl ester
SDCN RASW2V



AN.S DCR-1595299
CN.S Acetic acid 4-hydroxy-3-sulfo-phenyl ester
SDCN RASW2W



AN.S DCR-1595300
CN.S Acetic acid 4-acetoxy-3-sulfo-phenyl ester
SDCN RASW2X



AN.S DCR-1595320
CN.S (E)-3-(2,5-Bis-benzyloxy-phenyl)-acrylic acid
SDCN RASW3H



AN.S DCR-1595316
CN.S (E)-3-(5-Acetoxy-2-hydroxy-phenyl)-acrylic acid
SDCN RASW3D



AN.S DCR-1595317
CN.S (E)-3-(2,5-Diacetoxy-phenyl)-acrylic acid
SDCN RASW3E



AN.S DCR-1595318
CN.S (E)-3-(2-Benzyloxy-5-hydroxy-phenyl)-acrylic acid
SDCN RASW3F



AN.S DCR-1595319
CN.S (E)-3-(5-Benzyloxy-2-hydroxy-phenyl)-acrylic acid
SDCN RASW3G



AN.S DCR-1595312
CN.S (E)-3-[5-Hydroxy-2-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid
SDCN RASW39



AN.S DCR-1595313
CN.S (E)-3-[2-Hydroxy-5-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid
SDCN RASW3A



AN.S DCR-1595314
CN.S (E)-3-[2,5-Bis-(toluene-4-sulfonyloxy)-phenyl]-acrylic acid
SDCN RASW3B



AN.S DCR-1595315
CN.S (E)-3-(2-Acetoxy-5-hydroxy-phenyl)-acrylic acid
SDCN RASW3C



=> d ibib ab hitstr 20-21
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' - CONTINUE?
(Y)/N:y

L220 ANSWER 20 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2008:334640 USPATFULL Full-text
TITLE: Use of 2,5-Dihydroxybenzenesulphonic Acid in the Production of Medicaments for the Treatment of Angiodependent Diseases Such as Cancer and Psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro, Madrid, SPAIN
Romero Garrido, Antonio, Madrid, SPAIN
Gimenez Gallego, Guillermo, Madrid, SPAIN
Valverde Lopez, Serafin, Madrid, SPAIN
Lozano Puerto, Rosa Maria, Madrid, SPAIN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20080293816	A1	20081127	
APPLICATION INFO.:	US 2005-588166	A1	20050216	(10)
	WO 2005-ES70017		20050216	
			20080807	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	ES 2004-371	20040217

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LADAS & PARRY LLP, 26 WEST 61ST STREET, NEW YORK, NY, 10023, US
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 623
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity

of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapoptotic capacities thereof, in the treatment of chronic psoriatic plaques.

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 20123-80-2, 2,5-Dihydroxybenzenesulfonic acid calcium salt 862162-74-1
(use of dihydroxybenzenesulfonic acid in drugs for treatment of angiodependent diseases)

RN 88-46-0 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 20123-80-2 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 862162-74-1 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:?) (CA INDEX NAME)



●x K

L220 ANSWER 21 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2008:130980 USPATFULL Full-text
TITLE: Use of 2,5-Dihydroxybenzene Compounds and Derivatives for the Treatment of Psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro, Madrid, SPAIN
Gimenez Gallego, Guillermo, Madrid, SPAIN
Morgan, Inigo Saenz de Tejada, Madrid, SPAIN
Angulo Frutos, Javier, Madrid, SPAIN
Valverde Lopez, Serafin, Madrid, SPAIN
Romero Garrido, Antonio, Madrid, SPAIN
Lozano Puerto, Rosa Maria, Madrid, SPAIN
PATENT ASSIGNEE(S): Action Medicines, Madrid, SPAIN
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080113948	A1	20080515
APPLICATION INFO.:	US 2007-839520	A1	20070815 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	ES 2006-2218	20060816
	ES 2007-1856	20070702

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE- 10TH FL., NEW YORK, NY, 10151, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 1755
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis.
IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 51579-69-2 57775-26-5 59687-22-8 60630-38-8 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
(use of hydroxybenzene compds. and derivs. for treatment of hematol. dyscrasias and cancer)
RN 88-46-0 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 88-46-0 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 636-01-1 USPATFULL
CN 2-Propenoic acid, 3-(2,5-dihydroxyphenyl)- (CA INDEX NAME)



RN 21799-87-1 USPATFULL
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 51579-69-2 USPATFULL
CN Benzenesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 57775-26-5 USPATFULL
CN Benzenesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 59687-22-8 USPATFULL
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 60630-38-8 USPATFULL
CN Benzenesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 79122-68-2 USPATFULL
CN Benzenesulfonic acid, 2,5-bis(acetyloxy)-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 USPATFULL
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 159252-66-1 USPATFULL
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 748106-93-6 USPATFULL
CN Benzenesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-71-5 USPATFULL
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-72-6 USPATFULL
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 1007839-87-3 USPATFULL
CN Benzenemethanesulfonic acid, 5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-89-5 USPATFULL
CN Benzenemethanesulfonic acid, 2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-91-9 USPATFULL
CN Benzenemethanesulfonic acid, 2,5-bis[[(4-methylphenyl)sulfonyl]oxy]- (CA INDEX NAME)



RN 1007839-93-1 USPATFULL
CN Benzenemethanesulfonic acid, 2-(acetyloxy)-5-hydroxy- (CA INDEX NAME)



RN 1007839-94-2 USPATFULL
CN Benzenemethanesulfonic acid, 5-(acetyloxy)-2-hydroxy- (CA INDEX NAME)



RN 1007839-96-4 USPATFULL
CN Benzenemethanesulfonic acid, 2,5-bis(acetyloxy)- (CA INDEX NAME)



RN 1007840-16-5 USPATFULL
CN 2-Propenoic acid, 3-[5-hydroxy-2-[[(4-methylphenyl)sulfonyl]oxy]phenyl]-
(CA INDEX NAME)



RN 1007840-17-6 USPATFULL
CN 2-Propenoic acid, 3-[2-hydroxy-5-[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-18-7 USPATFULL
CN 2-Propenoic acid, 3-[2,5-bis[[(4-methylphenyl)sulfonyl]oxy]phenyl]- (CA INDEX NAME)



RN 1007840-19-8 USPATFULL
CN 2-Propenoic acid, 3-[2-(acetyloxy)-5-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-20-1 USPATFULL
CN 2-Propenoic acid, 3-[5-(acetyloxy)-2-hydroxyphenyl]- (CA INDEX NAME)



RN 1007840-21-2 USPATFULL
CN 2-Propenoic acid, 3-[2,5-bis(acetyloxy)phenyl]- (CA INDEX NAME)



RN 1007840-22-3 USPATFULL
CN 2-Propenoic acid, 3-[5-hydroxy-2-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-23-4 USPATFULL
CN 2-Propenoic acid, 3-[2-hydroxy-5-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007840-24-5 USPATFULL
CN 2-Propenoic acid, 3-[2,5-bis(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 1007849-27-5 USPATFULL
CN Benzenesulfonic acid, 2-(acetyloxy)-5-hydroxy-, calcium salt (2:1) (CA INDEX NAME)



1/2 Ca

=> d ibib ed ab ind 22
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' - CONTINUE? (Y)/N:y

L220 ANSWER 22 OF 22 MEDLINE on STN DUPLICATE 16
ACCESSION NUMBER: 2005510146 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 16183548
TITLE: Dobesilate in the treatment of plaque psoriasis.
AUTHOR: Cuevas Pedro; Arrazola Jose M
CORPORATE SOURCE: Servicio de Histologia, Departamento de Investigacion, Hospital Ramon y Cajal, Ctra. de Colmenar, km. 9.100, E-28034-Madrid, Spain.. pedro.cuevas@hrc.es
SOURCE: European journal of medical research, (2005 Sep 12) Vol. 10, No. 9, pp. 373-6.
Journal code: 9517857. ISSN: 0949-2321.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200511
ENTRY DATE: Entered STN: 27 Sep 2005
Last Updated on STN: 9 Nov 2005
Entered Medline: 8 Nov 2005
ED Entered STN: 27 Sep 2005
Last Updated on STN: 9 Nov 2005
Entered Medline: 8 Nov 2005
AB Fibroblast growth factor (FGF)-mediated pathways participate in many of the cellular events implicated in the pathogenesis of psoriasis. Thus, targeting FGF signals may be potentially therapeutic in the treatment of psoriasis. We report for the first time on a 43-year-old man with chronic-type plaque psoriasis with a daily topical treatment of dobesilate, a new FGF inhibitor. As early as at day 14, the patient had cleared or achieved excellent improvement of psoriatic skin lesions. Topical dobesilate offers the

potential for treatment of plaque psoriasis without atrophy or other local side effects associated with the use of topical corticosteroids.

CT Check Tags: Male
Adult
*Calcium Dobesilate: TU, therapeutic use
*Fibroblast Growth Factors: AI, antagonists & inhibitors
*Hemostatics: TU, therapeutic use
Humans
*Psoriasis: DT, drug therapy

RN 20123-80-2 (Calcium Dobesilate); 62031-54-3 (Fibroblast Growth Factors)

CN 0 (Hemostatics)

=> file stnguide
FILE 'STNGUIDE' ENTERED AT 11:53:31 ON 25 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 18, 2009 (20090918/UP).

```
=> d his ful

     (FILE 'HOME' ENTERED AT 07:58:56 ON 25 SEP 2009)

     FILE 'STNGUIDE' ENTERED AT 07:58:59 ON 25 SEP 2009

     FILE 'HCAPLUS' ENTERED AT 07:59:16 ON 25 SEP 2009
                ACT PAG520HCAAPP/A
                ---------
L1             5 SEA SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
                ---------

     FILE 'WPIX' ENTERED AT 07:59:33 ON 25 SEP 2009
                ACT PAG520WPIAPP/A
                ---------
L2             1 SEA SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
                ---------

     FILE 'REGISTRY' ENTERED AT 07:59:47 ON 25 SEP 2009
                ACT PAG520REGAPP/A
                ---------
L3  (          5)SEA SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L4               SEL PLU=ON  L3 1- RN :      82 TERMS
L5            82 SEA SPE=ON  ABB=ON  PLU=ON  L4
                ---------
                ACT PAG520PSET1/A
                ---------
L6  (          5)SEA SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L7               SEL PLU=ON  L6 1- RN :      82 TERMS
L8  (         82)SEA SPE=ON  ABB=ON  PLU=ON  L7
L9               STR
L10           28 SEA SUB=L8 SSS FUL L9
                ---------
                ACT PAG520CROSS/A
                ---------
L11 (          5)SEA SPE=ON  ABB=ON  PLU=ON  US2007-839520/APPS
L12              SEL PLU=ON  L11 1- RN :      82 TERMS
L13 (         82)SEA SPE=ON  ABB=ON  PLU=ON  L12
L14              STR
L15 (         28)SEA SUB=L13 SSS FUL L14
L16 (        270)SEA SPE=ON  ABB=ON  PLU=ON  (1007839-71-5/CRN OR 1007839-72-6/C
                 RN OR 1007839-87-3/CRN OR 1007839-89-5/CRN OR 1007839-91-9/CRN
                 OR 1007839-93-1/CRN OR 1007839-94-2/CRN OR 1007839-96-4/CRN OR
                 1007840-16-5/CRN OR 1007840-17-6/CRN OR 1007840-18-7/CRN OR
                 1007840-19-8/CRN OR 1007840-20-1/CRN OR 1007840-21-2/CRN OR
                 1007840-22-3/CRN OR 1007840-23-4/CRN OR 1007840-24-5/CRN OR
                 1007849-27-5/CRN OR 159252-66-1/CRN OR 21799-87-1/CRN OR
                 51579-69-2/CRN OR 57775-26-5/CRN OR 59687-22-8/CRN OR 60630-38-
                 8/CRN OR 636-01-1/CRN OR 748106-93-6/CRN OR 79122-68-2/CRN OR
                 88-46-0/CRN)
L17           293 SEA SPE=ON  ABB=ON  PLU=ON  L15 OR L16
                ---------
L18           129 SEA SPE=ON  ABB=ON  PLU=ON  L17 NOT PMS/CI
                 SAVE TEMP L18 PAG520CROSS2/A

     FILE 'STNGUIDE' ENTERED AT 08:03:05 ON 25 SEP 2009
                D SAVED

     FILE 'WPIX' ENTERED AT 08:03:39 ON 25 SEP 2009
```

```
                ACT PAG520WPIANS/A
               ---------
L19          34 SEA SPE=ON  ABB=ON  PLU=ON  (1595296-K/AN.S OR 1595296-M/AN.S
                OR 1595297-K/AN.S OR 1595297-M/AN.S OR 1595298-K/AN.S OR
                1595298-M/AN.S OR 3322-U/AN.S OR 528-U/AN.S OR 9091-U/AN.S OR
                DCR-108109/AN.S OR DCR-10897/AN.S OR DCR-12641/AN.S OR
                DCR-1595296/AN.S OR DCR-1595297/AN.S OR DCR-1595298/AN.S OR
                DCR-1595299/AN.S OR DCR-1595300/AN.S OR DCR-1595312/AN.S OR
                DCR-1595313/AN.S OR DCR-1595314/AN.S OR DCR-1595315/AN.S OR
                DCR-1595316/AN.S OR DCR-1595317/AN.S OR DCR-1595318/AN.S OR
                DCR-1595319/AN.S OR DCR-1595320/AN.S OR DCR-1669096/AN.S OR
                DCR-1669099/AN.S OR DCR-1669100/AN.S OR DCR-1669101/AN.S OR
                DCR-1669102/AN.S OR DCR-1669103/AN.S OR DCR-1669104/AN.S OR
                DCR-216917/AN.S OR DCR-36113/AN.S OR DCR-528/AN.S OR DCR-7558/A
                N.S OR DCR-86449/AN.S OR DCR-9091/AN.S OR DCR-91462/AN.S OR
                DCR-96282/AN.S OR DCR-97073/AN.S OR DCR-97733/AN.S OR 108109-K/
                AN.S OR 108109-M/AN.S OR 10897-K/AN.S OR 10897-M/AN.S OR
                12641-K/AN.S OR 12641-M/AN.S OR 1595299-K/AN.S OR 1595299-M/AN.
                S OR 1595300-K/AN.S OR 1595300-M/AN.S OR 1595312-K/AN.S OR
                1595312-M/AN.S OR 1595313-K/AN.S OR 1595313-M/AN.S OR 1595314-K
                /AN.S OR 1595314-M/AN.S OR 1595315-K/AN.S OR 1595315-M/AN.S OR
                1595316-K/AN.S OR 1595316-M/AN.S OR 1595317-K/AN.S OR 1595317-M
                /AN.S OR 1595318-K/AN.S OR 1595318-M/AN.S OR 1595319-K/AN.S OR
                1595319-M/AN.S OR 1595320-K/AN.S OR 1595320-M/AN.S OR 1669096-K
                /AN.S OR 1669096-M/AN.S OR 1669099-K/AN.S OR 1669099-M/AN.S OR
                1669100-K/AN.S OR 1669100-M/AN.S OR 1669101-K/AN.S OR 1669101-M
                /AN.S OR 1669102-K/AN.S OR 1669102-M/AN.S OR 1669103-K/AN.S OR
                1669103-M/AN.S OR 1669104-K/AN.S OR 1669104-M/AN.S OR 216917-K/
                AN.S OR 216917-M/AN.S OR 36113-K/AN.S OR 36113-M/AN.S OR
                528-K/AN.S OR 528-M/AN.S OR 7558-K/AN.S OR 7558-M/AN.S OR
                86449-K/AN.S OR 86449-M/AN.S OR 9091-K/AN.S OR 9091-M/AN.S OR
                91462-K/AN.S OR 91462-M/AN.S OR 96282-K/AN.S OR 96282-M/AN.S
                OR 97073-K/AN.S OR 97073-M/AN.S OR 97733-K/AN.S OR 97733-M/AN.S
                )
               ---------
                D CODE L2
L20              1 SEA SPE=ON  ABB=ON  PLU=ON  DCR-1669102/AN.S
                D TRI

     FILE 'ZCAPLUS' ENTERED AT 08:06:08 ON 25 SEP 2009
L21              QUE SPE=ON  ABB=ON  PLU=ON  CUEVAS SANCHEZ, P?/AU,AUTH
L22              QUE SPE=ON  ABB=ON  PLU=ON  CUEVASSANCHEZ, P?/AU,AUTH
L23              QUE SPE=ON  ABB=ON  PLU=ON  CUEVAS, P?/AU,AUTH
L24              QUE SPE=ON  ABB=ON  PLU=ON  SANCHEZ, P?/AU,AUTH
L25              QUE SPE=ON  ABB=ON  PLU=ON  GIMENEZ GALLEGO, G?/AU,AUTH
L26              QUE SPE=ON  ABB=ON  PLU=ON  GIMENEZGALLEGO, G?/AU,AUTH
L27              QUE SPE=ON  ABB=ON  PLU=ON  GIMENEZ, G?/AU,AUTH
L28              QUE SPE=ON  ABB=ON  PLU=ON  GALLEGO, G?/AU,AUTH
L29              QUE SPE=ON  ABB=ON  PLU=ON  MORGAN, I?/AU,AUTH
L30              QUE SPE=ON  ABB=ON  PLU=ON  SAENZ DE TEJADA MORGAN, I?/AU,AUTH

L31              QUE SPE=ON  ABB=ON  PLU=ON  SAENZDETEJADA, I?/AU,AUTH
L32              QUE SPE=ON  ABB=ON  PLU=ON  SAENZ, I?/AU,AUTH
L33              QUE SPE=ON  ABB=ON  PLU=ON  DETEJADA, I?/AU,AUTH
L34              QUE SPE=ON  ABB=ON  PLU=ON  DE TEJADA, I?/AU,AUTH
L35              QUE SPE=ON  ABB=ON  PLU=ON  ANGULO FRUTOS, J?/AU,AUTH
L36              QUE SPE=ON  ABB=ON  PLU=ON  ANGULOFRUTOS, J?/AU,AUTH
L37              QUE SPE=ON  ABB=ON  PLU=ON  ANGULO, J?/AU,AUTH
L38              QUE SPE=ON  ABB=ON  PLU=ON  FRUTOS, J?/AU,AUTH
L39              QUE SPE=ON  ABB=ON  PLU=ON  VALVERDE LOPEZ, S?/AU,AUTH
```

```
L40             QUE SPE=ON  ABB=ON  PLU=ON  VALVERDELOPEZ, S?/AU,AUTH
L41             QUE SPE=ON  ABB=ON  PLU=ON  VALVERDE, S?/AU,AUTH
L42             QUE SPE=ON  ABB=ON  PLU=ON  LOPEZ, S?/AU,AUTH
L43             QUE SPE=ON  ABB=ON  PLU=ON  ROMERO GARRIDO, A?/AU,AUTH
L44             QUE SPE=ON  ABB=ON  PLU=ON  ROMEROGARRIDO, A?/AU,AUTH
L45             QUE SPE=ON  ABB=ON  PLU=ON  ROMERO, A?/AU,AUTH
L46             QUE SPE=ON  ABB=ON  PLU=ON  GARRIDO, A?/AU,AUTH
L47             QUE SPE=ON  ABB=ON  PLU=ON  LOZANO PUERTO, R?/AU,AUTH
L48             QUE SPE=ON  ABB=ON  PLU=ON  LOZANOPUERTO, R?/AU,AUTH
L49             QUE SPE=ON  ABB=ON  PLU=ON  LOZANO, R?/AU,AUTH
L50             QUE SPE=ON  ABB=ON  PLU=ON  PUERTO, R?/AU,AUTH
L51             QUE SPE=ON  ABB=ON  PLU=ON  (ACTION(1W)MEDICINE#)/CS,SO,PA
L52             QUE SPE=ON  ABB=ON  PLU=ON  AY<2008 OR PY<2008 OR PRY<2008 OR
                MY<2008 OR REVIEW/DT
L53             QUE SPE=ON  ABB=ON  PLU=ON  SKIN
L54             QUE SPE=ON  ABB=ON  PLU=ON  ?DERM?
L55             QUE SPE=ON  ABB=ON  PLU=ON  ?PSORIA?
L56             QUE SPE=ON  ABB=ON  PLU=ON  ANTIPSORIA?
                E PSORIASIS/CT
                E E3+ALL
L57             QUE SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
                E ANTIPSORIA/CT
                E SKIN TREATMENT/CT
                E E31+ALL
                E E46+ALL
L58             QUE SPE=ON  ABB=ON  PLU=ON  A61P0017-06/IPC

    FILE 'HCAPLUS' ENTERED AT 08:12:17 ON 25 SEP 2009
                D SCAN L1

    FILE 'STNGUIDE' ENTERED AT 08:12:27 ON 25 SEP 2009

    FILE 'HCAPLUS' ENTERED AT 08:13:18 ON 25 SEP 2009
L59          780 SEA SPE=ON  ABB=ON  PLU=ON  L18
L60           11 SEA SPE=ON  ABB=ON  PLU=ON  L59 (L)((L53 OR L54 OR L55 OR
                  L56))
                  D SCAN TI HIT
L61           10 SEA SPE=ON  ABB=ON  PLU=ON  L59 AND L58
L62            6 SEA SPE=ON  ABB=ON  PLU=ON  L59 AND L57
                  D SCAN TI HIT

    FILE 'ZCAPLUS' ENTERED AT 08:15:45 ON 25 SEP 2009
                E DERMATOLOGICAL AGENTS/CT
                E E67+ALL
L63             QUE SPE=ON  ABB=ON  PLU=ON  "DERMATOLOGICAL AGENTS"+PFT,OLD,NEW
                /CT

    FILE 'HCAPLUS' ENTERED AT 08:16:22 ON 25 SEP 2009
L64             3 SEA SPE=ON  ABB=ON  PLU=ON  L59 AND L63
L65             1 SEA SPE=ON  ABB=ON  PLU=ON  L64 AND (L55 OR L56)
L66             7 SEA SPE=ON  ABB=ON  PLU=ON  L59 AND (L55 OR L56)
L67            20 SEA SPE=ON  ABB=ON  PLU=ON  (L60 OR L61 OR L62) OR (L64 OR L65
                  OR L66)
L68            20 SEA SPE=ON  ABB=ON  PLU=ON  L67 AND (L53 OR L54 OR L55 OR L56)

L69            20 SEA SPE=ON  ABB=ON  PLU=ON  (L67 OR L68)
L70            14 SEA SPE=ON  ABB=ON  PLU=ON  L69 AND (L21 OR L22 OR L23 OR L24
                  OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
                  OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
                  OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
```

```
                L51)
                SAVE TEMP L70 PAG520HCAINV/A
L71             6 SEA SPE=ON  ABB=ON  PLU=ON  L69 NOT L70
                D SCAN TI HIT

     FILE 'STNGUIDE' ENTERED AT 08:20:34 ON 25 SEP 2009

     FILE 'REGISTRY' ENTERED AT 08:20:56 ON 25 SEP 2009
L72             1 SEA SPE=ON  ABB=ON  PLU=ON  57775-26-5/RN
                D SCAN

     FILE 'HCAPLUS' ENTERED AT 08:21:14 ON 25 SEP 2009
L73             1 SEA SPE=ON  ABB=ON  PLU=ON  L71 AND CHOLESTEROL/TI
                D BIB

     FILE 'STNGUIDE' ENTERED AT 08:21:39 ON 25 SEP 2009

     FILE 'WPIX' ENTERED AT 08:24:17 ON 25 SEP 2009
L*** DEL         QUE (B14-N17C OR C14-N17C OR B12-107 OR C12-A07)/MC
L*** DEL   21165 S L58 OR L74
L74              QUE SPE=ON  ABB=ON  PLU=ON  (B14-N17C OR C14-N17C OR B12-A07
                 OR C12-A07)/MC
L75        32388 SEA SPE=ON  ABB=ON  PLU=ON  L58 OR L74
L76        16186 SEA SPE=ON  ABB=ON  PLU=ON  L75 AND (L55 OR L56)
L77         5786 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND G015/M0,M1,M2,M3,M4,M5,M6
L78         1752 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND (G015/M0,M1,M2,M3,M4,M5,M6
                 (P) T/DCN)

     FILE 'STNGUIDE' ENTERED AT 08:28:29 ON 25 SEP 2009

     FILE 'WPIX' ENTERED AT 08:29:33 ON 25 SEP 2009
L79         4373 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND (G015/M0,M1,M2,M3,M4,M5,M6
                 (P) P420/M0,M1,M2,M3,M4,M5,M6)
L80         1362 SEA SPE=ON  ABB=ON  PLU=ON  L78 AND L79

     FILE 'STNGUIDE' ENTERED AT 08:30:15 ON 25 SEP 2009

     FILE 'WPIX' ENTERED AT 08:32:58 ON 25 SEP 2009
L81         5336 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND (G015/M0,M1,M2,M3,M4,M5,M6
                 (P) P943/M0,M1,M2,M3,M4,M5,M6)
L82         1308 SEA SPE=ON  ABB=ON  PLU=ON  L80 AND L81
                 D TRI FRAGHITSTR

     FILE 'STNGUIDE' ENTERED AT 08:34:39 ON 25 SEP 2009

     FILE 'WPIX' ENTERED AT 08:36:16 ON 25 SEP 2009
L83              QUE SPE=ON  ABB=ON  PLU=ON  (G015/M0,M1,M2,M3,M4,M5,M6 (P) (H4
                 OR K4 OR J0 OR B81?)/M0,M1,M2,M3,M4,M5,M6)
L84         1081 SEA SPE=ON  ABB=ON  PLU=ON  L82 AND L83
                 D TRI FRAGHITSTR 1-10
L85              QUE SPE=ON  ABB=ON  PLU=ON  (G015/M0,M1,M2,M3,M4,M5,M6 (P) (H4
                 OR K4 OR J0 OR B81?)/M0,M1,M2,M3,M4,M5,M6)(NOTP)(D? OR E? OR
                 F?)/M0,M1,M2,M3,M4,M5,M6
L*** DEL       0 S L84 AND L85]
L86          353 SEA SPE=ON  ABB=ON  PLU=ON  L84 AND L85
                 D TRI FRAGHITSTR 1-4
L87              QUE SPE=ON  ABB=ON  PLU=ON  (G015/M0,M1,M2,M3,M4,M5,M6 (P) (H4
                 OR K4)/M0,M1,M2,M3,M4,M5,M6)(NOTP)(D? OR E? OR F?)/M0,M1,M2,M3,
                 M4,M5,M6
                 D HIS40
```

```
L88          240 SEA SPE=ON  ABB=ON  PLU=ON  L86 AND L87
                 DEL SELECT
                 SELECT L88 1- DCR
                 DEL SELECT
L89              QUE SPE=ON  ABB=ON  PLU=ON  (G015/M0,M1,M2,M3,M4,M5,M6 (P) (H4
                 OR K4)/M0,M1,M2,M3,M4,M5,M6)(NOTP)(D? OR E? OR F? OR H1)/M0,M1,
                 M2,M3,M4,M5,M6
L90          177 SEA SPE=ON  ABB=ON  PLU=ON  L88 AND L89
                 D TRI FRAGHITSTR 1-3
L91              QUE SPE=ON  ABB=ON  PLU=ON  (G015/M0,M1,M2,M3,M4,M5,M6 (P)
                 (H441 OR H442 OR K431)/M0,M1,M2,M3,M4,M5,M6)(NOTP)(D? OR E? OR
                 F? OR H1)/M0,M1,M2,M3,M4,M5,M6
L92              QUE SPE=ON  ABB=ON  PLU=ON  ((G015/M0,M1,M2,M3,M4,M5,M6 (P)
                 (H441 OR H442 OR K431)/M0,M1,M2,M3,M4,M5,M6)(NOTP)(D? OR E? OR
                 F? OR H1)/M0,M1,M2,M3,M4,M5,M6)(P)T/DCN
L93          178 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND L92
                 D TRI FRAGHITSTR
L94              QUE SPE=ON  ABB=ON  PLU=ON  ((G015/M0,M1,M2,M3,M4,M5,M6 (P)
                 (H441 OR H442 OR K431)/M0,M1,M2,M3,M4,M5,M6)(NOTP)(D? OR E? OR
                 F? OR H1? OR H2? OR K6?)/M0,M1,M2,M3,M4,M5,M6)(P)T/DCN
L95          171 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND L94
                 D TRI FRAGHITSTR
L96              QUE SPE=ON  ABB=ON  PLU=ON  (((G015/M0,M1,M2,M3,M4,M5,M6 (P)
                 (H441 OR H442 OR K431)/M0,M1,M2,M3,M4,M5,M6)(NOTP)(D? OR E? OR
                 F? OR H1? OR H2? OR K6?)/M0,M1,M2,M3,M4,M5,M6))(P)T/DCN
L97          171 SEA SPE=ON  ABB=ON  PLU=ON  L76 AND L96
L98           56 SEA SPE=ON  ABB=ON  PLU=ON  L97 AND L58 AND L74
L99            0 SEA SPE=ON  ABB=ON  PLU=ON  L98 AND (B14-N17C/BIX,BIEX,ABEX,TT
                 OR C14-N17C/BIX,BIEX,ABEX,TT)
                 D HIS50
L100         152 SEA SPE=ON  ABB=ON  PLU=ON  L96 AND (B14-N17C OR C14-N17C)/MC
L101          58 SEA SPE=ON  ABB=ON  PLU=ON  L100 AND L58
                 D TRI FRAGHITSTR
L102         113 SEA SPE=ON  ABB=ON  PLU=ON  L100 AND (L55 OR L56)
L103         115 SEA SPE=ON  ABB=ON  PLU=ON  (L101 OR L102)
                 DEL SELECT
                 SELECT L102 1- DCN
                 DEL SELECT
L104          56 SEA SPE=ON  ABB=ON  PLU=ON  L101 AND L102
L105          58 SEA SPE=ON  ABB=ON  PLU=ON  L101 OR L104
                 DEL SELECT
                 SELECT L105 1-25 DCN
L106        1009 SEA SPE=ON  ABB=ON  PLU=ON  (R00180/SDCN OR R03057/SDCN OR
                 R10974/SDCN OR R18653/SDCN OR R18808/SDCN OR RACANB/SDCN OR
                 RACRCN/SDCN OR RACRCO/SDCN OR RACRCQ/SDCN OR RACRCY/SDCN OR
                 RACRCZ/SDCN OR RACRDB/SDCN OR RACRDC/SDCN OR RACRDE/SDCN OR
                 RACRDF/SDCN OR RACRDG/SDCN OR RACRDH/SDCN OR RACRDN/SDCN OR
                 RACRDO/SDCN OR RACRDQ/SDCN OR RACRDR/SDCN OR RACRDS/SDCN OR
                 RACRDV/SDCN OR RACRD0/SDCN OR RADRS8/SDCN OR RAF0PZ/SDCN OR
                 RA0DJE/SDCN OR RA0HDM/SDCN OR RA00C8/SDCN OR RA00GT/SDCN OR
                 RA00H3/SDCN OR RA00TQ/SDCN OR RA012O/SDCN OR RA0120/SDCN OR
                 RA02SP/SDCN OR RA04OB/SDCN OR RA088T/SDCN OR RA1HNP/SDCN OR
                 RA1YR6/SDCN OR RA6EV7/SDCN OR R00076/SDCN OR R00122/SDCN OR
                 R00137/SDCN OR R00291/SDCN OR R00689/SDCN OR R01330/SDCN OR
                 R01987/SDCN OR R02044/SDCN OR R02049/SDCN OR R02069/SDCN OR
                 R03442/SDCN OR R04259/SDCN OR R06973/SDCN OR R09011/SDCN OR
                 R10769/SDCN OR R11063/SDCN OR R12996/SDCN OR R20748/SDCN OR
                 R21749/SDCN OR R23692/SDCN OR RAAJSH/SDCN OR RAALE1/SDCN OR
                 RAAMCC/SDCN OR RAAMCD/SDCN OR RAAMCE/SDCN OR RAAMCF/SDCN OR
                 RAAMCG/SDCN OR RAAMCI/SDCN OR RAAMCK/SDCN OR RAAMCN/SDCN OR
```

RAAMCO/SDCN OR RAAMCP/SDCN OR RAAMCQ/SDCN OR RAAMCR/SDCN OR
RAAMCS/SDCN OR RAAMCT/SDCN OR RAAMCW/SDCN OR RAAMCX/SDCN OR
RAAMCY/SDCN OR RAAMCZ/SDCN OR RAAMDF/SDCN OR RAAMDG/SDCN OR
RAAMDJ/SDCN OR RAAMDL/SDCN OR RAAMDM/SDCN OR RAAMDN/SDCN OR
RAAMDO/SDCN OR RAAMDP/SDCN OR RAAMDR/SDCN OR RAAMDS/SDCN OR
RAAMDT/SDCN OR RAAMDU/SDCN OR RAAMD0/SDCN OR RAAMD1/SDCN OR
RAAMD2/SDCN OR RAAMD6/SDCN OR RAAM1I/SDCN OR RAAM1J/SDCN OR
RAAM1K/SDCN OR RAAM1L/SDCN OR RAAM1M/SDCN OR RAAM1N/SDCN OR
RAAM1O/SDCN OR RAAM1P/SDCN OR RAAM1Q/SDCN OR RAAM1R/SDCN OR
RAAM1S/SDCN OR RAAM1T/SDCN OR RAAM1U/SDCN OR RAAM1V/SDCN OR
RAAM1W/SDCN OR RAAM1X/SDCN OR RAAM1Y/SDCN OR RAAM1Z/SDCN OR
RAAM2A/SDCN OR RAAM2B/SDCN OR RAAM2C/SDCN OR RAAM20/SDCN OR
RAAM21/SDCN OR RAAM22/SDCN OR RAAM23/SDCN OR RAAM24/SDCN OR
RAAM26/SDCN OR RAAM27/SDCN OR RAAM28/SDCN OR RAAM29/SDCN OR
RAANIU/SDCN OR RAAQNG/SDCN OR RABNAH/SDCN OR RABNAI/SDCN OR
RABNAK/SDCN OR RABNAO/SDCN OR RABNAQ/SDCN OR RABNAR/S
DEL SELECT
SELECT L105 26-40 DCN

L107 418 SEA SPE=ON ABB=ON PLU=ON (RA02SP/SDCN OR R18653/SDCN OR
R01614/SDCN OR R04292/SDCN OR R13080/SDCN OR R23692/SDCN OR
RA0DWB/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA01SC/SDCN OR
RA02JW/SDCN OR RA04OB/SDCN OR RA1C7N/SDCN OR RA28R6/SDCN OR
RA5D1M/SDCN OR R00095/SDCN OR R00298/SDCN OR R03361/SDCN OR
R04116/SDCN OR R04227/SDCN OR R04654/SDCN OR R09668/SDCN OR
RA0K9J/SDCN OR RA00C8/SDCN OR RA01E9/SDCN OR RA1HNP/SDCN OR
RA43CA/SDCN OR RA74YB/SDCN OR RA74YC/SDCN OR RA74YE/SDCN OR
RA74YZ/SDCN OR RA74Y7/SDCN OR RA74Y8/SDCN OR RA74ZA/SDCN OR
RA74ZI/SDCN OR RA74ZY/SDCN OR RA74ZZ/SDCN OR RA74Z0/SDCN OR
RA74Z1/SDCN OR RA74Z2/SDCN OR RA74Z3/SDCN OR RA74Z4/SDCN OR
RA74Z5/SDCN OR RA74Z7/SDCN OR RA74Z8/SDCN OR RA74Z9/SDCN OR
RA750A/SDCN OR RA750B/SDCN OR RA7500/SDCN OR RA7501/SDCN OR
RA7502/SDCN OR RA7503/SDCN OR RA7505/SDCN OR RA7506/SDCN OR
RA7507/SDCN OR RA7508/SDCN OR R00271/SDCN OR R00991/SDCN OR
RA0CGV/SDCN OR RA0C4V/SDCN OR RA0HNY/SDCN OR RA0IKS/SDCN OR
RA0KH3/SDCN OR RA0LMH/SDCN OR RA0MTA/SDCN OR RA0WLX/SDCN OR
RA006H/SDCN OR RA01BE/SDCN OR RA01Q7/SDCN OR RA01SX/SDCN OR
RA015V/SDCN OR RA02DZ/SDCN OR RA021Q/SDCN OR RA027G/SDCN OR
RA027I/SDCN OR RA027J/SDCN OR RA03SR/SDCN OR RA03YX/SDCN OR
RA03YY/SDCN OR RA05GM/SDCN OR RA05JM/SDCN OR RA05WC/SDCN OR
RA07GX/SDCN OR RA1HN1/SDCN OR RA1QEQ/SDCN OR RA1QSX/SDCN OR
RA1YFH/SDCN OR RA13IL/SDCN OR RA13XQ/SDCN OR RA152R/SDCN OR
RA18TQ/SDCN OR RA2VNT/SDCN OR RA20DZ/SDCN OR RA3ITX/SDCN OR
RA3SGW/SDCN OR RA41J1/SDCN OR RA44DH/SDCN OR RA6SD5/SDCN OR
RA6VEH/SDCN OR RA6VEI/SDCN OR RA6VEJ/SDCN OR RA6VEK/SDCN OR
RA6VEL/SDCN OR RA6VEM/SDCN OR RA6VEN/SDCN OR RA6VEO/SDCN OR
RA6VEP/SDCN OR RA6VER/SDCN OR RA6VES/SDCN OR RA6VET/SDCN OR
RA6VEU/SDCN OR RA6VEV/SDCN OR RA6VEW/SDCN OR RA6VEX/SDCN OR
RA6VEY/SDCN OR RA6VEZ/SDCN OR RA6VFA/SDCN OR RA6VFB/SDCN OR
RA6VFC/SDCN OR RA6VFD/SDCN OR RA6VFE/SDCN OR RA6VFF/SDCN OR
RA6VFG/SDCN OR RA6VFH/SDCN OR RA6VFI/SDCN OR RA6VFJ/SDCN OR
RA6VFK/SDCN OR RA6VFL
DEL SELECT
SELECT L105 41-58 DCN

L108 324 SEA SPE=ON ABB=ON PLU=ON (RA00C8/SDCN OR RA0ETL/SDCN OR
RA0ETQ/SDCN OR RA0G5V/SDCN OR RA0KVH/SDCN OR RA0K9J/SDCN OR
RA0YL4/SDCN OR RA00GT/SDCN OR RA02JW/SDCN OR RA02SP/SDCN OR
RA04OB/SDCN OR RA1HNP/SDCN OR RA28R6/SDCN OR RA43CA/SDCN OR
R00477/SDCN OR R00669/SDCN OR R01119/SDCN OR R03562/SDCN OR
R04115/SDCN OR R04292/SDCN OR R09668/SDCN OR R13080/SDCN OR
R18653/SDCN OR R23692/SDCN OR RA00H1/SDCN OR RA00NS/SDCN OR

```
                RA01SC/SDCN OR RA012P/SDCN OR RA043B/SDCN OR RA043C/SDCN OR
                RA043E/SDCN OR RA043F/SDCN OR RA043G/SDCN OR RA043H/SDCN OR
                RA043I/SDCN OR RA043J/SDCN OR RA043K/SDCN OR RA043L/SDCN OR
                RA043M/SDCN OR RA043N/SDCN OR RA043O/SDCN OR RA043P/SDCN OR
                RA1C7N/SDCN OR RA1ILG/SDCN OR RA1ILH/SDCN OR RA1ILU/SDCN OR
                RA1ILW/SDCN OR RA1ILX/SDCN OR RA1ILY/SDCN OR RA1ILZ/SDCN OR
                RA1IMB/SDCN OR RA1IMK/SDCN OR RA1IMO/SDCN OR RA1IM0/SDCN OR
                RA1IM2/SDCN OR RA1IM4/SDCN OR RA1IM9/SDCN OR RA1INB/SDCN OR
                RA1IND/SDCN OR RA1IN0/SDCN OR RA1IN2/SDCN OR RA1IN5/SDCN OR
                RA1IN6/SDCN OR RA1IN7/SDCN OR RA1OOA/SDCN OR RA1OOC/SDCN OR
                RA1OOD/SDCN OR RA1OOF/SDCN OR RA1OO0/SDCN OR RA1OO2/SDCN OR
                RA1OO3/SDCN OR RA1OO4/SDCN OR RA1OO5/SDCN OR RA1OO6/SDCN OR
                RA1OO7/SDCN OR RA1OO8/SDCN OR RA1OO9/SDCN OR RA1WSI/SDCN OR
                RA1WSJ/SDCN OR RA1WSQ/SDCN OR RA1WTY/SDCN OR RA17JY/SDCN OR
                RA17KF/SDCN OR RA17KG/SDCN OR RA17K3/SDCN OR RA195G/SDCN OR
                RA195H/SDCN OR RA195I/SDCN OR RA195J/SDCN OR RA195K/SDCN OR
                RA195L/SDCN OR RA195M/SDCN OR RA195N/SDCN OR RA195O/SDCN OR
                RA2FSP/SDCN OR RA250K/SDCN OR RA250R/SDCN OR RA250S/SDCN OR
                RA250T/SDCN OR RA250V/SDCN OR RA250W/SDCN OR RA250X/SDCN OR
                RA250Y/SDCN OR RA2510/SDCN OR RA2511/SDCN OR RA2512/SDCN OR
                RA2513/SDCN OR RA2514/SDCN OR RA2515/SDCN OR RA2516/SDCN OR
                RA2517/SDCN OR RA2518/SDCN OR RA2519/SDCN OR RA33DB/SDCN OR
                RA33DC/SDCN OR RA33DD/SDCN OR RA33DO/SDCN OR RA33DP/SDCN OR
                RA33DW/SDCN OR RA33D7/SDCN OR RA33D8/SDCN OR RA33EN/SDCN OR
                RA33ER/SDCN OR RA33ES/SDCN OR RA33E1/S
                DEL SELECT
L109        1658 SEA SPE=ON  ABB=ON  PLU=ON  (L106 OR L107 OR L108)
                D TRI 1-10
                D QUE L10
                D QUE L9
L110           0 SEA SUB=L109 SSS SAM L9
L111           1 SEA SPE=ON  ABB=ON  PLU=ON  L2 NOT L105
L112        1685 SEA SPE=ON  ABB=ON  PLU=ON  L109 OR L19
L113           1 SEA SUB=L112 SSS SAM L9
                D TRI
L114          22 SEA SUB=L112 SSS FUL L9
                SAVE TEMP L114 PAG520WPIS/A
L115           0 SEA SPE=ON  ABB=ON  PLU=ON  L114 NOT L19

     FILE 'LREGISTRY' ENTERED AT 09:07:43 ON 25 SEP 2009
                ACT PAG520PSTR/Q
               ---------
L116            STR
               ---------

     FILE 'WPIX' ENTERED AT 09:07:58 ON 25 SEP 2009
L117           0 SEA SSS SAM L116
                D TRI L114 1-22
                SELECT L114 1- SDCN
L118          16 SEA SPE=ON  ABB=ON  PLU=ON  (RASW2T/DCN OR RASW2U/DCN OR
                RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW3A/DCN OR
                RASW3B/DCN OR RASW3C/DCN OR RASW3D/DCN OR RASW3E/DCN OR
                RASW3F/DCN OR RASW3G/DCN OR RASW3H/DCN OR RASW39/DCN OR
                RAUHHC/DCN OR RAUHHD/DCN OR RAUHHE/DCN OR RAUHHF/DCN OR
                RAUHHG/DCN OR RAUHHH/DCN OR RAUHH9/DCN OR RA2Y7A/DCN) OR
                L114/DCR
L119           6 SEA SPE=ON  ABB=ON  PLU=ON  L118 AND (L58 OR L74 OR (L55 OR
                L56))
                D TRI 1-6
L120          14 SEA SPE=ON  ABB=ON  PLU=ON  L118 AND (L53 OR L54 OR L55 OR
```

```
                L56)
L121          14 SEA SPE=ON  ABB=ON  PLU=ON  (L119 OR L120)
L122          13 SEA SPE=ON  ABB=ON  PLU=ON  L121 AND (L21 OR L22 OR L23 OR L24
                 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
                 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
                 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
                 L51)
L123           1 SEA SPE=ON  ABB=ON  PLU=ON  L121 NOT L122
                 D TRI

     FILE 'STNGUIDE' ENTERED AT 09:12:36 ON 25 SEP 2009

     FILE 'WPIX' ENTERED AT 09:13:10 ON 25 SEP 2009
                 D HITSTR 1

     FILE 'STNGUIDE' ENTERED AT 09:13:11 ON 25 SEP 2009

     FILE 'STNGUIDE' ENTERED AT 09:13:28 ON 25 SEP 2009

     FILE 'STNGUIDE' ENTERED AT 09:56:56 ON 25 SEP 2009

     FILE 'LREGISTRY' ENTERED AT 09:57:08 ON 25 SEP 2009
L124             STR L9

     FILE 'REGISTRY' ENTERED AT 09:58:57 ON 25 SEP 2009
L125           0 SEA SSS SAM L124

     FILE 'STNGUIDE' ENTERED AT 09:59:08 ON 25 SEP 2009

     FILE 'LREGISTRY' ENTERED AT 09:59:47 ON 25 SEP 2009
L126             STR L124

     FILE 'REGISTRY' ENTERED AT 10:01:43 ON 25 SEP 2009
L127           0 SEA SSS SAM L126

     FILE 'STNGUIDE' ENTERED AT 10:02:03 ON 25 SEP 2009

     FILE 'REGISTRY' ENTERED AT 10:04:04 ON 25 SEP 2009
L128             SCREEN 1812 OR 1758
L129           3 SEA SSS SAM (L128 AND L126)
                 D SCAN

     FILE 'STNGUIDE' ENTERED AT 10:04:55 ON 25 SEP 2009
                 D QUE STAT

     FILE 'REGISTRY' ENTERED AT 10:10:33 ON 25 SEP 2009
L130        1799 SEA SSS FUL (L128 AND L126)
                 SAVE TEMP L130 PAG520PSETC2/A
                 D SAVED
L131        1294 SEA SPE=ON  ABB=ON  PLU=ON  L130 NOT PMS/CI
L132          18 SEA SPE=ON  ABB=ON  PLU=ON  L5 AND L131

     FILE 'LREGISTRY' ENTERED AT 10:15:12 ON 25 SEP 2009
L133             STR L9

     FILE 'REGISTRY' ENTERED AT 10:21:11 ON 25 SEP 2009
L134           0 SEA SSS SAM L133
L135             SCREEN 1838
L136             SCREEN 1840
L137           0 SEA SSS SAM ((L135 NOT L136) AND L133)
```

```
L138            STR L133
L139          0 SEA SSS SAM L138
L140          0 SEA SSS SAM ((L135 NOT L136) AND L138)

     FILE 'LREGISTRY' ENTERED AT 10:26:17 ON 25 SEP 2009
L141            STR L138

     FILE 'REGISTRY' ENTERED AT 10:33:14 ON 25 SEP 2009
L142          1 SEA SSS SAM L141
                D SCAN
                D QUE STAT

     FILE 'STNGUIDE' ENTERED AT 10:33:42 ON 25 SEP 2009

     FILE 'REGISTRY' ENTERED AT 10:37:52 ON 25 SEP 2009
L143        173 SEA SSS FUL L141
                SAVE TEMP L143 PAG520PSETC6/A
L144        170 SEA SPE=ON  ABB=ON  PLU=ON  L143 NOT PMS/CI
L145        146 SEA SPE=ON  ABB=ON  PLU=ON  L144 NOT OC5/ES

     FILE 'LREGISTRY' ENTERED AT 10:39:45 ON 25 SEP 2009
L146            STR L141

     FILE 'REGISTRY' ENTERED AT 10:40:33 ON 25 SEP 2009
L147          4 SEA SUB=L143 SSS SAM L146
L148        160 SEA SUB=L143 SSS FUL L146
                SAVE TEMP L148 PAG520RSETC6/A
L149        133 SEA SPE=ON  ABB=ON  PLU=ON  L145 AND L148
L150       1427 SEA SPE=ON  ABB=ON  PLU=ON  L131 OR L149
                SAVE TEMP L150 PAG520CROSSF/A

     FILE 'STNGUIDE' ENTERED AT 10:42:22 ON 25 SEP 2009
                D SAVED

     FILE 'HCAPLUS' ENTERED AT 10:43:03 ON 25 SEP 2009
L151       1760 SEA SPE=ON  ABB=ON  PLU=ON  L150
L152         11 SEA SPE=ON  ABB=ON  PLU=ON  L151 AND L58
L153          8 SEA SPE=ON  ABB=ON  PLU=ON  L151 AND L57
L154          9 SEA SPE=ON  ABB=ON  PLU=ON  L151 AND (L55 OR L56)
L155         14 SEA SPE=ON  ABB=ON  PLU=ON  (L152 OR L153 OR L154)

     FILE 'ZCAPLUS' ENTERED AT 10:44:32 ON 25 SEP 2009
                E SKIN DISEASES/CT
                E E25+ALL
L156            QUE SPE=ON  ABB=ON  PLU=ON  "SKIN, DISEASE"+PFT,OLD,NEW,NT/CT

     FILE 'HCAPLUS' ENTERED AT 10:44:55 ON 25 SEP 2009
L157         95 SEA SPE=ON  ABB=ON  PLU=ON  L151 AND (L156 OR L64 OR (L53 OR
                L54 OR L55 OR L56 OR L57))
L158        316 SEA SPE=ON  ABB=ON  PLU=ON  L151 (L)(THU OR PKT OR PAC OR DMA
                OR BAC)/RL
L*** DEL   4113 S L57 AND L58
L159         63 SEA SPE=ON  ABB=ON  PLU=ON  L157 AND L158

     FILE 'STNGUIDE' ENTERED AT 10:49:07 ON 25 SEP 2009

     FILE 'ZCAPLUS' ENTERED AT 10:49:56 ON 25 SEP 2009
L160            QUE SPE=ON  ABB=ON  PLU=ON  DISEAS? OR DISORDER? OR SYNDROM?
                OR CONDITION? OR SYMPTOM? OR COMPLICATION OR DISTURB? OR
                DISTRESS? OR DYSFUNC? OR (DYS(1W)FUNC?)
```

```
     FILE 'HCAPLUS' ENTERED AT 10:50:22 ON 25 SEP 2009
L161         18 SEA SPE=ON  ABB=ON  PLU=ON  L159 AND ((L53 OR L54) (3A) L160)
L162         27 SEA SPE=ON  ABB=ON  PLU=ON  L155 OR L161
L163         27 SEA SPE=ON  ABB=ON  PLU=ON  L162 AND ((L53 OR L54 OR L55 OR
                L56 OR L57 OR L58) OR L64)
L164         27 SEA SPE=ON  ABB=ON  PLU=ON  (L162 OR L163)
L165         14 SEA SPE=ON  ABB=ON  PLU=ON  L164 AND (L21 OR L22 OR L23 OR L24
                OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
                OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
                OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
                L51)
L166         13 SEA SPE=ON  ABB=ON  PLU=ON  L164 NOT L165
                D SCAN TI HIT
L167          3 SEA SPE=ON  ABB=ON  PLU=ON  L166 AND L57
                D BIB 1-3
                D HITSTR 1-3

     FILE 'STNGUIDE' ENTERED AT 10:54:46 ON 25 SEP 2009

     FILE 'WPIX' ENTERED AT 10:56:03 ON 25 SEP 2009
L168          4 SEA SSS SAM (L128 AND L126)
                D QUE STAT
L169         82 SEA SSS FUL (L128 AND L126)
                SAVE TEMP L169 PAG520WPIS2/A
L170          1 SEA SSS SAM L141
                D QUE STAT
L171         15 SEA SSS FUL L141
                SAVE TEMP L171 PAG520WPIS3/A
L172         97 SEA SPE=ON  ABB=ON  PLU=ON  L169 OR L171
                SAVE TEMP L172 PAG520WPIF/A
                D SAVED
                SELECT L172 1- SDCN
L173        122 SEA SPE=ON  ABB=ON  PLU=ON  (RABCOA/DCN OR RABCO3/DCN OR
                RABCO8/DCN OR RABCO9/DCN OR RABNDP/DCN OR RABNDQ/DCN OR
                RAGHZJ/DCN OR RAGHZM/DCN OR RAHO0Q/DCN OR RAI7ME/DCN OR
                RAKQX2/DCN OR RALH0H/DCN OR RAL3SN/DCN OR RAL3SO/DCN OR
                RAL3SP/DCN OR RAL3SQ/DCN OR RAL3SR/DCN OR RAL3ST/DCN OR
                RANFVN/DCN OR RAN401/DCN OR RAN403/DCN OR RAPVAI/DCN OR
                RAPVAJ/DCN OR RAPVAK/DCN OR RAQW9I/DCN OR RAQW9P/DCN OR
                RAQW9R/DCN OR RAR1ZL/DCN OR RASW2T/DCN OR RASW2U/DCN OR
                RASW2V/DCN OR RASW2W/DCN OR RASW2X/DCN OR RASW2Y/DCN OR
                RASW2Z/DCN OR RASW3A/DCN OR RASW3B/DCN OR RASW3C/DCN OR
                RASW3D/DCN OR RASW3E/DCN OR RASW3F/DCN OR RASW3G/DCN OR
                RASW3H/DCN OR RASW30/DCN OR RASW38/DCN OR RASW39/DCN OR
                RASW4A/DCN OR RASW50/DCN OR RASXL7/DCN OR RAUHHC/DCN OR
                RAUHHD/DCN OR RAUHHE/DCN OR RAUHHF/DCN OR RAUHHG/DCN OR
                RAUHHH/DCN OR RAUHH9/DCN OR RAUVSQ/DCN OR RAUVSR/DCN OR
                RAWFMV/DCN OR RAWUPX/DCN OR RAW47P/DCN OR RAW47Q/DCN OR
                RAW47R/DCN OR RAW47S/DCN OR RAW47T/DCN OR RAW47U/DCN OR
                RAXSIA/DCN OR RA0MNZ/DCN OR RA002O/DCN OR RA007X/DCN OR
                RA0083/DCN OR RA2NB0/DCN OR RA2Y7A/DCN OR RA3MBV/DCN OR
                RA4GNI/DCN OR RA4GOC/DCN OR RA4GOL/DCN OR RA4KMT/DCN OR
                RA4KMZ/DCN OR RA4KN3/DCN OR RA4KN4/DCN OR RA4NBT/DCN OR
                RA4NBW/DCN OR RA6Q5K/DCN OR RA63TX/DCN OR RA660M/DCN OR
                RA8AOM/DCN OR RA9JSH/DCN OR RA9JSI/DCN OR RA9XSQ/DCN OR
                RB0D0S/DCN OR RB0D0T/DCN OR RB0D0U/DCN OR RB0D0V/DCN OR
                R11693/DCN OR R11694/DCN OR R20556/DCN OR R21482/DCN) OR
                L172/DCR
L174         10 SEA SPE=ON  ABB=ON  PLU=ON  L173 AND (L58 OR L74 OR (L55 OR
```

```
                L56))
L175          7 SEA SPE=ON  ABB=ON  PLU=ON  L174 AND (L21 OR L22 OR L23 OR L24
                OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
                OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
                OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
                L51)
L176          3 SEA SPE=ON  ABB=ON  PLU=ON  L174 NOT L175
                D TRI HITSTR 1-3
L177          3 SEA SPE=ON  ABB=ON  PLU=ON  L176 AND ((L53 OR L54 OR L55 OR
                L56) OR L160)
L178          3 SEA SPE=ON  ABB=ON  PLU=ON  (L176 OR L177)

     FILE 'REGISTRY' ENTERED AT 11:04:33 ON 25 SEP 2009
L179         28 SEA SPE=ON  ABB=ON  PLU=ON  L5 AND L150

     FILE 'STNGUIDE' ENTERED AT 11:04:50 ON 25 SEP 2009

     FILE 'REGISTRY' ENTERED AT 11:05:09 ON 25 SEP 2009
L180          7 SEA SPE=ON  ABB=ON  PLU=ON  L150 AND MEDLINE/LC

     FILE 'MEDLINE' ENTERED AT 11:05:22 ON 25 SEP 2009
L181        392 SEA SPE=ON  ABB=ON  PLU=ON  L180

     FILE 'REGISTRY' ENTERED AT 11:05:33 ON 25 SEP 2009
                SET SMARTSELECT ON
L182            SEL PLU=ON  L179 1- NAME :      13 TERMS
                SET SMARTSELECT OFF

     FILE 'MEDLINE' ENTERED AT 11:05:36 ON 25 SEP 2009
L183         17 SEA SPE=ON  ABB=ON  PLU=ON  L182
L184        399 SEA SPE=ON  ABB=ON  PLU=ON  L181 OR L183
                E PSORIASIS/CT
                E E137+ALL
L185            QUE SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT

     FILE 'ZCAPLUS' ENTERED AT 11:07:08 ON 25 SEP 2009
L186            QUE SPE=ON  ABB=ON  PLU=ON  EPIDERMOPOIESIS

     FILE 'MEDLINE' ENTERED AT 11:07:26 ON 25 SEP 2009
L187            QUE SPE=ON  ABB=ON  PLU=ON  "SKIN DISEASES, PAPULOSQUAMOUS"+PFT
                ,OLD,NEW,NT/CT
                D HIS50
L188          1 SEA SPE=ON  ABB=ON  PLU=ON  L184 AND ((L55 OR L56) OR L185 OR
                (L186 OR L187))
                D TRI
                D BIB
L189          1 SEA SPE=ON  ABB=ON  PLU=ON  L188 AND (L21 OR L22 OR L23 OR L24
                OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
                OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
                OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
                L51)
L190          0 SEA SPE=ON  ABB=ON  PLU=ON  L188 NOT L189

     FILE 'STNGUIDE' ENTERED AT 11:10:05 ON 25 SEP 2009

     FILE 'REGISTRY' ENTERED AT 11:10:59 ON 25 SEP 2009
L191          4 SEA SPE=ON  ABB=ON  PLU=ON  L150 AND EMBASE/LC

     FILE 'EMBASE' ENTERED AT 11:11:10 ON 25 SEP 2009
L192        794 SEA SPE=ON  ABB=ON  PLU=ON  L191
```

```
L193          69 SEA SPE=ON  ABB=ON  PLU=ON  L182
L194         838 SEA SPE=ON  ABB=ON  PLU=ON  (L192 OR L193)
                 E PSORIASIS/CT
                 E E161+ALL
L195             QUE SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT,OLD,NEW,NT/CT
L196             QUE SPE=ON  ABB=ON  PLU=ON  "ERYTHEMATOSQUAMOUS SKIN DISEASE"+P
                 FT,OLD,NEW,NT/CT
L197           2 SEA SPE=ON  ABB=ON  PLU=ON  L194 AND ((L55 OR L56) OR L186 OR
                 (L195 OR L196))
L198           1 SEA SPE=ON  ABB=ON  PLU=ON  L197 AND (L21 OR L22 OR L23 OR L24
                 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
                 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
                 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
                 L51)
L199           1 SEA SPE=ON  ABB=ON  PLU=ON  L197 NOT L198
                 D BIB
                 D TRI

     FILE 'REGISTRY' ENTERED AT 11:13:43 ON 25 SEP 2009
L200          11 SEA SPE=ON  ABB=ON  PLU=ON  L150 AND (BIOSIS OR BIOTECHNO OR
                 CABA OR DRUGU OR VETU)/LC

     FILE 'BIOSIS, BIOTECHNO, CABA, DRUGU, VETU' ENTERED AT 11:14:12 ON 25 SEP
     2009
L201         437 SEA SPE=ON  ABB=ON  PLU=ON  L200
L202          45 SEA SPE=ON  ABB=ON  PLU=ON  L182
L203         469 SEA SPE=ON  ABB=ON  PLU=ON  (L201 OR L202)

     FILE 'ZCAPLUS' ENTERED AT 11:15:20 ON 25 SEP 2009
L204             QUE SPE=ON  ABB=ON  PLU=ON  WILLAN (1A) LEPRA
L205             QUE SPE=ON  ABB=ON  PLU=ON  PARAPSORIA?

     FILE 'BIOSIS, BIOTECHNO, CABA, DRUGU, VETU' ENTERED AT 11:16:26 ON 25 SEP
     2009
L206           0 SEA SPE=ON  ABB=ON  PLU=ON  L203 AND ((L55 OR L56) OR L186 OR
                 (L204 OR L205))
L207           2 SEA SPE=ON  ABB=ON  PLU=ON  L203 AND ((L53 OR L54) (5A) L160)

L208           0 SEA SPE=ON  ABB=ON  PLU=ON  L207 AND (L21 OR L22 OR L23 OR L24
                 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
                 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
                 OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
                 L51)
L209           2 SEA SPE=ON  ABB=ON  PLU=ON  L207 NOT L208
                 D SCAN
                 D TRI 2
                 D KWIC 1-2

     FILE 'STNGUIDE' ENTERED AT 11:18:53 ON 25 SEP 2009

     FILE 'REGISTRY' ENTERED AT 11:20:02 ON 25 SEP 2009
L210         333 SEA SPE=ON  ABB=ON  PLU=ON  L150 AND (USPATFULL OR USPAT2 OR
                 USPATOLD)/LC

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 11:20:08 ON 25 SEP 2009
L211         409 SEA SPE=ON  ABB=ON  PLU=ON  L210
L212           5 SEA SPE=ON  ABB=ON  PLU=ON  L211 AND (L55/CLM OR L56/CLM OR
                 L186/CLM OR L204/CLM OR L205/CLM)
L213           3 SEA SPE=ON  ABB=ON  PLU=ON  L212 AND (L21 OR L22 OR L23 OR L24
                 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
```

```
                OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
                OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
                L51)
L214          2 SEA SPE=ON  ABB=ON  PLU=ON  L212 NOT L213
                D SCAN
                D KWIC 1
                D KWIC 2
                D SCAN
                D BIB 1

     FILE 'STNGUIDE' ENTERED AT 11:23:48 ON 25 SEP 2009
                D QUE L160
                D QUE L186
                D QUE L104
                D QUE L204
                D QUE L205

     FILE 'HCAPLUS, WPIX, PASCAL, JAPIO, MEDLINE, BIOSIS, EMBASE, CABA,
     CEABA-VTB, LIFESCI, KOSMET, BIOENG, BIOTECHNO, BIOTECHDS, DRUGU, DRUGB,
     VETU, VETB, SCISEARCH, CONFSCI, DISSABS, RDISCLOSURE' ENTERED AT 11:29:03
     ON 25 SEP 2009
L215        425 SEA SPE=ON  ABB=ON  PLU=ON  L182
L216         13 SEA SPE=ON  ABB=ON  PLU=ON  L215 AND ((L55 OR L56) OR L186 OR
                (L204 OR L205) OR L58)
L217         12 SEA SPE=ON  ABB=ON  PLU=ON  L216 AND (L21 OR L22 OR L23 OR L24
                OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33
                OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42
                OR L43 OR L44 OR L45 OR L46 OR L47 OR L48 OR L49 OR L50 OR
                L51)
L218          1 SEA SPE=ON  ABB=ON  PLU=ON  L216 NOT L217
                D SCAN

     FILE 'STNGUIDE' ENTERED AT 11:33:45 ON 25 SEP 2009

     FILE 'REGISTRY' ENTERED AT 11:33:54 ON 25 SEP 2009

     FILE 'STNGUIDE' ENTERED AT 11:34:02 ON 25 SEP 2009
                D QUE STAT L10
                D QUE NOS L17
                D QUE NOS L18
                D QUE NOS L71
                D QUE STAT L114
                D QUE L123
                D QUE STAT L130
                D QUE NOS L131
                D QUE STAT L143
                D QUE STAT L148
                D QUE NOS L150
                D QUE NOS L179
                D QUE NOS L166
                D QUE NOS L214
                D QUE STAT L169
                D QUE STAT L171
                D QUE NOS L172
                D QUE NOS L178
                D QUE NOS L190
                D QUE NOS L199
                D QUE NOS L209
                D QUE NOS L218
```

```
     FILE 'HCAPLUS, WPIX, USPATFULL, EMBASE, BIOSIS, DRUGU' ENTERED AT
     11:40:01 ON 25 SEP 2009
L219         21 DUP REM L71 L123 L166 L214 L178 L190 L199 L209 L218 (8 DUPLICAT
                    ANSWERS '1-15' FROM FILE HCAPLUS
                    ANSWERS '16-17' FROM FILE WPIX
                    ANSWERS '18-19' FROM FILE USPATFULL
                    ANSWER '20' FROM FILE EMBASE
                    ANSWER '21' FROM FILE DRUGU
               SAVE TEMP L219 PAG520MAINP/A

     FILE 'STNGUIDE' ENTERED AT 11:40:18 ON 25 SEP 2009

     FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' ENTERED AT 11:40:52 ON 25
     SEP 2009
               D IBIB ED ABS HITIND HITSTR 1-15

     FILE 'STNGUIDE' ENTERED AT 11:40:57 ON 25 SEP 2009

     FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' ENTERED AT 11:43:26 ON 25
     SEP 2009
               D IALL ABEQ TECH ABEX HITSTR 16-17

     FILE 'STNGUIDE' ENTERED AT 11:43:27 ON 25 SEP 2009

     FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' ENTERED AT 11:44:54 ON 25
     SEP 2009
               D IBIB AB KWIC HITSTR 18-19

     FILE 'STNGUIDE' ENTERED AT 11:44:56 ON 25 SEP 2009

     FILE 'HCAPLUS, WPIX, EMBASE, DRUGU, USPATFULL' ENTERED AT 11:48:08 ON 25
     SEP 2009
               D IBIB ED AB IND 20-21

     FILE 'STNGUIDE' ENTERED AT 11:48:09 ON 25 SEP 2009
               D QUE NOS L70
               D QUE NOS L122
               D QUE NOS L165
               D QUE NOS L213
               D QUE NOS L175
               D QUE NOS L189
               D QUE NOS L198
               D QUE NOS L208
               D QUE NOS L217

     FILE 'HCAPLUS, WPIX, USPATFULL, MEDLINE, EMBASE' ENTERED AT 11:50:56 ON
     25 SEP 2009
L220         22 DUP REM L70 L122 L165 L213 L175 L189 L198 L208 L217 (43 DUPLICA
                    ANSWERS '1-15' FROM FILE HCAPLUS
                    ANSWERS '16-19' FROM FILE WPIX
                    ANSWERS '20-21' FROM FILE USPATFULL
                    ANSWER '22' FROM FILE MEDLINE
               SAVE TEMP L220 PAG520INV/A

     FILE 'STNGUIDE' ENTERED AT 11:51:10 ON 25 SEP 2009

     FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' ENTERED AT 11:51:49 ON 25 SEP
     2009
               D IBIB ED ABS HITIND HITSTR 1-15
```

FILE 'STNGUIDE' ENTERED AT 11:51:59 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' ENTERED AT 11:52:37 ON 25 SEP 2009
D IALL ABEQ TECH ABEX HITSTR 16-19

FILE 'STNGUIDE' ENTERED AT 11:52:41 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' ENTERED AT 11:53:04 ON 25 SEP 2009
D IBIB AB HITSTR 20-21

FILE 'STNGUIDE' ENTERED AT 11:53:05 ON 25 SEP 2009

FILE 'HCAPLUS, WPIX, MEDLINE, USPATFULL' ENTERED AT 11:53:18 ON 25 SEP 2009
D IBIB ED AB IND 22

FILE 'STNGUIDE' ENTERED AT 11:53:19 ON 25 SEP 2009

FILE 'STNGUIDE' ENTERED AT 11:53:31 ON 25 SEP 2009

FILE HOME

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 18, 2009 (20090918/UP).

FILE HCAPLUS

FILE COVERS 1907 - 25 Sep 2009 VOL 151 ISS 14
FILE LAST UPDATED: 24 Sep 2009 (20090924/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer

to NEWS 9.

FILE WPIX
FILE LAST UPDATED: 18 SEP 2009 <20090918/UP>
MOST RECENT UPDATE: 200960 <200960/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.4 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
and FI-Terms have been updated with reclassifications to
mid-June 2009.
No update date (UP) has been created for the reclassified
documents, but they can be identified by
specific update codes (see HELP CLA for details)<<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.com/stn_guide.html

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdate

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/DWPIAnaVist2_0608.html

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2009 HIGHEST RN 1186290-74-3
DICTIONARY FILE UPDATES: 24 SEP 2009 HIGHEST RN 1186290-74-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE ZCAPLUS

FILE COVERS 1907 - 25 Sep 2009 VOL 151 ISS 14
FILE LAST UPDATED: 24 Sep 2009 (20090924/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

FILE LREGISTRY
LREGISTRY IS A STATIC LEARNING FILE

CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE MEDLINE
FILE LAST UPDATED: 24 Sep 2009 (20090924/UP). FILE COVERS 1949 TO DATE.

MEDLINE and LMEDLINE have been updated with the 2009 Medical Subject Headings (MeSH) vocabulary and tree numbers from the U.S. National Libra of Medicine (NLM). Additional information is available at

http://www.nlm.nih.gov/pubs/techbull/nd08/nd08_medline_data_changes_2009.

On February 21, 2009, MEDLINE was reloaded. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

FILE EMBASE
FILE COVERS 1974 TO 25 Sep 2009 (20090925/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

FILE BIOSIS
FILE COVERS 1926 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 23 September 2009 (20090923/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926
through 1968. These records have been re-indexed to match current
BIOSIS indexing.

FILE BIOTECHNO
FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>
FILE COVERS 1980 TO 2003.
THIS FILE IS A STATIC FILE WITH NO UPDATES

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
/CT AND BASIC INDEX <<<

FILE CABA
FILE COVERS 1973 TO 3 Sep 2009 (20090903/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The CABA file was reloaded 7 December 2003. Enter HELP RLOAD for details.

FILE DRUGU
FILE LAST UPDATED: 22 SEP 2009 <20090922/UP>
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<
>>> THESAURUS AVAILABLE IN /CT <<<

FILE VETU
FILE LAST UPDATED: 2 JAN 2002 <20020102/UP>
FILE COVERS 1983-2001

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Sep 2009 (20090924/PD)
FILE LAST UPDATED: 24 Sep 2009 (20090924/ED)
HIGHEST GRANTED PATENT NUMBER: US7594277
HIGHEST APPLICATION PUBLICATION NUMBER: US20090241233
CA INDEXING IS CURRENT THROUGH 24 Sep 2009 (20090924/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Sep 2009 (20090924/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

USPATFULL now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

To ensure comprehensive retrieval of US patent information, including
US patent application information, search USPATFULL in combination with
USPAT2.

FILE USPATOLD

FILE COVERS U.S. PATENTS 1790-1975

Produced using data provided by Univentio.

This database was created using Optical Character Recognition (OCR) technology. For this reason, some characters may be missing or mistranslated. In order to improve searchability and retrieval, CA indexing information has been added to the Title, Inventor, and Patent Assignee fields where possible. Please see HELP CASDATA for more information on the availability of CAS indexing in this database.

USPATOLD now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 24 Sep 2009 (20090924/PD)
FILE LAST UPDATED: 24 Sep 2009 (20090924/ED)
HIGHEST GRANTED PATENT NUMBER: US20090202559
HIGHEST APPLICATION PUBLICATION NUMBER: US20090241217
CA INDEXING IS CURRENT THROUGH 24 Sep 2009 (20090924/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Sep 2009 (20090924/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

USPAT2 now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

To ensure comprehensive retrieval of US patent information, including US patent application information, search USPAT2 in combination with USPATFULL.

FILE PASCAL
FILE LAST UPDATED: 21 SEP 2009 <20090921/UP>
FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE JAPIO
FILE LAST UPDATED: 28 AUG 2009 <20090828/UP>
MOST RECENT PUBLICATION DATE: 28 MAY 2009 <20090528/PD>
>>> GRAPHIC IMAGES AVAILABLE <<<

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION (SLART) IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE CEABA-VTB
FILE LAST UPDATED: 21 SEP 2009 <20090921/UP>
FILE COVERS 1966 TO DATE

>>> DECHEMA, the producer of CEABA-VTB is using a new classification scheme.
The new classification schemes are available as a PDF file
and may be downloaded free-of-charge from:
http://www.stn-international.com/cc-de.html
and
http://www.stn-international.com/cc-en.html<<<

FILE LIFESCI
FILE COVERS 1978 TO 9 Sep 2009 (20090909/ED)

```
FILE KOSMET
FILE LAST UPDATED: 26 AUG 2009       <20090826/UP>
FILE COVERS 1968 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
    IN THE BASIC INDEX (/BI) FIELD  <<<

FILE BIOENG
FILE LAST UPDATED: 13 AUG 2009       <20090813/UP>
FILE COVERS 1982 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
    THE BASIC INDEX <<<

FILE BIOTECHDS
FILE LAST UPDATED: 24 SEP 2009       <20090924/UP>
FILE COVERS 1982 TO DATE

>>> USE OF THIS FILE IS LIMITED TO BIOTECH SUBSCRIBERS <<<


FILE DRUGB
 >>>  FILE COVERS 1964 TO 1982 - CLOSED FILE  <<<


FILE VETB
FILE LAST UPDATED: 25 SEP 94      <940925/UP>
FILE COVERS 1968-1982


FILE SCISEARCH

FILE COVERS 1974 TO 24 Sep 2009 (20090924/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE CONFSCI
FILE COVERS 1973 TO 30 Jun 2009 (20090630/ED)

CSA has resumed updates, see NEWS FILE

FILE DISSABS
FILE COVERS 1861 TO 8 SEP 2009 (20090908/ED)

Only fair use as provided by the United States copyright law is
permitted.  PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO
WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF
THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED,
INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY
KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED
MATERIALS OR THEIR USE.

FILE RDISCLOSURE
FILE LAST UPDATED: 11 SEP 2009       <20090911/UP>
FILE COVERS 1960 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE IN THE
    BASIC INDEX (/BI) AND TITLE (/TI) FIELDS <<<
```

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=>